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List of Abbreviations 
• ALL: Acute Lymphoblastic Leukaemia 
• B-cell: B-lymphocyte 
• T-cell: T-lymphocyte 
• CML: Chronic Myelogenous Leukaemia 
• CpG: Cytosine, phosphate, Guanine dinucleotide 
• A: Adenine 
• C: Cytosine 
• T: Thymine 
• G: Guanine 
• PCR: Polymerase Chain Reaction 
• RRBS: Reduced Representation Bisulphite Sequencing 
• DNA: Deoxyribose Nucleic Acid 
• kb: kilo-base-pair 
• bp: base pairs 
• CoBRA: Combined Bisulphite Restriction Analysis 
• MPS: Massively Parallel Sequencing 
• MPBS: Massively Parallel Bisulphite Sequencing 
• TET: Ten-Eleven Translocation 
• DMAP: Differential Methylation Analysis Package 
• MPBSgee: Massively Parallel Bisulphite Sequencing GEE package 
• GEE: Generalised Estimating Equations 
• GNU: GNU’s Not Unix (recursive acronym) 
• GPL-2: GNU Public Licence 2 
• WGBS: Whole-Genome Bisulphite Sequencing 
• AID/APOBEC 
• TH1: Helper T-cell, type 1 
• TH2: Helper T-cell, type-2 
• HPA: Hypothalamic Pituitary Axis 
• ACTH: Adrenal Corticotrophic Hormone 
• CRH: Corticotrophin Releasing Hormone 
• PBS: Phosphate Buffered Saline 
• FCS: Fetal Calf Serum 
• RPMI: Roswell Parks Memorial Institute media 
• log: Base 10 logarithm 
• ln: Natural logarithm 
• DMR: Differentially Methylated Region 
• MALDI-TOF: Matrix-Assisted Laser Desorption/Ionisation – Time of 
Flight 
• 7AAD: 7-Aminoactinomycin D 
• dsDNA: double-stranded DNA 
• ChIP: Chromatin Immunoprecipitation 
• U: Standard Units 
• CFSE: Carboxyfluorescein Succinimidyl Ester 
• Gaussian: Normally-Distributed 
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Acute lymphoblastic leukaemia (ALL) is a malignant proliferation of 
immature lymphocytes, mainly occurring in childhood. The pathogenesis of 
the disease is characterised by multiple molecular abnormalities, including 
aberrant gene expression and abnormal patterns of DNA methylation. This 
project focussed on DNA methylation, the presence of methyl groups on the 
5’ position of cytosine residues, which has a profound effect on gene 
expression and regulation. 
 
This project investigated the possibility that glucocorticoid drugs, used in the 
treatment of ALL, may induce changes in DNA methylation patterns in ALL 
cells, as part of their more global effects on gene expression. This hypothesis 
was based on previous reports of changes in DNA methylation in response to 
glucocorticoid exposure in non-ALL cells, in particular rat hepatoma cells. 
The ALL cell-line, NALM-6, was chosen to culture model ALL cell 
populations, and cells were exposed to the glucocorticoid dexamethasone and 
compared to unexposed cells. The massively parallel bisulphite sequencing 
technique Reduced Representation Bisulphite Sequencing (RRBS) was used to 
compare the DNA methylation patterns of glucocorticoid-exposed and 
unexposed cells across the genome. The RRBS results were then analysed 
statistically, using generalised estimating equations. 
 
The statistical analysis of the RRBS results found 281 areas of the genome 
with significant differences in methylation between the dexamethasone-
exposed and unexposed NALM-6 cells. However, these differences could not 
be validated using a separate biochemical technique, Sequenom MassArray. 
Therefore, we cannot definitively conclude that reproducible changes in DNA 

















You are a fish. 
Lying still in the shallow curve of the spine. 
Leaping high in the angry surf of the heart. 
Waiting deep in the calm harbour of the belly. 
 







You are a fish. 
What bait has been 




Leukaemia by Glenn Colquhoun, from ‘Diseases I 
have known’ in Playing God (2002). Reproduced with 
permission, courtesy of Steele Roberts publishers. 




Definition and Clinical Features 
 
As with every leukaemia, Acute Lymphoblastic Leukaemia (ALL) is a disease 
caused by the cancerous proliferation of leukocytes, or ‘white blood cells’ 
(Robbins et al., 2010). Unlike most of the leukaemias, however, ALL is 
primarily a disease that affects children (60% of all cases of ALL occur in 
children and young people aged less than twenty, with peak incidence at 2-5 
years); indeed, ALL is the single most common cancer in children, accounting 
for around a third of all paediatric cancer diagnoses (Harrison, 2011; Inaba et 
al., 2013; Pui et al., 2008). 
 
ALL is defined as a proliferation of immature lymphocytes (known as 
lymphoblasts), which are the leukocytes of the adaptive immune response, 
and it can be further categorised as B-cell ALL (B-ALL) or T-cell ALL (T-ALL) 
depending on whether the proliferative cells are premature B or T cells 
(Swerdlow et al., 2008). Of the two, approximately 85% of all paediatric ALL 
cases are of pre B-cell lineage and, as such, B-ALL will be the primary focus of 
this thesis. Clinically, ALL is a disease of abrupt or ‘stormy’ onset reflecting 
the rapid proliferation of lymphoblasts in the disease (Robbins et al., 2010). 
The clinical symptoms associated with the disease are related to three main 
pathological processes; firstly, the rapid proliferation of the cancerous 
lymphoblasts within the bone marrow, leading to ‘crowding out’ of the 
normal haematopoietic cells in the marrow and resulting in anaemia (with 
resultant fatigue), thrombocytopenia (with associated bruising and bleeding 
risk) and neutropenia (with associated fever and infection risk); secondly, 
organ infiltration by circulating blasts giving rise to organomegaly; and 
thirdly, the systemic effects of cytokines released by the proliferating 
lymphoblasts (Mitchell et al., 2009; Robbins et al., 2010). ALL can be primarily 
diagnosed on the basis of a full blood count and smear and subsequent bone 
marrow biopsy, typically showing a high overall white cell count (due to 
circulating blasts), low counts of the normal leukocyte populations, 
thrombocytopenia, anaemia and abnormal blasts on peripheral blood smear 




The prognosis for ALL, in terms of survival rates, has improved significantly 
over the last 40 years, to the point where survival for paediatric ALL is 
approaching 90% with modern chemotherapy regimens (Inaba et al., 2013; Pui 
et al., 2009). However, the disease and treatment are still significant causes of 
morbidity and mortality for patients. There remain significant toxic side-
effects to current multi-agent chemotherapy regimens (regimens which 
typically last 2-3 years), and there are significantly worse prognoses for 
certain groups of ALL patients (Inaba et al., 2013; Mitchell et al., 2009; Pui et 
al., 2008). As such, there is considerable research interest in targeted 
chemotherapy agents, based on knowledge of the molecular biology of the 
disease, to provide more effective and less toxic treatments (Pui et al., 2008). 
 
 
Figure 1.1: Bone marrow aspirate smear (Wright’s stain) from a patient 
with ALL. Many neoplastic lymphoblast cells can be seen, with a high 
nucleus to cytoplasm ratio and homogeneous chromatin. Source: 
http://en.wikipedia.org/wiki/File:Acute_leukemia-ALL.jpg copied under 
GNU Free Documentation License.  
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Genetics and Molecular Biology of B-ALL 
 
Like any other cancer, B-ALL displays a great many distinctive molecular and 
genetic abnormalities, when compared with other leukaemias or to normal 
lymphocytes or lymphoblasts. Many chromosomal, sequence and epigenetic 
abnormalities have been identified and are being identified by molecular 
research in ALL. While epigenetic abnormalities are of primary interest to this 
project, it is important to be aware that there is a wide range of molecular 
lesions in B-ALL, the most common of which will be briefly discussed. 
 
Chromosomal abnormalities are common in B-ALL, with approximately 75% 
of B-ALL cases displaying aneuploidy or chromosomal rearrangements 
(Mullighan, 2012). In cells displaying chromosomal aneuploidy, increased 
chromosome number (hyperdiploidy) is clinically associated with a 
favourable outcome while loss of chromosomes (hypodiploidy) is generally 
unfavourable (Harrison and Foroni, 2002; Mullighan, 2012). In cells with 
chromosomal rearrangements, the biological effect of the rearrangement can 
be related to the disruption of key genes, which may be broken or fused 
together. The most common chromosomal rearrangement in B-ALL, 
occurring in 15-25% of cases, is the t(12;21)(p13;q22) translocation, resulting in 
the fusion of the ETV6 gene, and RUNX1, both transcription factors involved 
in haematopoiesis that are commonly altered in leukaemias (Bohlander, 2005; 
Mullighan, 2012). Other common translocations that are each observed in 2-
6% of B-ALL cases include the t(1;19)(q23;p13) translocation, producing a 
TCF3-PBX1 gene fusion that interferes with haematopoietic differentiation 
(Lu and Kamps, 1997) and the so-called ‘Philadelphia Chromosome’ or 
t(9;22)(q34;q11) translocation, that is more commonly seen in chronic 
myelogenous leukaemia (CML), resulting in a fusion of the BCR and ABL1 
genes that increases differentiation of haematopoietic cells and deregulates 
their differentiation (Mullighan, 2012; Van Etten, 2002). Additionally, 
rearrangements of the MLL and CRLF2 genes are moderately common in B-
ALL, occurring in up to 7% of cases (Mullighan, 2012). 
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On a submicroscopic scale, genetic mutations are also a feature in B-ALL, 
notably (and most commonly) in genes involved in B-cell development. The 
most common of these are mutations in the gene PAX5, which is mutated in 
around 30% of cases of B-ALL and mutations in IKZF1 (around 15% of 
paediatric cases), among many others identified in various studies 
(Mullighan, 2012). 
 
Epigenetic Abnormalities in B-ALL 
 
As mentioned, the epigenetic alterations observed in B-ALL, rather than the 
genetic abnormalities, are of greatest interest in this project. The epigenetic 
abnormalities discussed here focus on abnormalities of DNA methylation in 
gene promoters (DNA methylation is discussed in greater detail later in this 
chapter), which are among the most common molecular lesions reported in B-
ALL. Indeed, a study by Weeks et al. (2010) reported that abnormal 
methylation in the TES gene promoter is the single most common known 
molecular abnormality in B-ALL, occurring in greater than 90% of all cases. 
 
Other single-gene promoter methylation abnormalities in ALL have been 
known of for some time; for example, the p15 and p73 tumour-suppressor 
genes were found to be hypermethylated, compared to normal B-
lymphocytes, in a subset of B-ALL cases during the late 1990s (Corn et al., 
1999; Herman et al., 1997), with subsequent studies identifying a great many 
other individual genes with similar abnormalities when compared to normal 
cells, thought to be important in the biology of B-ALL, including CTGF, 
CHD1, CALC1, NOTCH3 and HES5, among many others (Corn et al., 2000; 
Kuang et al., 2013; Roman et al., 2001; Welch et al., 2013). 
 
Furthermore, more sophisticated studies have been able to examine the 
methylation patterns of several gene promoters of B-ALL cells 
simultaneously. For example, studies by (Wong et al., 2012) and (Martin-
Subero et al., 2009) used multi-gene arrays to show that at least 58 genes may 
be commonly methylated in B-ALL, and that B-ALL displays unique 
methylation abnormalities that distinguish B-ALL cells from both normal and 
non B-ALL leukaemia cells. 
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A more recent study by Nordlund et al. (2013) goes further, showing again 
that B-ALL blasts differ markedly from normal blood cells and that, in 
unsupervised hierarchical clustering based on methylation of 435,941 CpG 
sites on the Illumina 450k BeadChip array, normal blood cells of different 
lineages will cluster together, distinct from all ALL subtypes. They further 
showed that there was a generally hypermethylated pattern in ALL samples, 
compared to normal cells, similar to other findings (Figueroa et al., 2013; 
Martin-Subero et al., 2009). Lastly, they found that methylation patterns of 
these CpG sites could be used to classify ALL into methylation subtypes, 
which then correlated to clinical prognosis (Nordlund et al., 2013). As such, 
this seems to clearly demonstrate that methylation abnormalities exist in ALL 
and that specific methylation patterns have an impact on the clinical course of 
the disease. 
 
Thus, it is well established that methylation abnormalities are a distinctive 
and common molecular feature of B-ALL disease. This is important 
biologically, as DNA methylation changes in gene promoters have important 
implications for the expression of those genes, as will be discussed. 
 
1.2 DNA Methylation 
 
DNA Methylation as a Chemical Modification of DNA 
 
 
DNA methylation is considered one of the epigenetic modifications, defined 
as biologically important alterations of chromatin structure that do not affect 
the underlying genetic sequence. Together with histone modifications, DNA 
methylation is among the best-studied epigenetic modifications and is the 
most common known modification of the DNA molecule (Singal and Ginder, 
1999). 
 
Chemically, DNA methylation is the addition of a methyl (CH3) group to the 
5’-carbon position of the aromatic ring of the nucleotide cytosine, thus 
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forming 5-methylcytosine (Razin and Riggs, 1980; Singal and Ginder, 1999), 
the structure of which is shown in Figure 1.2. The DNA methyltransferase 
family of enzymes catalyses in vivo methylation of cytosine rings in vertebrate 
cells. These enzymes only methylate cytosine residues that are immediately 
followed by a guanine residue (when running 5’ to 3’), which are called CpG 
cytosines and the dinucleotide 5’… C G …3’ sequence is called a CpG site (the 
p in CpG refers to the phosphate group between the nucleotides in the DNA 
strand); therefore, only CpG cytosines are observed to be methylated in 
vertebrates (Blackledge and Klose, 2011; Deaton and Bird, 2011; Razin and 
Riggs, 1980; Singal and Ginder, 1999).  
 
 
CpG Islands and the Control of Gene Expression by CpG Methylation 
 
CpG sites are notably scarce in the majority of the genome; however, certain 
areas, typically 0.5-5 kb in length, contain significantly higher frequency of 
CpG sites than the surrounding genomic sequences (Blackledge and Klose, 
2011; Deaton and Bird, 2011; Razin and Riggs, 1980). These CpG rich areas of 
the genome are known as ‘CpG Islands’ and are important in the biology of 
DNA methylation. 
 
Figure 1.2: Structure of 5-methylcytosine. Source: PubChem, National 
Library of Medicine (US Government). Released to the public domain, 
with permission to copy and distribute this image.  
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CpG islands have been observed to correlate with areas that have a high 
density of gene promoters within the human genome (and other mammalian 
genomes). In fact, 50-70% of all mammalian gene promoters are within CpG 
islands, which are important in the control of expression of downstream 
genes (Blackledge and Klose, 2011; Fazzari and Greally, 2004; Singal and 
Ginder, 1999). Thus, it is unsurprising that CpG methylation within CpG 
islands plays a role in the control of gene expression; more specifically, high 
frequencies of methylated CpG sites in the gene promoter have been shown 
to be associated with transcriptional silencing of the downstream gene 
(Blackledge and Klose, 2011; Singal and Ginder, 1999). 
 
The Bisulphite Conversion Reaction and other Methylation Sensitive 
Techniques 
 
To study DNA methylation, one needs to be able to accurately distinguish 
between methylated and unmethylated cytosine residues in DNA sequences. 
Techniques that are capable of discriminating between the two either exploit 
the different chemical or physical properties of the methylated residues. 
Many of the commonly used study approaches exploit the fact that 
unmethylated cytosine residues may be oxidatively deaminated to form uracil 
during a reaction with sodium bisulphite, while methylated cytosines to not 
undergo this reaction (Hayatsu et al., 1970; Shapiro et al., 1970). This creates a 
methylation-specific sequence change at each cytosine residue, and this 
sequence difference can be detected by downstream techniques. For example, 
certain restriction sites may be affected by the presence or absence of 
methylation in a cytosine residue, meaning that the cleavage of DNA at such 
a site will differ depending on the methylation. This differential cleavage can 
then be detected by restriction fragment length analysis (this technique is 
known as CoBRA). 
 
Alternatively, primers specific for a sequence that is methylated (with 
unconverted CpG cytosines) or unmethylated (vice versa) can be designed, 
such that a PCR reaction with these primers will only amplify a product if the 
template DNA is methylated or unmethylated (depending on the primer 
design) (Hernandez et al., 2013). 
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Lastly, the methylation specific sequence differences can be detected by direct 
sequencing, known as bisulphite sequencing. Direct sequencing has the 
advantage of being a single-CpG resolution technique, that is, it resolves the 
methylation status of every CpG cytosine sequenced (Hernandez et al., 2013). 
Until recently, however, the size of genomic regions that could be analysed by 
bisulphite sequencing was limited by the sequencing technology available to 
the order of thousands or perhaps tens of thousands of base pairs (Hernandez 
et al., 2013). However, the relatively recent development of massively parallel 
sequencing (MPS) has significantly expanded the power of bisulphite 
sequencing based methylation analyses. 
 
As previously mentioned, CpG sites are often clustered in CpG islands, where 
they co-locate with gene promoters and are important for the regulation of 
gene expression (Singal and Ginder, 1999). Therefore, while whole genome 
bisulphite sequencing at high depth would be the gold standard for whole 
genome methylation analysis using MPS, much of the information on how 
methylation of CpG sites is affecting gene promoter biology can be attained 
by sequencing CpG-rich areas, achieving high sequencing depth within CpG 
islands while only covering a minority of the genome (thus reducing 
sequencing costs). As such, reduced representation bisulphite sequencing 
(RRBS) is a technique that has been developed to allow a small sample of the 
genome to be sequenced after enrichment for CpG dense genomic regions. 
 
The principle behind CpG enrichment in RRBS is the use of digestion with the 
MspI restriction enzyme. This enzyme cuts at each  restriction 
site in the genome; therefore, as this sequence contains a CpG site, every 
fragment generated by the digestion will have at least one CpG site at the 5’ 
overhang (and will likely have more CpG sites within the fragment body). 
Thus, if shorter fragments, typically 40-220 bp, are isolated by size selection 
then the selected fragments will have a CpG frequency of 1/220 bp or greater, 
giving these fragments a much higher CpG frequency than the genome as a 
whole (Meissner et al., 2008). These fragments can then be sequenced by MPS, 




greater than 12% of all CpG sites and, importantly, receiving sequences from 
60-90% of all CpG islands (Chatterjee et al., 2012; Meissner et al., 2008; Smith 
et al., 2009). As an example demonstrating the enrichment for CpG islands, 
Figure 1.3 shows the number of CpG islands and the number of MspI 





In addition to direct sequencing, mass spectrometry can be used to tell the 
difference between a methylated (unconverted) and unmethylated (converted 
to uracil/thiamine) cytosine residue after bisulphite conversion (Ehrich et al., 
2005). Sequenom MassArray mass-spectrometry is an established technique 
that uses MALDI-TOF mass spectrometry to measure the mass difference 
between a thiamine residue at a CpG site (indicating that the CpG cytosine 
















































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1.3: The number of (A) MspI fragments and (B) CpG islands for each 





after PCR amplification) or a cytosine (indicating that the CpG cytosine was 




In addition to methylated cytosine, it was shown relatively recently that 
another chemical modification of cytosine exists in vivo, this being 5-
hydroxymethylation (Kriaucionis and Heintz, 2009; Tahiliani et al., 2009). 
Hydroxymethylated cytosine is formed by oxidation of 5-methylcytosine and 
is catalysed by the TET enzymes (after the ten-eleven-translocation gene), to 
leave a CH3OH group on the 5’ position of the cytosine ring (the structure of 
5-hydroxymethylcytosine is shown in Figure 1.4) (Tahiliani et al., 2009). This 
is important in the context of DNA methylation biology, as the TET enzymes 
act as biological initiators of DNA methylation, and conversion of 5-
methylcytosine to 5-hydroxymethylcytosine is one of the steps in the TET-
assisted DNA demethylation process (Delatte et al., 2014; Guo et al., 2011). 
DNA demethylation via hydroxymethylation has been shown not to rely on 
cell replication with active demethylation by the DNA excision/repair 
machinery being implicated instead (Guo et al., 2011). It is thought that 
demethylation is initiated by the oxidation of 5-methylcytosine to 5-
hydroxymethylcytosine. From here, 5-hydroxymethylcytosine can be oxidised 
(again by the TET enzymes) to 5-carboxylcytosine or 5-formylcytosine; 
alternatively, 5-hydroxymethylcytosine may instead be deaminated to 5-
hydroxymethyluridine by AID/APOBEC enzymes (Delatte et al., 2014; Guo et 
al., 2011; Tahiliani et al., 2009; Yin et al., 2013). Lastly, 5-formylcytosine, 5-
carboxylcytosine or 5-hydroxymethyluridine are recognised and removed by 
the base excision repair enzymes to be replaced by unmethylated cytosine 
(Delatte et al., 2014; Guo et al., 2011). As one would expect from these data, it 
is possible to detect changes in the levels of 5-hydroxymethylcytosine during 
demethylation events, which suggests a TET-mediated mechanism (Ficz et al., 
2013). 
 
Within the context of the wider genome, levels of 5-hydroxymethylcytosine 
have been found to be higher within CpG islands and higher in euchromatin 
than in heterochromatin (Ficz et al., 2011). This would imply that TET 
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enzymes are active in maintaining the relatively demethylated state of CpG 
islands (compared with non CpG island CpGs); furthermore, TET knockdown 
has been shown to be associated with increased methylation and decreased 
expression in genes associated with cell pluripotency, and consequent 







1.3 Glucocorticoids: Biological Actions, Medical Uses and Potential 
Epigenetic Effects 
 
Control of Endogenous Glucocorticoids and Glucocorticoid Mode of Action 
 
Glucocorticoids are a highly significant drug class, used extensively in the 
treatment of various medical conditions, notably autoimmune and 
inflammatory disorders, adrenal insufficiency and various leukaemias 
(Adcock and Ito, 2005; Pui and Evans, 2006). Members of this drug class are 
biological analogues of the steroid hormone cortisol, which is secreted in vivo 
from the adrenal cortex (Adcock and Ito, 2005).  
 
Figure 1.4: Structure of 5-hydroxymethylcytosine. Source: PubChem, 
National Library of Medicine (US Government). Released to the 
public domain, with permission to copy and distribute this image. 
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Physiologically, cortisol secretion is controlled through the hypothalamus-
pituitary-adrenal (HPA) axis. The hypothalamus is the highest control area 
for cortisol secretion, and it receives and processes a variety of neural, 
endocrine and cytokine signals, which determine the release of corticotropin 
releasing hormone (CRH) from the periventricular nucleus of the 
hypothalamus into the hypothalamic-pituitary portal circulation (Rhen and 
Cidlowski, 2005; Rivest, 2001; Webster et al., 2002). In turn, CRH stimulates 
the anterior pituitary gland to release adrenocorticotropic hormone (ACTH), 
which then induces the release of cortisol from the adrenal cortex into the 
bloodstream (where it is mostly bound to corticosteroid binding proteins) 
(Rhen and Cidlowski, 2005). 
 
Once in the bloodstream, cortisol (and the glucocorticoid drugs) can 
theoretically act upon any cell in the body that expresses the glucocorticoid-
receptor, which is almost every cell in the body (Rhen and Cidlowski, 2005). 
The gene for the glucocorticoid receptor, NR3C1, is located on chromosome 
5q31.3 (Smith and Cidlowski, 2010). This encodes a protein product, which is 
a member of the nuclear hormone receptor family and, therefore, is a ligand-
dependent transcription factor containing a steroid-binding domain, a DNA-
binding domain and two protein-interaction domains (Adcock and Ito, 2005; 
Hayashi et al., 2004; Karin, 1998; Rhen and Cidlowski, 2005). Cortisol and 
other glucocorticoids bind to the steroid-binding domain of the receptor, 
leading to receptor activation and the dissociation of molecular chaperones 
associated with the inactive receptor (notably members of the heat-shock 
protein family) (Adcock and Ito, 2005; Rhen and Cidlowski, 2005). 
 
The active receptor/glucocorticoid complex can then affect cell processes, 
mainly by altering the expression of genes in the target cell. Gene expression 
is altered through two main mechanisms; firstly, the active receptor complex 
migrates to the cell nucleus where it can bind to another activated 
glucocorticoid receptor to form a homodimer, which can then act as a 
transcription factor and bind directly to DNA at areas of the genome called 
glucocorticoid-responsive-elements (GREs) and recruit proteins to activate or 
inhibit the expression of GRE related genes; secondly, the receptor can bind 
other protein transcription factors to modify their actions. A notable example 
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of this mode of action is the inhibition of the pro-inflammatory transcription 
factors NF-κΒ and AP-1 via protein-protein interactions (Adcock and Ito, 
2005; Beato et al., 1995; Rhen and Cidlowski, 2005; Vandevyver et al., 2013). 
There is also some evidence that the activated glucocorticoid receptor may act 
through non-genomic mechanisms; that is, without acting through the 
transcription machinery; however, glucocorticoids can be broadly considered 
to be drugs that act by affecting gene expression (Adcock and Ito, 2005; 
Hafezi-Moghadam et al., 2002; Rhen and Cidlowski, 2005). 
 
Biological Effects of Glucocorticoids 
 
The downstream effects of glucocorticoid actions are varied, cell-type specific 
and are related to the genes that are affected by glucocorticoid receptor 
activation. That said, two of the most important biological effects of 
glucocorticoids used for pharmacological therapy are the suppression of 
inflammation and the regulation of the immune system. Inflammation is an 
innate response to a variety of bodily insults including infection, mechanical 
irritation and non-infective antigen reactivity (such as allergy and 
autoimmunity) and is an essential part of the immune response; however, 
excessive or inappropriate inflammation can cause damage and disease (Rhen 
and Cidlowski, 2005; Robbins et al., 2010). Briefly, the clinical hallmarks of 
inflammation are classically described as calor, dolor, rubor, tumor and functio 
laesa (heat, pain, redness, swelling and loss of function) and are related to 
increased vasodilation, vasopermeability and cell migration in response to 
inflammatory cell signals (Robbins et al., 2010). 
 
Glucocorticoid receptor activation, and the associated changes in gene 
expression, triggers a cascade of cellular events that inhibit inflammation. For 
example, the production of pro-inflammatory cytokines is inhibited through 
glucocorticoid induction of anti-inflammatory proteins such as annexin-I, 
which inhibits the enzyme phospholipase A2α that is involved in 
prostaglandin and leukotriene synthesis (Antonicelli et al., 2001; Kim et al., 
2001). At the same time, enzymes involved in prostaglandin synthesis, such as 
cyclooxygenase-2, are down-regulated at the transcriptional level, further 
reducing prostaglandin synthesis, notably through repression of NF-κB by 
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the glucocorticoid receptor (Rhen and Cidlowski, 2005; Tanabe and Tohnai, 
2002). Inhibition of NF-κB, AP-1 and other pro-inflammatory transcription 
factors also leads to a reduction in the production of many other 
inflammatory cytokines such as TNFα, IL-1β, IL-2, IL-3 and others, which is 
key to the powerful anti-inflammatory and immune-suppressive actions of 
glucocorticoids (Glass and Saijo, 2010; Vandevyver et al., 2013). Additionally, 
anti-inflammatory cytokines such as IL-10 and the suppressor-of-cytokine-
signalling protein family are up-regulated by the activated glucocorticoid 
receptor (Adcock and Ito, 2005; Hermoso and Cidlowski, 2003). 
 
Glucocorticoids, and the synthetic glucocorticoid dexamethasone in 
particular, are also known to bias the immune response to a TH2-mediated 
response (i.e.,, humeral rather than cell-mediated) (DeKruyff et al., 1998; 
Young et al., 2002). This effect is mediated through inhibiting pro-TH1 
cytokines such as IL-12 in T-cells and antigen presenting cells, and favouring 
the production of pro-TH2 cytokines such as IL-4 (DeKruyff et al., 1998). In 
turn, IL-4 production is associated with increased GATA3 gene expression 
and naïve T-cell differentiation to TH2 cells (Seki et al., 2004). 
 
In addition to reducing the production of inflammatory cytokines, 
glucocorticoids will also induce apoptosis of both healthy and malignant 
lymphocytes and it is this effect that is key to the use of glucocorticoids in the 
treatment of leukaemias such as ALL (Pui et al., 2009; Smith and Cidlowski, 
2010). The activation of the apoptotic pathway in these cells appears to be 
dependent on the glucocorticoid-related alterations in gene expression, with 
studies showing that failure of the glucocorticoid receptor to affect the 
transcriptional machinery (e.g.,, through receptor dimerization failure) leads 
to resistance to the apoptotic effects of glucocorticoids (Reichardt et al., 1998; 
Smith and Cidlowski, 2010). With regard to the actual proteins involved in the 
apoptotic response, it has been found that the protein BIM (encoded by the 
gene BCL2L11), a member of the BCL2-like family of apoptosis regulators, 
plays a key role in this process (Smith and Cidlowski, 2010). BIM expression 
is induced in glucocorticoid-treated lymphocytes in various lymphocyte and 
lymphocytic/lymphoblastic cell-lines (Iglesias-Serret et al., 2007; Schmidt et 
al., 2006; Smith and Cidlowski, 2010) and failure to induce BIM expression is 
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associated with a decreased sensitivity to the apoptotic effects of 
glucocorticoids (Bachmann et al., 2007; Bouillet et al., 1999); however, the 
overall cellular mechanisms of glucocorticoid-induced apoptosis remain 
incompletely understood. 
 
As well as their immune-modulatory and anti-inflammatory actions, 
glucocorticoids have a number of systemic effects, related to cortisol’s role in 
the physiological stress response. Glucocorticoids will raise systemic blood 
pressure through two main mechanisms; firstly, through the partial 
mineralocorticoid effects of the glucocorticoids, leading to increased renal 
sodium retention; and secondly, through increased vasoconstriction in 
response to catecholamines and angiotensin-II, related to up-regulation of the 
angiotensin-II receptor and other effects on vascular tone (Rhen and 
Cidlowski, 2005; Ullian, 1999). There are also metabolic actions of 
glucocorticoids, mainly involved in energy mobilisation. Lipid breakdown 
and release of fatty acids from adipose tissue along with protein breakdown 
in muscle and gluconeogenesis in the liver are promoted by glucocorticoids, 
leading to hyperglycaemia and a catabolic state in response to this drug class 
(Dallman et al., 1993; Mitch, 2000; Rhen and Cidlowski, 2005). High levels of 
circulating glucocorticoids are also associated with stunted growth in 
children, bone breakdown and impaired wound repair (Rhen and Cidlowski, 
2005). 
 
Use of Glucocorticoids and Other Chemotherapy Agents in Leukaemia 
Therapy 
 
Glucocorticoids have been used in the treatment of leukaemias for decades, 
with high-dose glucocorticoids used in chemotherapy for ALL since the 
1950s, and high dose glucocorticoids are also well established for the 
treatment of multiple myeloma and chronic lymphocytic leukaemia (Kyle and 
Rajkumar, 2004; Pearson and Eliel, 1950; Pui and Evans, 2006). In general, 
chemotherapy for leukaemia is often split into drug regimens for inducing 
remission of the cancer and drug regimens for pharmacologically maintaining 
remission for a given period of time. In both ALL and multiple myeloma, 
steroids are used in the remission-induction phase of treatment, as part of 
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multi-drug treatments. The structures of the synthetic glucocorticoids 
dexamethasone and prednisone, which are commonly used in the treatment 
of these leukaemias, as well as the structure of the endogenous glucocorticoid 
cortisol, are shown in Figure 1.11 for reference. 
 
 
In ALL, a synthetic glucocorticoid (typically either prednisone or 
dexamethasone) is combined with vincristine (a vinca alkaloid) and at least 
one other drug (such as asparaginase or an anthracycline) in the remission 
induction cocktail (Pui and Evans, 2006). Vincristine works by blocking the 
tubulin proteins of the mitotic spindle, preventing tubulin polymerisation and 
resulting in mitotic failure (New Zealand Medicines and Medical Devices 
Safety Authority, 2011). Asparaginase is an enzyme that metabolises 
circulating asparagine, which ALL cells are unable to synthesise sufficient 
quantities of, reducing the levels of asparagine in the blood and starving the 
ALL cells of the amino acid (Verma et al., 2007). Lastly, anthracyclines are 
Figure 1.11: The structures of (A) the steroid hormone cortisol, (B) the synthetic 
glucocorticoid prednisone, and (C) the synthetic glucocorticoid dexamethasone. 
Source: PubChem, National Library of Medicine (US Government). Released to 





cytotoxic antibiotics that exert their cytotoxic effects through various actions 
including inhibition of DNA synthesis, mutagenesis and inhibition of mitotic 
pathways (New Zealand Medicines and Medical Devices Safety Authority, 
2013). This drug cocktail may be repeated in so-called ‘reinduction’ therapy as 
part of an intensification phase of drug treatment, with a combination of 
methotrexate, mercaptopurine and asparaginase also used in this phase. 
Methotrexate is a folate analogue that interferes with purine synthesis (and 
thus interferes with DNA synthesis), while mercaptopurine is a purine 
analogue that also acts by interfering with DNA synthesis (New Zealand 
Medicines and Medical Devices Safety Authority, 2008; Pui and Evans, 2006). 
Continuation therapy for ALL usually lasts for greater than 24 months and 
uses a combination of methotrexate and mercaptopurine (Pui and Evans, 
2006). 
 
Glucocorticoids and DNA Methylation 
 
As mentioned, glucocorticoids classically act by affecting gene expression at a 
transcriptional level. There have been several studies that have suggested that 
this change in gene expression is associated with changes in DNA 
methylation after exposure to glucocorticoids. For example, changes in DNA 
methylation in certain genomic regions have been observed in guinea pigs 
exposed to glucocorticoids in utero compared with no glucocorticoid exposure 
(Crudo et al., 2012). In addition, chronic stress disorders, which present with 
raised plasma cortisol, are associated with changes in DNA methylation in 
neural cells, with some studies linking these methylation changes to 
glucocorticoid exposure (Hunter, 2012; Lee et al., 2010). It has also been 
shown that exposure to dexamethasone is associated with DNA methylation 
changes in neural stem cells (Bose et al., 2010). 
 
Among other studies suggesting methylation changes with glucocorticoids, 
dexamethasone exposure was linked with inhibition of C/EBPα (a pro-
adipogenic gene) promoter hypermethylation in glucocorticoid-related bone 
marrow adiposity (Li et al., 2013). Glucocorticoid exposure has also been 
found to be associated with reduced DNA methyltransferase 1 expression in 
pituitary adenoma cells, with resultant loss of genomic DNA methylation 
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(Yang et al., 2012). Dexamethasone exposure has been associated with 
increased methylation of the CRH promoter in neurons of the periventricular 
nucleus of the hypothalamus (an important site of control of the HPA axis), 
which is thought to be important in glucocorticoid-associated repression of 
CRH release from the hypothalamus (Sharma et al., 2013). Additionally, 
systemic glucocorticoid use in COPD patients has been associated with 
changes in DNA methylation throughout the genome (Wan et al., 2012). 
 
Furthermore, a series of experiments have been carried out by the Grange 
laboratory of the French Institut Jacques Monod du Centre National de la 
Recherche Scientifique demonstrating demethylation of CpG sites within the 
liver tyrosine aminotransferase gene (Tat) (the expression of which is 
regulated by glucocorticoids) that was associated with dexamethasone 
exposure (Kress et al., 2001). They observed demethylation of three CpG sites 
within the Tat GRE over 72 hours in rat hepatoma cell-lines (Thomassin et al., 
2001). Subsequent findings showed that this demethylation event was 
occurring as a result of an active mechanism, independent of DNA 
replication, and that there was evidence of DNA backbone cleavage during 
demethylation, which is possibly involved in the demethylation mechanism 
(Kress et al., 2006). 
 
Chromatin reorganisation is considered essential for the interactions between 
DNA and transcription factors, and the chromatin architecture is thus seen as 
key to the regulation of gene expression in general (Voss and Hager, 2014). 
Access to the DNA is essential for transcription factors to bind their target 
sequences and, therefore, to regulate gene expression, and it is through 
regulating access to the DNA that chromatin architecture is thought to 
influence gene expression (Voss and Hager, 2014). Like other transcription 
factors, there is evidence that GR binding to DNA requires ‘open’ or 
accessible chromatin, indicating that chromatin reorganisation is an essential 
prerequisite for direct GR/DNA interaction (John et al., 2011; Wiench et al., 
2011). Indeed, John et al. (2011) have argued that tissue-specific patterns of 
GR binding to DNA are primarily driven by differences in chromatin 
accessibility. It has been found that the GR receptor can bind to a GRE in open 
chromatin (as determined by digital DNase1 sensitivity studies) prior to 
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hormone exposure (this being found to be the case in 80% of GR binding sites 
as determined by ChIP sequencing) or in chromatin that is remodelled to an 
open configuration in response to hormone exposure (the remaining 20%) 
(John et al., 2011). Additionally, accessibility of chromatin is correlated with 
DNA methylation at the binding sites, with demethylated DNA correlated 
with open chromatin and methylated DNA correlated with closed chromatin 
(Wiench et al., 2011). Furthermore, in a region of GR binding (the GRE for the 
mouse Suox gene) where chromatin is remodelled (or opened) to allow the GR 
to bind to DNA, there was evidence of active DNA demethylation (Wiench et 
al., 2011). This demethylation event was reported to take place rapidly, with 
evidence of demethylation within 5 min of glucocorticoid exposure (Wiench 
et al., 2011). This time course is incompatible with a DNA replication-
dependent mode of demethylation and implies an active mechanism, similar 
to the implication of active demethylation at the Tat gene GRE (Kress et al., 
2006). These results imply that DNA methylation can be rapidly and actively 
altered, probably as part of the chromatin remodelling that is known to occur 
as part of the glucocorticoid response (Burd and Archer, 2013). Given that the 
results suggest active demethylation, there is also the possibility that TET-
mediated demethylation and associated DNA hydroxymethylation may play 
a role in the glucocorticoid response. 
 
On the basis of the evidence in the literature supporting the possibility of 
glucocorticoid-associated modification of DNA methylation, and the known 
biological effects of glucocorticoids on leukaemia cells, such as ALL and 
myeloma cells, I have hypothesised that glucocorticoids may modify DNA 
methylation in the setting of leukaemia. I have previously carried out a single 
genome-wide methylation analysis using RRBS to compare NALM-6 B-ALL 
cell-line cultured with or without the glucocorticoid dexamethasone. This 
experiment involved cell culture of NALM-6 cells for three days at 37°C and 
5% CO2 in RPMI with 4.5 g/L glucose 1 mM sodium pyruvate and 10% fetal 
calf serum for three days with either 250 ng/mL dexamethasone or no 
dexamethasone. The cells were counted and the growth curves are shown in 
Figure 1.12, indicating that the dexamethasone reduced the proliferation of 







The cells were then lysed to extract DNA after 72 hours in culture, and MspI 
digested DNA libraries were prepared for massively-parallel-sequencing to 
allow the (reduced) genome-wide methylation patterns of the two samples to 
be compared using the RRBS technique (described earlier). The results of this 
experiment, which will be considered in greater detail in chapter 3, were that 
there were 108 restriction fragments, meeting the experiment’s criteria for 
inclusion in the analysis, that showed a significant difference in methylation 
between the two samples (based on a 2-fold change in methylation, and a p-
value below the experimental threshold, as calculated using a Chi-squared 
test) of which 73 were in CpG islands and located in the promoter regions of 
genes, see Figure 1.13 (Foster, 2014). As such, this experiment supports the 
hypothesis that there are many significant changes in methylation occurring 






























Figure 1.12: Cell cultures of NALM-6 cells with dexamethasone at 250 
ng/mL vs. no dexamethasone. The graph shows the cell counts for each cell 





However, this single experiment leaves several questions to be answered. 
Firstly, the results of the experiment need to be shown to be reproducible, 
through repeating the same experiment, and allowing the methylation 
changes to be reliably characterised. This experiment also only examines the 
samples at the end of the 72-hour cell culture, giving no information on the 
kinetics of the changes in methylation. Lastly, the role of DNA 
hydroxymethylation within the context of dexamethasone-induced 
demethylation has not been explored. Therefore, this project will aim to build 
on these results to better characterise any changes in methylation associated 
with exposure to dexamethasone. 
 
















Figure 1.13: Statistical analysis of 2013 RRBS data comparing 
dexamethasone treated and untreated NALM-6 cells from Foster (2014), 
plotting the p value (on a negative logarithm axis) of differences 
(dexamethasone treated vs. control) between fragments meeting the 
inclusion criteria (ordered by chromosome number then position within 
chromosome). The dashed line indicates the Bonferroni-corrected 
significance threshold and the colours are based on chromosome numbers. 
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1.4 Aims of the Project 
 
Given the information presented in this chapter, this project will aim to: 
• Show that NALM-6 cells are affected in vitro by dexamethasone 
exposure. 
• Replicate my earlier experiment, as described in Foster (2014), to 
determine whether the methylation changes that were previously 
observed in NALM-6 cells can be shown in a separate experiment. 
• Use the results of this experiment, and my earlier experiment, to 
generate a list of areas of the NALM-6 genome with consistently 
significant changes in methylation after dexamethasone exposure. This 
will include a full analysis of the results, the sources of error and the 
internal validity of the studies. 
• Validate these changes with a separate (non-RRBS) method. 
• If time allows, examine these areas of the genome at various time 




2. Materials and Methods 
 
2.1 Cell Culture of Leukaemia Cell Lines 
 
NALM-6 Cell Culture 
 
NALM-6 is a B-ALL cell line with a diploid (46, XY) karyotype with a 
t(5;12)(q33.2;p13.2) translocation (Drexler, 2001; Hurwitz et al., 1979). This cell 
line expresses the B-cell antigen CD19 and the common lymphoid progenitor 
antigen CD10 (also known as the common ALL antigen) but does not express 
the mature B-cell antigens CD20 or CD21, consistent with the pre-B 
phenotype seen in B-ALL cells (Drexler, 2001). The Morison group acquired 
the NALM-6 cells used in this project from Associate Professor Richard Lock 
of the Children’s Cancer Institute, Australia.  
 
NALM-6 cells were thawed at 37°C from -80°C storage for cell culture 
experiments and transferred to RPMI liquid media with 4.5 g/L glucose and 
10% fetal calf serum. Cells were incubated at 37°C with 5% CO2	 and were 
kept in culture for a maximum of one month after thawing to prevent 
unacceptable genetic drift from the stock cells. All NALM-6 cell culture 
procedures (such as preparation of samples for flow cytometry, and changing 
of culture flasks) were carried out using sterile equipment in Class-II 
Biological Safety Cabinets, to avoid microbiological contamination of the cell 
cultures. 
 
Cell Culture with Dexamethasone 
 
Powdered dexamethasone (> 97% purity) was obtained from Sigma-Aldrich. 
This was dissolved in absolute ethanol, in sterile conditions, to give a 
concentration of 2 mg/mL. This dexamethasone solution was then added to 
cell culture media (as described above) to create a 20 %g/mL dexamethasone 
concentrate. For cell culture experiments with dexamethasone, the 20 %g/mL 
concentrate was added to the cell culture to give a final dexamethasone 
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concentration of 250 ng/mL (640 nM). Control cells received an equivalent 
amount of ethanol (125 nL/mL). 
 
Counting of Cells and Live/Dead staining by Flow Cytometry 
 
During all cell culture experiments, the concentration of cells in each 
experimental culture was determined using flow cytometry. For my 
experiments, the Beckmann-Coulter Gallios flow cytometer was used. 
 
To determine cell concentration by flow cytometry, calibration beads were 
acquired from Life Technologies. These synthetic beads have quite different 
physical properties to biological cells (either living or dead) and therefore 
have different patterns of light scatter as measured by the flow cytometer. The 
different scatter patterns of beads and (NALM-6) cells are shown in Figure 
2.1. Samples for flow cytometry were prepared by centrifuging 750 %L of the 
cell culture suspension to be counted and resuspending the cell pellet in 250 
%L of PBS. Fifty microlitres of calibration beads, with a pre-determined stock 
concentration of 1,040 beads/%L, were added to the cell suspension. The 
300 %L sample could then be analysed by the flow cytometer, which recorded 
the forward scatter (FS) and side scatter (SS) for each particle (cell or bead) for 
35,000 particles in the suspension. These data could then be used to determine 
the proportion of particles that are beads or cells. As the concentration of 
beads in the sample is known, the concentration of cells in the original cell 




 where Ccells(culture) is the cell 
concentration of the cell culture, ncells( flow)  is the number of particles (of the 
35,000 total counts) that are cells (rather than beads), nbeads( flow) is the number of 
particles (of the 35000 counted) that are beads, Cbeads( flowsample)  is the 
concentration of beads in the flow cytometer sample (173.3 beads/%L), 
Vflowsample  is the volume of the flow cytometer sample (300 %L) and Vculture  is the 
volume of the cell culture spun down to be resuspended in PBS (750 %L). This 
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equation can also be expressed as Ccells(culture) = k
pcells
1− pcells
 where pcells  is the 
proportion of all particles that are cells and k = Cbeads( flowsample).Vflowsample
Vculture
= 69.32 . 
 
 
To determine if cells were alive or dead, the cell viability fluorescent dye 
7AAD was used to fluorescently mark dead cells. Cells were centrifuged at 
250×g for 5 min, the supernatant was discarded and they were incubated for 
30 min with 0.5 %L of 7AAD solution after resuspension in PBS (before 
addition of calibration beads). This dye binds to dsDNA, but is completely 
excluded from living cells; thus it will fluorescently dye the DNA of dead 
cells (see Figure 2.3 and Schmid et al., 1992). Electrons within the 7AAD 




















Figure 2.1: Example plot of Side Scatter (SS) and Forward Scatter (FS) of laser 
light, as measured by the Gallios flow cytometer, for a sample containing 
NALM-6 cells and calibration beads. Each particle in the sample is plotted as 
a single dot by the Gallios, with colours indicating the density of plotted 
particles. This plot demonstrates that beads (A) scatter light differently from 




molecule are excited by the 488 nm wavelength (blue) laser of the flow 
cytometer and will emit photons at 600-800 nm (far-red) wavelengths, see 
Figure 2.3 (Schmid et al., 1992). The flow cytometer could, therefore, detect 
dead cells based on positive 7AAD fluorescence. The fluorescent cut-off for 
classifying cells as dead was determined by staining a mixture of live and 






The FlowJo software package (Tree Star), and the flowCore R package (Hahne 
et al., 2009) were used for analysis of flow cytometry data (e.g. gating 
live/dead cells based on 7AAD staining or determining bead vs. cell 
populations), and for generating graphs of these data (such as Figures 2.1 and 
2.2). Any downstream statistical analyses of the data were then performed 
using R (R Core Team, 2014). 
 






FL4 INT LOG: FL4 INT LOG
25.5
Figure 2.2: Flow cytometric assessment of cell viability. Example 
histogram of event frequency over 7AAD fluorescence, labelled FL4 (log 
scale). The peak labelled (A) shows live cells that are 7AAD negative, 
while the shifted peak (B) shows dead cells (7AAD positive). These peaks 
were used to set the live/dead gate (shown). 
A B 
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Cell Proliferation Studies Using Flow Cytometry 
 
In cell culture experiments where the proliferation of cells was determined, 
the proliferation dye CFSE was used. Before the start of the experiment, the 
cells were counted by flow cytometry to determine their concentration. The 
cells were then spun down at 250×g for 5 min and the supernatant was 
discarded. The cells were then resuspended at 2×107 cells/mL in PBS, an 
equal volume of 5 mM CFSE in PBS was added and the cells were incubated 
for 8 min at room temperature. FCS was then added to quench the dye before 
the cells were washed in RPMI media three times. 
 
CFSE is a fluorescent dye that stains the existing cytoplasmic components of 
the starting cells to be used in the cell proliferation experiment. As the cells 
make new cytoplasmic components in order to divide, the fluorescent 
cytoplasmic components get ‘washed out’ by newly synthesised (and 
therefore unstained) cytoplasmic components. As the cells maintain an 
approximately constant mean cell volume, this means that cellular 
fluorescence will halve on average at each cell division. Therefore, by 
measuring cell fluorescence by flow cytometry, it is possible to determine 
how many cell divisions a cell has undergone after the start of the experiment. 
As CFSE (excited by the Gallios’ FL1 laser) has a different emission spectrum 
to 7-AAD (excited by the Gallios’ FL4 laser), and as the calibration beads do 
not rely on fluorescence, this technique could be combined with cell counting 
and live/dead determination using flow cytometry, as described. Figure 2.3 
shows the excitation and emission spectra for 7-AAD and CFSE. Both dyes are 






2.2 Collection of Other Biological Samples 
 
Collection of Human Blood 
 
All human venous blood samples were acquired using BD sterile needles and 
BD Vacutainer blood tubes (BD), with sodium heparin or EDTA used as the 
tube anticoagulant. 
 
DNA Extraction from Biological Samples 
 
In preparation for DNA extraction, cell-culture samples (from cell lines or 
purified lymphocytes) were centrifuged at 350×g for 5 min and the 
supernatant discarded. Whole-genomic DNA extraction from cell pellets was 
carried out using the QIAamp DNA Blood Mini Kit (QIAGEN), according to 
the manufacturer’s instructions except that DNA was eluted in 100 %L elution 
buffer, instead of 200 %L, to increase DNA sample concentration. This kit was 
also used with the same protocol to extract DNA from cell-culture to prepare 
samples for Sequenom mass-spectrometry analysis. No more than 107 cells 
Figure 2.3: Emission (solid lines) and excitation (dashed lines) spectra for 7-




were fed through a single DNA binding column, to ensure that the binding 
capacity of the columns was not exceeded. 
 
DNA extraction from whole blood involved mixing 1 part blood to 9 parts 
0.17 M NH4Cl, to lyse the red blood cells, relying on the fact that red blood 
cells are more susceptible to hypotonic shock than other blood cells. This 
suspension was centrifuged at 2000 rpm for 8 min and the supernatant 
discarded. The cell pellets were then suspended in 2 mL lysis buffer and 
incubated overnight at 37°C with 20 U/%L proteinase K.  
 
One millilitre of chloroform, at -20°C, was then mixed with the sample, the 
resultant mixture was centrifuged at 2000 rpm for eight minutes, and the 
aqueous layer was taken. 
 
The DNA was precipitated by adding 200 %L of 3 M NaOAc and 4 mL of 
100% ethanol, and the resultant suspension was centrifuged at 2000 rpm for 
eight minutes. The supernatant was then drained without disturbing the 
DNA precipitate, the DNA was washed in 70% ethanol, and it was then re-
spun. The supernatant was drained and residual ethanol was allowed to 
evaporate before the DNA precipitate was resuspended in 400 %L TE. 
 
After extraction, the approximate DNA concentration was determined 
spectrophotometrically using the ND-1000 spectrophotometer (NanoDrop). 
 
2.3 Analyses of DNA Methylation 
 
Preparation of Bisulphite-Converted DNA Libraries for RRBS 
 
The method used for RRBS library preparation was a modified version of the 
method described by Chatterjee et al. (2012), developed by Dr Euan Rodger 
(Department of Pathology, University of Otago). For each library, 2.5 %g of 
purified genomic DNA was incubated in with MspI (20 U/%L) and 10% NEB 
Buffer-4 (Illumina) overnight at 37°C. This incubation, and all subsequent 
temperature-sensitive incubations were carried out using the Bio-Rad 
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DNAEngine Peltier Thermal Cycler (Bio-Rad Laboratories). The digested 
DNA was then recovered using the QIAquick PCR Purification Kit 
(QIAGEN), according to manufacturer’s instructions except that the DNA 
was eluted from the QIAquick spin column in 60 %L of elution buffer. 
 
To repair the ‘sticky’ overhanging ends present after MspI digestion of the 
DNA, end repair was carried out on the fragments by incubating the 60 %L 
purified DNA with 40 %L of the TruSeq DNA Sample Preparation Kit’s end 
repair solution (Illumina) for 30 min at 30°C. The DNA was subsequently 
purified using the MinElute PCR Purification Kit (QIAGEN), used according 
to the manufacturer’s instructions except that the DNA was eluted from the 
MinElute spin column in 17.5 %L of elution buffer. 
 
Poly-A tails were then added to the 3’ end of the DNA fragments, carried out 
by incubating the 17.5 %L DNA fragment sample with 12.5 %L of the TruSeq 
DNA Sample Preparation Kit’s A-tailing mix (Illumina) for 30 min at 37°C. 
Subsequently, an adaptor sequence was ligated to the DNA fragments. A 
unique sequence was used for each library, allowing each sample to be 
uniquely identified when up to four libraries were run on a single sequencing 
lane of the flow cell of the Illumina HiSeq 2000 sequencer. For the RRBS 
libraries prepared from NALM-6 cell culture with or without 250 ng/mL 
dexamethasone, the control library had adaptor number 005 ligated, while the 
dexamethasone treated library had adaptor number 019 ligated. Adaptors 
were ligated by incubating the 30 %L DNA fragment sample from poly-A 
tailing with 2.5 %L of the TruSeq DNA adaptor (Illumina), 2.5 %L TruSeq 
ligase mix (Illumina) and 2.5 %L QIAquick elution buffer (QIAGEN) for 10 
min at 30°C. Following adaptor ligation, the DNA fragments were recovered 
using AMPure XP magnetic beads (Agincourt, Beckmann-Coulter). These 
magnetic beads bind to DNA, allowing the DNA fragments to be separated 
from the supernatant on a magnetic stand. The DNA was then eluted in 18 %L 
TE buffer. 
 
The purified DNA fragments were then electrophoresed at 50 V for 90 min in 
a 3% NuSeive (Lonza) low-melting-point agarose gel (after the addition of 
2 %L of loading buffer to each sample), along with a 25 bp marker 
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(Invitrogen). This marker was used as a guide to excise fragments of 150-325 
bp which correspond to lengths of 40-220 bp prior to adenylation and adaptor 
ligation. Unfortunately, the marker was poorly resolved in the initial size 
selection (see Figure 2.4), so fragments were excised between the brighter 125 
and 500 bp bands of the marker, and the second size selection was relied 
upon to select the correct fragment lengths. The DNA fragments were then 
purified from the excised gel sections using the QIAquick Gel Extraction Kit 






The purified DNA fragments were then bisulphite converted using the 
ZymoTech EZ DNA Methylation Kit (Zymo Research), according to the 
manufacturer’s instructions except that the bisulphite converted DNA was 
eluted in 20 %L. This step converted all unmethylated cytosines to uracil 
(which were replaced by thiamine in the subsequent PCR step) but did not 
convert methylated cytosines, allowing the position of all methylated 
cytosines to be determined by comparison to the known human genome 
sequence. 
 
Figure 2.4: NuSeive gel after excision of fragments between 125 and 500 bp 
(‘bright’ bands of the 25 bp marker lanes, indicated with arrows). Lanes are 
labelled (M) for marker, (D) for dexamethasone treated sample and (C) for 
control sample. 
M C D M
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After bisulphite conversion, the DNA fragments were amplified by PCR. To 
determine the number of cycles to use for the PCR reaction, small scale ‘semi-
quantitative’ PCR was used to test the amplification of the fragments at 18 
and 22 cycles (shown in Figure 2.4). The PCR reactions were carried out in 
12 %L volumes, containing 1.2 %L 10× PhuTurbo Cx Reaction Buffer 
(Stratagene), 0.55 %L PfuTurbo Cx HotStart DNA Polymerase (Stratagene), 2 
%L TruSeq Primer Cocktail (Illumina), 1.25 %L dNTPs (2.5 mM), 1.25 %L 
bisulphite converted DNA and the remaining volume Milli-Q water, and the 
cycling conditions were 95°C for 2 min followed by cycles of 95°C for 30 s, 
65°C for 30 s and 72°C for 45 s then a cool down of 72°C for 5 min. The PCR 
products were then run on a NuSeive gel (Lonza) for 90 min at 50 V. The gel 
image for this semi-quantitative PCR is shown in Figure 2.5, and on the basis 
of this experiment, it was decided that the bulk of the DNA fragments should 
be amplified for 20 PCR cycles, under the same cycling conditions. The 
reactions were carried out in 8 tubes per sample, each containing 12 %L of the 
PCR master mix. The master mix contained 10 %L 10× PhuTurbo Cx Reaction 
Buffer (Stratagene), 12 %L dNTPs (2.5 mM), 8 %L TruSeq Primer Cocktail 
(Illumina), 12 %L bisulphite converted DNA 4.8 %L PhuTurbo Cx HotStart 





Figure 2.5: NuSeive gel showing product of semi-quantitative PCR. From 
left, the lanes are 25 bp ladder, control library at 18 cycles, dexamethasone 
treated library at 18 cycles, control library at 22 cycles, dexamethasone 
treated library at 22 cycles. Arrows indicate the 125 bp (below) and 500 bp 
bands. 
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Following this PCR reaction, the PCR products were run on a 3% NuSeive 
agarose gel (Lonza) for 90 min at 50 V, along with 25 bp marker (Invitrogen). 
Following this gel electrophoresis step, the primary size selection was 
repeated, and fragments between 150 and 325 bp were cut out of the gel (this 
corresponds to pre-adenylation and pre-adaptor-ligation lengths of 
approximately 40-220 bp). The gel excisions are shown in Figure 2.6. DNA 
fragments were then purified from the excised gel sections using the 
MinElute Gel Extraction Kit (QIAGEN), according to the manufacturer’s 
instructions. The purified fragments were then sent to the Otago Genomics 
and Bioinformatics Facility (Department of Biochemistry, University of 
Otago) for quality control and quantification of library fragment 






Preparation of Sequenom MassArray Samples 
 
PCR primers for the promoter regions of PTPRS, LY6E, CEP70, IL15, 
CRISPLD1, RAB31 and CTHRC1 were designed using the Sequenom 
EpiDesigner website (http://www.epidesigner.com/) and ordered from IDT. 
Figure 2.6: NuSeive gel after second size selection for fragments between 
150 and 325 bp. Lanes are, from left, control library, dexamethasone treated 
library, 25 bp ladder. The arrow indicates the 125 bp band. 
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These genes were chosen to validate the RRBS results presented in Chapter 3, 
and were selected as they contain or are very close to MspI fragments that 
showed statistical significance and a > 50% absolute methylation change by 
RRBS (see Chapter 3). They also met the > 50 read threshold that was found to 
be essential for tight RRBS validation (see Chapter 1). Additionally, IL15 
prevents apoptosis and promotes proliferation in lymphocytes (Mishra et al., 
2014; Bulphone-Paus et al., 1997), RAB31 is overexpressed in several human 
cancers (Chua et al., 2015) and CTHRC1 expression has been associated with 
poor prognosis in lung cancer (Ke et al., 2014). 
 
The primer sequences are shown in Table 2.1 and contain tails that are 
important for the Sequenom analysis, by providing known flanking regions 
either side of the amplicon. These primers were then optimised using whole 
peripheral blood DNA, before product was generated from DNA from 4 
separate cell culture experiments (giving 4 samples from cells treated with 






















Table 2.1: Table of primer sequences for each of the genes chosen for validation. Two 
regions near the start of PTPRS and LY6E were chosen and the lower case letters 







PCR product was generated in a PCR reaction containing 5 %L Kappa HiFi 
Uracil+ ReadyMix (Kappa Biosystems), 1 %L of each of the forward and 
reverse primers, 1 %L bisulphite converted DNA and 2 %L RNase-free water. 
Cycling conditions for the reactions were 94°C for 10 min, then 40 cycles of 
94°C for 30 s, 60°C for 30 s and 72°C for 1 min, followed by 5 min at 72°C and 
storage at 4°C. A gel showing the PCR product for the bisulphite-converted 
whole peripheral blood is also shown in Figure 2.7. The whole peripheral 
blood DNA was extracted as described earlier and bisulphite-converted using 
the Zymo EZ DNA Methylation-Gold Kit (Zymo Technologies), according to 
the manufacturer’s instructions. 
 
To ensure that product was generated for each of the 8 DNA samples for each 
gene, half the PCR product was run on a 2% agarose gel for 25 min at 100 V 
and the other half was kept to send to the Liggins Institute of the University 
of Auckland. The gels for each of the eight samples are presented in Figure 
2.8. 
  
Figure 2.7: Ethidium bromide stained PCR product from bisulphite-
converted whole peripheral blood DNA using the Sequenom primers, 
run on a 2% agarose gel. The lanes are, from left, 100 bp ladder (bottom 
band is 100 bp), LY6E1 primers, RAB31 primers, CEP70 primers, LY6E2 
primers, ladder, ladder, IL-15 primers, PTPRS1 primers (no product), 









Given that CTHRC1 and PTPRS1 apparently failed to amplify any product, 
they were not included in the samples sent for analysis, PTPRS1 was also not 
included as it failed to amplify product with whole-blood template.  
Figure 2.8: Gels showing the 8 samples (4 control, 4 dexamethasone-treated) 
amplified using each of the primer sets (labelled), one control and one 
dexamethasone sample ran out while preparing samples; therefore, some 
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2.4 Statistical and Computational Techniques 
 
General Computer Programming 
 
Unless specifically stated (e.g., for computing procedures carried out by 
DMAP), all computer scripts were written from scratch. Computer scripts and 
programs were written in the R or Python programming languages, which are 
freely distributed under the GNU Public Licences (GPL) 2 and 3 and Python 
Software Foundation (GPL compatible) open source software licences. 
 
In addition to defining novel functionality, computer scripts written during 
this project often made use of Python or R packages that were freely 
distributed. These include packages of the Python and R standard libraries, as 
well as the third party rpy2, data.table, geepack, boss and plotrix packages 
(Dowle et al.; Halekoh et al., 2006; Lemon et al., 2007; Voorman et al., 2012). 
All of these packages were distributed under open source licences. 
 
Data Processing of FastQ Sequencing Files from RRBS 
 
As up to four DNA libraries were multiplexed to a single lane of the Illumina 
HiSeq 2500 (Illumina) for the sequencing step of RRBS, the sequencing data 
were demultiplexed by NZGL (i.e., sorted into the samples to which the 
belonged) based on the ligated DNA adaptor sequences. The sequencing data 
were then returned in the form of zipped FastQ sequencing files and 
associated fast quality control (FastQC) data (Babraham Bioinformatics, 2015). 
 
The HiSeq 2500 sequencer returned a large number of 100 bp (or fewer, if the 
fragment is less than 100 bp) reads from the DNA fragments. The sequencing 
was ‘paired-end’; therefore, sequences could be sense or antisense. The fast-
QC files contained an analysis of all of the 100 bp sequences and returned the 
average sequence quality at each base position in the read. The sequence 
quality tends to decrease as base position increases. Additionally, the RRBS 
sequence quality tends to be lower than what would be expected from normal 
genomic libraries, due to the bisulphite conversion step. The fast-QC analyses 
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for the libraries are shown in Figure 2.9 and display the Phred Quality scores 
at each base position. The Phred scores are calculated such that Q = −10 log(P)
where Q is the Phred score and P is the probability of a base-calling error 
(such that a score of 10 would give a 90% accuracy rate, a score of 20 would 






On the basis of these results, it was decided to disregard sequences after 95 bp 
for the control library and 90 bp for the dexamethasone treated library to 
maintain acceptable sequence quality (known as quality trimming). This and 
Figure 2.9: Box-and-whisker plots of Phred score base-calling quality, by 
base position, for (above) the control library and (below) the 
dexamethasone-treated library. The lines are the mean quality. 
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all subsequent data processing steps were carried out using the dsm2864 
remote server (run by the Dunedin School of Medicine) using Mac Terminal 
(Bash) commands. These commands were carried out as described in 
‘Processing RRBS samples: a User Guide’ (Stockwell, 2013), with the 
commands concatenated into a Bash script (using the Nano built-in text editor 
on Mac OSX) to be run automatically.  
 
These commands used the Bismark alignment program (Babraham Institute) 
to remove the adaptor sequences (used to de-multiplex the sample libraries) 
and map the reads against the (bisulphite converted) GRCh37/hg19 reference 
human genome (Kruger & Andrews, 2011). They returned mapped sequence 
files in the ‘.sam’ format, which were used in the downstream analyses. The 
mapping efficiencies (i.e., the proportion of reads that could be successfully 
mapped to the human genome) for each library are shown in Table 2.2. 
 
Table 2.2: Mapping statistics for the RRBS Libraries. 
Sample Reads Mapped Efficiency (%) 
Control 27403967 20843391 76.1 
Dexamethasone  30221190 15915315 52.7 
 
 
The data files were then sent to Dr Aniruddha Chatterjee (Department of 
Pathology, University of Otago) and Dr Peter Stockwell (Department of 
Biochemistry, University of Otago) for systematic analysis using the DMAP 
software package, described by Stockwell et al. (2014). This software package 
returned a number of files containing the statistics on counts of methylated 
and unmethylated CpG sites within the reads mapped to each MspI fragment, 
the position of each fragment, and the fragment’s relationship to nearby genes 
and CpG islands. The DMAP software was also able to use a Fisher’s exact 
test to compare fragments between libraries (as described later in this section). 
The required data from different output files could then be grouped into a 
single file using Python scripting (scripts available on request). 
 
As discussed in Chapter 3, the results from the DMAP analysis suggested that 
this software package might produce an unacceptable rate of type-1 error; 
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however, this DMAP analysis does represent the current standard of RRBS 




Basic Statistical Techniques 
 
Several experiments in this project produced binary results. This includes the 
counting of cell culture concentrations by flow cytometry (the cytometer 
could either call a particle a bead or a cell), live/dead determination by flow 
cytometry (the cytometer could either call a cell live or dead) and RRBS (each 
sequencing read could call a CpG methylated or unmethylated). For all of 
these techniques, the raw ‘success vs. failure’ data were available from the 
experiment and the experimental result was based on the proportion of 
successes.  
 
Where appropriate, the 95% confidence intervals of the proportion are given 
with the results for these experiments. These results are based on the Clopper-
Pearson (or ‘exact’) method for calculating the confidence interval of the 
proportion, unless otherwise stated, as described by Clopper and Pearson 
(1934). These confidence intervals were calculated automatically in R using 
the binom.test function in the ‘stats’ package (included in the standard 
distribution of R) (R Core Team, 2014). When cell counts were calculated, 
using proportions of cells, with the equation Ccells(culture) = k
pcells
1− pcells
 (see earlier), 
where k = Cbeads( flowsample).Vflowsample
Vculture
. The value of k was assumed to have 
negligible error as the bead concentration was commercially determined, 
while volumes were determined using calibrated pipettes and the confidence 
intervals were calculated using the 95% confidence intervals of the 
proportion. 
 
For comparing two sets of binary data (such as comparing dexamethasone-
treated against control libraries from RRBS), the Chi-squared test was used. 
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For RRBS libraries, the MspI fragments (created by MspI digestion) were used 
as the basic unit of analysis. The same fragments were compared between the 
dexamethasone-treated and control libraries, with the basic binary datum 
being whether the CpGs within the fragment were methylated or 
unmethylated. For the analysis, each CpG in each read (a read being a single 
sequence returned from the Illumina sequencer) that mapped within the 
fragment was used as an independent datum. The fragments, with their series 
of methylated or unmethylated CpGs were then compared between samples 
using a Fisher’s exact test (for two sample analysis) or Chi-squared test 
(otherwise). This is the same statistical procedure previously described for 
genome-wide methylation analyses by Chatterjee et al. (2012) and Li et al. 
(2010). This test was carried out as part of the data analysis by the DMAP 
software. 
 
When mean values of a variable were reported (e.g., mean fluorescence in a 
sample from a cell-culture), they were shown with the 95% confidence 
intervals of the mean, unless otherwise stated. The 95% confidence interval 
was calculated using the formula CI = X ± t97.5
s
n
, where X  is the sample 
mean, s is the standard deviation of the sample, t97.5  is the 97.5 percentile of 
the appropriate t distribution and n is the sample size. If two means were 
compared directly, a Student’s (pooled variance) t-test was used if there was a 
less than 2-fold difference in the standard deviations of the two samples; 
otherwise, Welch’s t-test was used (unless otherwise stated). 
 
When linear or logistic regression was used (as a model or to add a graphical 
trend line), the regression models were calculated automatically using R. In 
general, linear regression was used when the effect of a variable or variables 
on a continuous outcome was modelled, while logistic regression was used 
for binary outcomes. For linear regression models, the lm function was used 
with the syntax model<-lm(outcome ~ variable1 + variable2 + … 
+ variableN), while logistic regression models were calculated using the 
glm function with the syntax model<-glm(outcome ~ variable1 + 
variable2 + … + variableN, family=’binomial’), both of these 
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functions are in the ‘stats’ package of the basic R distribution (R Core Team, 
2014).  
 
RRBS and Binomially-Distributed Data 
 
As the currently available analyses of RRBS data assume that the data are 
distributed binomially, an understanding of the nature of these data is 
important. Based on placental data validating methylation determined by 
RRBS by using Sequenom, it was shown that at least 50 data points were 
required to give good correlation between the methylation of 1,944 individual 
CpGs determined by RRBS against methylation determined by Sequenom. 
The statistical analyses of these data were undertaken by myself, Dr Matt 
Parry (Department of Mathematics and Statistics, University of Otago) and Dr 
Aniruddha Chatterjee (Department of Pathology, University of Otago), while 
all the experiments and experimental design involved in generating the raw 
data were carried out by Ingrid Knarston (Department of Pathology, 
University of Otago) and Dr Erin Macaulay (Department of Pathology, 
University of Otago).  
 
This 50-point cut-off is a much more stringent cut-off than many previous 
studies, which suggest cut-offs of ~10-20 data points (Ziller et al., 2014). Using 
a 50-point threshold, the r2 for a linear regression model investigating the 
association between the two techniques was 0.62, compared to a 10-point 
threshold, where it was 0.37; see Figures 1.4 and 1.5 (for both linear models, p 
< 2.2e-16  based on an F-test, with the null hypothesis that the true slope of the 
fitted line is zero). However, even the 50-point cut-off shows considerable 
deviation from the Sequenom value. Therefore, we conclude that greater than 
50 read coverage is required before RRBS can call the methylation of a single 



























Figure 1.4: Plot of the methylation of studied single CpGs in the placental 
genome, as measured by RRBS and Sequenom. Data points are those CpGs 
for which > 50 trials (i.e., sequences) are available and the line is the fitted 







In theory, using 50 data points would mean that RRBS could determine the 
methylation of a single CpG site with a true whole-sample methylation of 0.5 
to within 0.15 of the true value 95% of the time. This calculation is based on 
the binomial distribution and is affected by the true methylation of a CpG site 
as well as the number of trials (i.e., the number of data points) in a sample. 
Figures 1.6, 1.7 and 1.8 illustrate this point by showing the theoretical 
probabilities of getting a > 5%, > 10%, > 20% and > 30% difference from a true 
























Figure 1.5: Plot of the methylation of studied single CpGs in the placental 
genome, as measured by RRBS and Sequenom. Data points are those CpGs 
for which > 10 trials (i.e., sequences) are available and the line is the fitted 
linear regression model. 
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methylation value of 10%, 50% and 70% against the number of reads available 
for that CpG site using RRBS. These figures show that even at 50 reads depth 
there is a considerable chance of a > 10% deviation from the true methylation 
value by chance, and raises serious doubts about any methylation value 
reported with 20 or fewer reads. These plots were generated by creating an R 
script that made use of the dbinom function (i.e., using the binomial 
probability mass function).  
 
In the context of a comparison between two proportions (such as when 
comparing dexamethasone treated and control RRBS libraries), 50 data-point 
samples would enable a Cohen’s proportion effect size of h = 0.6 or greater to 
be detected with 85% power, where h is defined by 
h = 2.arcsin P1 − 2.arcsin P2 , where P1  and P2  are the true methylation 
values (as a proportion) of the two populations being sampled. This 
transformation accounts for the fact that binomial techniques have greater 
power to detect a proportion difference of a given magnitude when values are 
closer to 0 or 1 as opposed to when values are closer to 0.5 (Cohen, 1988). 
Figure 1.9 shows all the values of P1  and P2  that will result in h = 0.6; note 
that this relationship will break down as the curve nears the point where 
P1 = P2  (where true power will be 0% rather than 85%). The shape of this curve 
is important as it reflects the fact that, even at the relatively high RRBS 
coverage of ≥ 50 data-points, there is a limitation in the methylation 
differences that can be detected by RRBS, which is in the range of what may 
be biologically important (particularly where methylation is close to 0.5). 
 
Of course, these assumptions are based on single CpG sites, while the DMAP 
software of Stockwell et al. (2014) (the Morison lab’s current RRBS analysis 
package) compares genomic regions (i.e., 40-220 bp MspI fragments) 
containing several CpG sites. In theory, this greatly increases power as there 
are many more CpGs observed within a region. Using this approach, many 
regions will have very high CpG counts, making any methylation differences 
between samples much more likely to be significant. It should be pointed out, 
however, that this region-based analysis assumes that methylation 
observations from sequenced CpGs are all independent of each other; 
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however, this assumption does not appear to have been tested when the 
standard RRBS analysis packages (including DMAP) were developed, and it 
is challenged later in this thesis (see Chapter 3). 
 
Overall, the main message of this subsection is that there is potential for type-
2 error (i.e., missing a true methylation difference) in this project’s study 
design (and by extension, other RRBS or WGBS based studies as well), 
especially as a great many fragments sequenced in an RRBS library fall short 
of the 50 reads threshold assumed above. It is also clear that stringent read-
depth criteria need to be applied before one can have confidence in reporting 
the methylation of a CpG site within a biological sample. These limitations 
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Figure 1.6: Probabilities of a > 5% (pink), > 10% (black), > 20% (red) 
and > 30% (green) difference from a true methylation value of 0.1 
(or 10% methylation) at different read numbers (i.e., numbers of 
data points). 
Figure 1.7: Probabilities of a > 5% (pink), > 10% (black), > 20% (red) and 
> 30% (green) difference from a true methylation value of 0.5 (or 50% 
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Figure 1.8: Probabilities of a > 5% (pink), > 10% (black), > 20% (red) and 
> 30% (green) difference from a true methylation value of 0.7 (or 70% 
methylation) at different read numbers (i.e., numbers of data points). 
Figure 1.9: Curve of  and  values theoretically detectable with 85% 





Development of Novel Methylation Graphics Software 
 
As RRBS (and its bigger sister, whole-genome-bisulphite-sequencing) are 
bisulphite sequencing based, they give single CpG resolution of the 
methylation pattern in the areas of the genome where there is coverage (as 
has been stated previously). Additionally, many RRBS or WGBS studies aim 
to identify small areas of the genome (e.g., single gene promoter regions) 
where the methylation pattern is of interest (e.g., differentially methylated 
promoter regions). Therefore, there is a need to display RRBS or WBGS data 
from small regions of the genome, at single-CpG resolution, in order to 
demonstrate methylation differences or other features of interest. 
 
In traditional single-gene methylation studies, so-called ‘lollipop plots’ are a 
popular way of displaying such data for small regions of the genome and are 
widely used in publications (Kuang et al., 2013; Pancione et al., 2010; Weeks et 
al., 2010). They display each CpG as a circle, which can be filled in black to 
indicate that it is methylated or unfilled to indicate that it is unmethylated. 
Multiple reads (e.g., multiple sequenced clones, multiple PCR sequences or 
multiple next-generation-sequencing reads) are stacked on top of each other 
to show the sequencing depth for the region, while individual CpGs within a 
read are laid out horizontally either stacked (to give a matrix of circles) or 
separated by an amount of whitespace that is proportional to the genomic 
distance between the sites (see Figure 2.11 for an example). 
 
There exist already several tools to produce such plots, such as the Internet 
application QUMA (Kumaki et al., 2008) and the R package MethVisual 
(Zackay and Steinhoff, 2010); however, these take sequence input in the 
FASTA format (the standard small-scale sequencing format). In contrast, 
RRBS and WGBS studies produce FASTQ format sequencing files, which are 
processed to SAM files, containing the mapping location and (if they have 
been produced by the Bismark platform) CpG methylation status. While it is 
possible to produce FASTA data from SAM files and provide a reference 
sequence from the reference genome files, it would be easier and more 
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efficient to be able to produce lollipop plots of small genomic areas by directly 
using the SAM file as the input data. 
 
Therefore, I developed a program that would read SAM files to produce these 
plots for a defined genomic area. The program was written in Python and R, 
with Python used for manipulation of the SAM file and to build a text-prompt 
based command-line-interface while the graphics capabilities of R were used 
to actually produce the plots. The program consists of three scripts, which 
have to be copied to the same directory as the SAM file. The program can 
then be launched from the command line by navigating to the file directory 
and giving the command python3.3 filemaker.py.  
 
The use of text prompts makes the program generalizable and user friendly, 
as shown in Figure 2.10. The scripts also achieve good performance, 
considering the size of the SAM files that they read (often 10 GB or more). The 
program can generally produce a plot in PDF format in less than five minutes 
on an iMac desktop computer with a 2.7 GHz Intel Core i5 processor and 8 
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● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ●
● ● ● ●● ● ● ● ● ● ● ● ●●● ●
● ●● ● ● ● ● ● ● ● ●●● ● ● ●
● ●● ● ● ● ● ● ● ● ●●● ● ● ●
● ●● ● ● ● ● ● ● ● ●●● ● ● ●
● ● ● ● ● ● ● ●●● ● ● ● ● ● ●
● ●●● ● ●
● ●●● ● ●
● ●●● ● ●
● ●●● ● ●
● ●●● ● ●
● ●●● ● ●
● ●●● ● ●
● ●●● ● ●
● ●●● ● ●
● ●●● ● ●
● ●●● ● ●
Figure 2.11: Example lollipop output from a SAM file with Bismark 
methylation calling. The region is chr12: 569481-569554. 
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R Package Development 
 
Convenience functions to allow more sophisticated RRBS analyses than those 
currently used (see Chapter 3) were bundled into an R package, MPBSgee. 
This package was written entirely in the R language, and critically depends 
on the data.table, geepack, boss and stats R packages. The techniques for 
bundling the appropriate code into a package, installing the package and 
building compressed distribution files were taken from Leisch (2009). The .R 
and .Rd source files and documentation files (respectively) were written using 
the R GUI for Mac OSX (Urbanek, 2014), while the DESCRIPTION and 
NAMESPACE files were written using the Nano built-in command line text 
editor in Mac OSX (Mavericks). 
 
Details on the contents of the package are discussed in Chapter 3; both the 
package and a package vignette are available on request. The package has a 







As outlined in Chapter 1, this project aimed to determine whether exposure to 
dexamethasone is associated with measureable changes in DNA methylation 
across the genome of ALL blasts. For convenience, I chose to carry out 
experiments measuring methylation after dexamethasone exposure using the 
NALM-6 ALL cell-line, as described in Chapter 2.  
 
The experiments carried out in this project can be divided into three, based on 
their primary aims. Firstly, experiments were carried out to show that 
NALM-6 cells display a measureable response to exposure to dexamethasone. 
Secondly, experiments were carried out to measure DNA methylation across 
the NALM-6 genome using RRBS, and to compare the methylation of cells 
that were exposed to dexamethasone to cells that were not exposed to the 
drug. Lastly, experiments were carried out to validate the differences found 
between dexamethasone treated cells and untreated cells using a different 
technique (Sequenom MassArray). As such, the organisation of this chapter 
reflects the primary aims of the experiments that were carried out, with 
experiments establishing a phenotypic response to dexamethasone presented 
first, then genome-wide methylation differences between dexamethasone 
treated and untreated NALM-6 cells; and lastly, validation of methylation 
differences. 
 
This chapter also demonstrates that problems exist when using conventional 
statistical techniques to analyse differences in methylation detected by RRBS. 
These problems exist with a variety of simple statistical techniques, including 
the use of the Chi-squared test or Fisher’s exact test, which are employed by 
DMAP, the Morison lab’s current methylation analysis tool (Stockwell et 
al., 2014). These problems arise from ‘within-read correlation’, a problem that 
is presented in this chapter. This chapter further outlines an alternative 
statistical analysis that overcomes many of the weaknesses identified with 
simple statistical analyses. Given that this statistical approach was developed 
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to analyse genome-wide methylation by RRBS, the statistical material is 
presented with the RRBS results in this chapter. 
 
3.2 Cell Culture with Dexamethasone: Phenotypic response. 
 
Multiple cell-culture experiments with 250 ng/mL dexamethasone showed 
that NALM-6 cells were sensitive to glucocorticoids, with the steroids 
reducing cell proliferation. These results are consistent with previous 
experiments carried out in the Morison lab by myself and by Ben Stegmann 
(Faculty of Medicine, University of Otago) as well as previously published 
results in the literature (Bachmann et al., 2007; Foster, 2014; Stegmann, 2014). 
The results of the cell culture experiments with dexamethasone, used for 
RRBS library preparation, are shown in Figure 3.1. As mentioned in Chapter 




























































Figure 3.1: Cell culture over 72 hours: total cell counts (A), and dead cell 
proportions (B) for NALM-6 cell culture with 250 ng/mL dexamethasone 
(blue lines) or without dexamethasone (red lines). Error bars are 95% 




These results show that there were reduced cell concentrations in 
dexamethasone treated cultures, compared with control. Dexamethasone 
exposure significantly increased dead cell counts at 72 hours; however, it 
appears that the difference in live cell counts is primarily due to reduced 
proliferation in the dexamethasone-treated cultures. At all times > 96% of all 
cells were alive in both cell cultures. 
 
Later cell culture experiments directly measured cell proliferation as well as 
counting and live/dead staining of cells. Figures 3.2 and 3.3 show the results 
of a 72 hour cell culture experiment, with and without 250 ng/mL 
dexamethasone, where proliferation was determined at 0, 3, 24, 48 and 72 
hours (DNA was also taken at these time points for use in later experiments). 
This shows that the dexamethasone-treated cells proliferated at a lower rate 
than the untreated cells over 72 hours, shown by higher CFSE fluorescence at 
72 hours for dexamethasone treated cells. It also shows that the cells seem to 
have divided more-or-less in unison, giving single peaks at all time points 
when CFSE fluorescence histograms were plotted (apart from the untreated 































Figure 3.2: Histograms of cell CFSE fluorescence (with calibration beads 
gated out) showing measurements at 0 hours (red), 3 hours (blue), 28 
hours (green) and 72 hours (orange) for (A) untreated NALM-6 cells and 








3.3 Genome-Wide Methylation Results 
 
2013 RRBS Results: Dexamethasone-Treated Against Untreated NALM-6 
Cells 
 
As mentioned previously, the comparison of methylation patterns in 
dexamethasone-treated against untreated NALM-6 cells by RRBS is a 
replication of preliminary work carried out in 2013 (Foster, 2014). In this prior 
experiment, RRBS libraries were prepared from dexamethasone treated (for 
72 hours) and untreated NALM-6 cells using a protocol almost identical to the 
one described in Chapter 2. The two libraries were then compared in a 
fragment-by-fragment approach, using a Chi-squared test (as described in 
Chapter 2). 
 
Overall, the two libraries had 83,000 MspI fragments in common that met the 
inclusion criteria of having at least 2 CpG sites and a depth of at least 10 reads 



























Figure 3.3: Mean CFSE fluorescence (logarithmic) over time for the 
dexamethasone treated cells (blue) and untreated cells (red). Error bars 
are 95% confidence intervals for the mean. 
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from at least 2 CpGs in the fragment. Of those, 108 fragments met the 
Bonferroni-corrected significance threshold of p < 6.02e-7. These are listed in 
Table 3.1, along with the relevant methylation statistics. 
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10	 8097589	 8097688	 GATA3	 123	 570	 21.58	 477	 823	 57.96	 -36.38	 4.19E-41	
15	 45670837	 45670950	 GATM	 15	 151	 9.93	 325	 467	 69.59	 -59.66	 4.81E-37	
8	 28480510	 28480599	 EXTL3	 189	 694	 27.23	 325	 549	 59.2	 -31.97	 1.22E-29	
19	 38755092	 38755177	 SPINT2	 14	 191	 7.33	 144	 264	 54.55	 -47.22	 4.63E-25	
1	 211589822	 211589909	 DTL	 88	 253	 34.78	 265	 362	 73.2	 -38.42	 5.51E-21	
2	 225907351	 225907439	 DOCK10	 198	 775	 25.55	 141	 248	 56.85	 -31.3	 1.58E-19	
7	 32768167	 32768280	 LSM5	 45	 209	 21.53	 551	 982	 56.11	 -34.58	 2.21E-19	
18	 48494295	 48494377	 ELAC1	 9	 889	 1.01	 69	 606	 11.39	 -10.38	 2.39E-18	
5	 17031712	 17031801	 BASP1	 106	 115	 92.17	 180	 393	 45.8	 46.37	 3.00E-18	
7	 556958	 557065	 PDGFA	 47	 235	 20	 380	 721	 52.7	 -32.7	 3.88E-18	
10	 103892887	 103893026	 PPRC1	 19	 30	 63.33	 14	 235	 5.96	 57.37	 4.35E-18	
1	 204042709	 204042822	 SOX13	 47	 219	 21.46	 286	 509	 56.19	 -34.73	 1.29E-17	
12	 118407134	 118407236	 RFC5	 70	 202	 34.65	 293	 419	 69.93	 -35.28	 1.34E-16	
1	 24069720	 24069804	 TCEB3	 83	 137	 60.58	 70	 328	 21.34	 39.24	 5.41E-16	
11	 77300674	 77300766	 AQP11	 45	 205	 21.95	 245	 434	 56.45	 -34.5	 5.88E-16	
11	 118938349	 118938458	 HYOU1	 38	 290	 13.1	 8	 684	 1.17	 11.93	 3.74E-15	
9	 135905537	 135905625	 GTF3C5	 25	 630	 3.97	 27	 106	 25.47	 -21.5	 6.77E-15	
8	 145016779	 145016914	 PLEC	 27	 61	 44.26	 11	 214	 5.14	 39.12	 2.95E-14	
10	 101296777	 101296913	 GOT1	 7	 27	 25.93	 121	 132	 91.67	 -65.74	 3.21E-14	
16	 54965172	 54965285	 IRX5	 50	 232	 21.55	 429	 864	 49.65	 -28.1	 3.27E-14	
17	 4440147	 4440253	 SPNS2	 31	 119	 26.05	 118	 163	 72.39	 -46.34	 3.50E-14	
Table 3.1: Results for fragments with significant methylation differences between the dexamethasone treated (Dex) library and control (Ctl) 
library. Methyl CpGs refer to how many individual CpGs in individual reads were methylated, while Total CpGs refer to how many 
individual CpGs were sequenced. The p value was calculated using a Chi-squared test. 
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1	 154531085	 154531175	 UBE2Q1	 0	 264	 0	 79	 406	 19.46	 -19.46	 5.97E-14	
16	 50582655	 50582774	 NKD1	 55	 189	 29.1	 461	 773	 59.64	 -30.54	 8.32E-14	
14	 36003158	 36003266	 INSM2	 42	 173	 24.28	 442	 800	 55.25	 -30.97	 2.79E-13	
1	 15736141	 15736272	 EFHD2	 21	 42	 50	 5	 140	 3.57	 46.43	 3.10E-13	
12	 3069284	 3069404	 TEAD4	 33	 170	 19.41	 172	 320	 53.75	 -34.34	 4.54E-13	
21	 38738601	 38738688	 DSCR3	 12	 1375	 0.87	 28	 389	 7.2	 -6.33	 5.77E-13	
2	 11485424	 11485532	 ROCK2	 48	 147	 32.65	 116	 158	 73.42	 -40.77	 2.22E-12	
14	 103851520	 103851645	 MARK3	 27	 126	 21.43	 11	 411	 2.68	 18.75	 2.89E-12	
9	 27573377	 27573491	 C9orf72	 58	 201	 28.86	 251	 427	 58.78	 -29.92	 4.76E-12	
18	 22931811	 22931914	 ZNF521	 86	 334	 25.75	 55	 612	 8.99	 16.76	 8.93E-12	
1	 12079260	 12079365	 MIIP	 48	 509	 9.43	 13	 876	 1.48	 7.95	 9.58E-12	
17	 35849812	 35849948	 DUSP14	 25	 95	 26.32	 19	 432	 4.4	 21.92	 1.14E-11	
10	 82213984	 82214093	 TSPAN14	 27	 208	 12.98	 6	 518	 1.16	 11.82	 1.85E-11	
17	 38519407	 38519519	 GJD3	 45	 183	 24.59	 360	 682	 52.79	 -28.2	 2.03E-11	
17	 41446176	 41446298	 ARL4D	 14	 51	 27.45	 16	 459	 3.49	 23.96	 4.50E-11	
10	 13570218	 13570310	 BEND7	 71	 84	 84.52	 84	 203	 41.38	 43.14	 6.05E-11	
22	 50745901	 50746013	 PLXNB2	 3	 166	 1.81	 119	 467	 25.48	 -23.67	 6.68E-11	
2	 28616369	 28616491	 FOSL2	 25	 65	 38.46	 18	 261	 6.9	 31.56	 6.83E-11	
1	 43424238	 43424353	 SLC2A1	 27	 105	 25.71	 23	 457	 5.03	 20.68	 6.92E-11	
17	 28706383	 28706471	 TMIGD1	 51	 194	 26.29	 76	 119	 63.87	 -37.58	 1.09E-10	
9	 114937423	 114937507	 SUSD1	 29	 266	 10.9	 2	 449	 0.45	 10.45	 1.15E-10	
20	 52209658	 52209758	 ZNF217	 46	 576	 7.99	 14	 1000	 1.4	 6.59	 1.17E-10	
17	 62492706	 62492794	 POLG2	 25	 280	 8.93	 40	 109	 36.7	 -27.77	 1.18E-10	
2	 676838	 676937	 TMEM18	 13	 557	 2.33	 70	 568	 12.32	 -9.99	 3.08E-10	
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2	 113403754	 113403874	 SLC20A1	 14	 177	 7.91	 4	 793	 0.5	 7.41	 3.12E-10	
4	 165878149	 165878218	 C4orf39	 19	 69	 27.54	 58	 71	 81.69	 -54.15	 3.63E-10	
19	 609127	 609215	 HCN2	 94	 324	 29.01	 86	 143	 60.14	 -31.13	 3.67E-10	
2	 172379361	 172379476	 CYBRD1	 38	 143	 26.57	 281	 496	 56.65	 -30.08	 4.29E-10	
3	 15140589	 15140684	 ZFYVE20	 55	 1210	 4.55	 6	 1199	 0.5	 4.05	 6.05E-10	
1	 32226205	 32226295	 BAI2	 88	 980	 8.98	 198	 1067	 18.56	 -9.58	 6.42E-10	
2	 9346950	 9347034	 ASAP2	 37	 243	 15.23	 22	 628	 3.5	 11.73	 1.70E-09	
14	 105957445	 105957534	 C14orf80	 10	 366	 2.73	 24	 126	 19.05	 -16.32	 1.70E-09	
9	 5628893	 5628980	 KIAA1432	 7	 630	 1.11	 13	 112	 11.61	 -10.5	 1.93E-09	
17	 81038238	 81038352	 METRNL	 42	 202	 20.79	 330	 747	 44.18	 -23.39	 2.54E-09	
12	 57081889	 57081984	 PTGES3	 55	 688	 7.99	 32	 1371	 2.33	 5.66	 3.50E-09	
9	 16727059	 16727114	 BNC2	 80	 95	 84.21	 9	 33	 27.27	 56.94	 3.58E-09	
4	 89204761	 89204880	 PPM1K	 17	 62	 27.42	 102	 140	 72.86	 -45.44	 3.66E-09	
2	 187350909	 187351021	 AC018867.1	 37	 488	 7.58	 12	 902	 1.33	 6.25	 4.10E-09	
20	 17512127	 17512191	 BFSP1	 44	 187	 23.53	 49	 79	 62.03	 -38.5	 4.21E-09	
8	 144897755	 144897866	 SCRIB	 35	 631	 5.55	 17	 1486	 1.14	 4.41	 5.46E-09	
21	 46494639	 46494753	 C21orf67	 53	 486	 10.91	 63	 1619	 3.89	 7.02	 5.56E-09	
10	 5855504	 5855602	 GDI2	 41	 437	 9.38	 0	 360	 0	 9.38	 6.39E-09	
14	 105444535	 105444628	 C14orf79	 75	 765	 9.8	 175	 861	 20.33	 -10.53	 6.56E-09	
19	 38720377	 38720469	 DPF1	 44	 250	 17.6	 301	 806	 37.34	 -19.74	 9.57E-09	
4	 186131208	 186131325	 KIAA1430	 42	 128	 32.81	 60	 511	 11.74	 21.07	 1.30E-08	
11	 67981379	 67981497	 SUV420H1	 39	 427	 9.13	 26	 1086	 2.39	 6.74	 1.36E-08	
21	 18985140	 18985258	 BTG3	 48	 274	 17.52	 330	 919	 35.91	 -18.39	 1.44E-08	
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2	 27341694	 27341807	 ABHD1	 34	 183	 18.58	 334	 808	 41.34	 -22.76	 1.44E-08	
1	 156470578	 156470693	 MEF2D	 47	 239	 19.67	 19	 382	 4.97	 14.7	 1.64E-08	
15	 63892628	 63892732	 AC118274.1	 13	 115	 11.3	 60	 135	 44.44	 -33.14	 2.09E-08	
6	 160210572	 160210661	 MRPL18	 6	 598	 1	 15	 155	 9.68	 -8.68	 2.53E-08	
8	 145654760	 145654853	 TONSL	 49	 317	 15.46	 268	 842	 31.83	 -16.37	 3.81E-08	
9	 100746900	 100746995	 ANP32B	 44	 792	 5.56	 3	 697	 0.43	 5.13	 3.89E-08	
12	 132628500	 132628589	 DDX51	 20	 1113	 1.8	 39	 533	 7.32	 -5.52	 3.90E-08	
1	 46859941	 46860061	 FAAH	 26	 138	 18.84	 276	 621	 44.44	 -25.6	 4.70E-08	
11	 2021947	 2022063	 C11orf89	 23	 92	 25	 223	 391	 57.03	 -32.03	 6.16E-08	
10	 134210759	 134210873	 PWWP2B	 16	 181	 8.84	 9	 742	 1.21	 7.63	 6.23E-08	
8	 87355016	 87355128	 SLC7A13	 20	 395	 5.06	 4	 876	 0.46	 4.6	 8.24E-08	
1	 9711854	 9711972	 PIK3CD	 42	 233	 18.03	 75	 1094	 6.86	 11.17	 9.67E-08	
16	 47006873	 47006971	 DNAJA2	 36	 596	 6.04	 9	 875	 1.03	 5.01	 1.01E-07	
17	 27895384	 27895472	 TP53I13	 5	 386	 1.3	 8	 50	 16	 -14.7	 1.09E-07	
1	 5874211	 5874306	 KCNAB2	 58	 265	 21.89	 117	 267	 43.82	 -21.93	 1.21E-07	
13	 108870962	 108871050	 LIG4	 14	 778	 1.8	 23	 249	 9.24	 -7.44	 1.25E-07	
1	 117909156	 117909261	 MAN1A2	 34	 253	 13.44	 12	 436	 2.75	 10.69	 1.45E-07	
16	 30406479	 30406595	 ZNF48	 57	 162	 35.19	 76	 487	 15.61	 19.58	 1.64E-07	
13	 21635649	 21635768	 SAP18	 24	 154	 15.58	 316	 837	 37.75	 -22.17	 1.66E-07	
2	 242674049	 242674151	 D2HGDH	 8	 1294	 0.62	 64	 1797	 3.56	 -2.94	 1.68E-07	
11	 66025132	 66025246	 KLC2	 19	 239	 7.95	 4	 533	 0.75	 7.2	 1.88E-07	
10	 75173686	 75173800	 ANXA7	 38	 168	 22.62	 21	 333	 6.31	 16.31	 1.98E-07	
7	 99064158	 99064268	 ATP5J2	 34	 90	 37.78	 41	 48	 85.42	 -47.64	 2.32E-07	
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17	 17655701	 17655788	 RAI1	 24	 1103	 2.18	 29	 349	 8.31	 -6.13	 2.45E-07	
3	 140661462	 140661553	 SLC25A36	 17	 809	 2.1	 59	 752	 7.85	 -5.75	 2.58E-07	
2	 242212267	 242212348	 HDLBP	 22	 144	 15.28	 1	 196	 0.51	 14.77	 2.76E-07	
19	 2900477	 2900576	 ZNF77	 33	 502	 6.57	 149	 916	 16.27	 -9.7	 2.82E-07	
19	 4472257	 4472367	 UBXN6	 29	 317	 9.15	 19	 852	 2.23	 6.92	 2.84E-07	
19	 49138981	 49139095	 DBP	 15	 159	 9.43	 8	 617	 1.3	 8.13	 2.85E-07	
2	 220462418	 220462521	 STK11IP	 1	 495	 0.2	 31	 510	 6.08	 -5.88	 2.98E-07	
6	 150071222	 150071410	 NUP43	 5	 283	 1.77	 33	 240	 13.75	 -11.98	 3.55E-07	
19	 54641758	 54641870	 CNOT3	 15	 272	 5.51	 2	 649	 0.31	 5.2	 3.64E-07	
11	 9406286	 9406405	 IPO7	 14	 150	 9.33	 5	 505	 0.99	 8.34	 4.00E-07	
13	 20533514	 20533621	 ZMYM2	 0	 236	 0	 26	 234	 11.11	 -11.11	 4.05E-07	
7	 151329188	 151329275	 PRKAG2	 52	 339	 15.34	 53	 145	 36.55	 -21.21	 4.06E-07	
11	 805388	 805488	 PIDD	 7	 971	 0.72	 58	 1340	 4.33	 -3.61	 4.42E-07	
19	 1383371	 1383455	 NDUFS7	 28	 76	 36.84	 12	 144	 8.33	 28.51	 4.92E-07	
10	 111967516	 111967636	 MXI1	 13	 203	 6.4	 10	 1050	 0.95	 5.45	 5.41E-07	





Overall, these results show many significant changes in methylation across 
the genome. However, sequence quality, PCR bias (i.e., disproportionate 
amplification of a single clonal sequence) and sequencing bias (i.e., repeated 
sequencing of one single DNA molecule) could explain some of this effect. 
This is why I have opted to repeat this experiment in the current project. 
 
2014 RRBS Results: Dexamethasone-Treated Against Untreated NALM-6 
Cells 
 
The results from this project showed much higher coverage over a larger area 
of the genome compared with the 2013 results due to the significantly 
increased read number. As with 2013, the results showed many significantly 
different fragments between the dexamethasone treated and control libraries 
across the genome. However, there were a number of inconsistencies between 
the two experiments. 
 
Firstly, the number of significant fragments was greatly increased in the 2014 
experiment compared with 2013. When the requirement for 2-fold 
methylation change was discarded, 736 fragments met the significance 
threshold in 2013, based on their p value for difference in a Chi-squared test. 
In 2014, 2,835 fragments met the significance criteria. The differences in the 
number of significant fragments cannot be explained by the fact that there 
were a greater number of fragments able to be included in the 2014 analysis, 
as the Bonferroni correction adjusts the significance threshold to compensate 
for this. Additionally, the distribution of the significant differences was 
strikingly different. In 2013, there was a slight bias towards lower methylation 
in the control library but most of the highly significant differences showed 
lower methylation in the dexamethasone-treated library. In comparison, the 
2014 results show a pronounced bias towards lower methylation in the 
control library, which was even greater for fragments with especially low p 
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Figure 3.4: The negative logarithm (base 10) of the 2014 p values for 
significantly different fragments plotted against the absolute methylation 
difference for each fragment. 
Figure 3.5: The negative logarithm (base 10) of the 2013 p values for 
significantly different fragments plotted against the absolute methylation 
difference for each fragment. 
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As shown, in 2014 2,728 of the 2,835 significant fragments (96.2%, 
95%CI=95.4-96.8%) showed higher methylation in the dexamethasone treated 
library (Figure 3.4). The probability of this observed result if there were an 
equal likelihood of greater or lesser methylation in the dexamethasone treated 
library is < 2.2e-16 (based on a binomial test), leading me to conclude that 
there is an underlying cause other than chance that has led to the observed 
result. Conversely, 407 of the 736 significant fragments in 2013 (55.2%, 
95%CI=51.6-58.9%) show higher methylation in the dexamethasone treated 
library, showing a much weaker effect (if any) with a probability of 0.005 of 
observing this result if there were an equal likelihood of greater or lesser 
methylation in the dexamethasone treated library. 
 
Within-read Correlation and Type-1 Error 
 
The number of significant results observed (much larger than expected) raises 
the possibility of type 1 error in the results. A possible explanation for this is 
that the Chi-squared and related tests are not appropriate to analyse 
methylation data. These tests rely on an assumption that each binary 
observation in a sample (in our case, the methylation of a single CpG within a 
fragment) is independent of every other binary observation. However, given 
that different CpG methylation observations within a single sequencing read 
come from the same length of DNA, from the same cell, it is biologically 
possible that the methylation of one CpG is not independent of another, as 
they share the same cellular methylation regulation machinery. 
 
The recent RRBS analysis packages published by Stockwell et al. (2014) (i.e., 
the DMAP package) and Liang et al. (2014) do not test for independence of 
CpGs within the genomic regions of interest. To address this issue, it was 
decided that the datasets had to be tested for non-independence between 
CpGs. Additionally, as there are some inconsistencies between the 2013 and 
2014 results, six gene promoter regions showing large differences between 
dexamethasone-treated and control libraries were validated using a separate 




As a proof of concept, regarding the need to control for within-read 
correlation, Figure 3.5 shows a region of the dexamethasone treated RRBS 
library where the methylation of CpGs seem to be highly correlated within 
reads. This is one of many regions in the RRBS libraries where there appears 





Figure 3.5: Schematic of the methylation for a region of chromosome 10, for 
the dexamethasone-treated library. Circles represent CpGs, which are 
grouped horizontally within reads (linked by dashed lines). Filled circles 
represent methylated CpGs, while unfilled circles represent unmethylated 
CpGs. This region shows that CpGs are more likely to be unmethylated if 
they are in a read with many other unmethylated CpGs and vice versa, 
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Independence of CpG Methylation Within Sequencing Reads 
 
Our previous studies that have aimed to use RRBS to analyse genome-wide 
methylation differences between samples have relied upon the DMAP 
software package. As described, this package compares methylation within 
defined genomic regions (i.e., MspI fragments) by use of a Chi-squared or 
Fisher’s exact test, which are based on the binomial distribution that was 
discussed in the previous section. When performing these statistical tests, it is 
assumed that the methylation of every CpG within every read is independent 
of every other CpG (Stockwell et al., 2014). However, this assumption was 
never tested during DMAP’s development. Additionally, other genomic-
region based analysis packages also appear to assume independence of every 
CpG, including the recently published packages by Liang et al. (2014), Jiang et 
al. (2014) and Akalin et al. (2012). It is therefore possible that studies that use 
these packages to analyse RRBS or WGBS data could produce spurious results 
due to non-independence of their observations, given that the Fisher’s exact, 
Chi-squared, logistic regression and Mann-Whitney U tests used by these 
packages all assume that the methylation of one CpG is independent of 
another. Other packages, such as those published by Sun et al. (2014) and 
Park et al. (2014), avoid the potential for non-independence of CpGs to bias 
their results by only calling methylation for individual CpGs; however, the 
package published by Park et al. (2014) can also look at 25 bp genomic regions 
and in this case they pool the data to make each CpG an independent 
observation and apply a beta-binomial model. 
 
In the case of single CpG methylation, every methylation observation would 
come from a different sequencing read and, presumably therefore, represent a 
separate and independent cell from within the biological sample (ignoring the 
possibility of PCR bias, which could preferentially amplify a sequence from a 
singe cell). However, it makes biological sense to want to identify 
differentially methylated regions containing several CpGs, as these types of 
areas have been associated with biological responses, notably changes in gene 
expression (Corn et al., 1999; Corn et al., 2000; Deaton and Bird, 2011; Dong et 
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al., 2010; Weeks et al., 2010). In contrast, the biological effect of single CpG 
methylation is not apparent.  
 
Therefore, in collaboration with Dr Matt Parry (Department of Mathematics 
and Statistics), I set out to test whether the methylation of one CpG in a small 
genomic region is independent of another from a same read. The simplest 
approach to this is to assume that the methylation of one CpG is affected by 
one CpG immediately next to it (with other CpGs ignored). Therefore, the 
CpG site is independent if the methylation of the CpG next to it does not 
affect its probability of being methylated. Put otherwise, if event A is defined 
as CpG-1 being methylated and event B is defined as CpG-2 being 
methylated, then if the two events are independent the probability of event A 
is the same as the probability of event A given event B; in contrast, if the two 
events are not independent this relationship will not hold. 
 
This scenario, where the probability of one outcome is affected, to a greater or 
lesser extent, by some other outcome can be modelled most simply by a 
Markov chain. A Markov chain is defined as a mathematical system that 
transitions between discrete states, where the next state in the chain can be 
affected by the current state (Norris, 1997). In our case, each genomic region-
of-interest would be modelled by a Markov chain that transitions between 
methylated and unmethylated states as we move from one CpG to another. 
 
Traditionally, Markov chains are used to model states that change in time, 
where a future state may be affected by the current state (but not a past state) 
(Norris, 1997). In our case, we are modelling a state that changes as we read 
(in an arbitrary direction) across the genome region of interest, where a jump 
from one CpG to another can be considered as the equivalent of a discrete 
amount of time. As such, we used a ‘discrete time’ Markov chain (as opposed 
to continuous time Markov chains, which are the basis for the Poisson 
distribution) to model our reads. Our particular two-state (methylated or 








In this diagram, M and U represent the two states (methylated or 
unmethylated) that the system can be in. At every transition from one CpG to 
the next, the state can start at M or U. Starting at M, there is a probability, α, 
that the state will switch to U as we pass to the next CpG, and there is a 
probability, 1-α, that the system will remain at state M. Conversely, starting at 
U, there is a probability, β, of a switch to M and a probability, 1-β, of 
remaining at U.  
 
From this, we can draw a matrix for the transition from one CpG to another 
where each row represents a possible starting state for the system. Each 
column represents a possible end state for the system and each cell represents 
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Figure 3.6: Diagram of a two state (M or U), discrete time Markov chain. 
Arrows represent state changes at each discrete time interval, while α and 
β represent probabilities. 
Table 3.2: Transition matrix for the described Markov chain, shown as a 
table and as a matrix, T. Rows indicate the state before the transition and 
columns indicate the state afterwards. 
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We previously stated that the methylation of a CpG is independent of the 
previous CpG if the probability of it being methylated is the same regardless 
of the methylation state of the previous CpG. In terms of our Markov 
transition matrix, this means that β (the probability of getting a methylated 
CpG given a previous unmethylated CpG) must equal 1-α (the probability of 
getting a methylated CpG given a previous methylated CpG) to satisfy our 
definition of independence. From here, it follows mathematically that α must 
also equal 1-β, indicating that the probability of getting an unmethylated CpG 
is also unaffected by the previous CpG. 
 
Within a small genomic region, such as an MspI fragment, RRBS data can be 
used to estimate α and β, and therefore determine whether this definition of 
independence holds within the region. As an example, consider the MspI 
fragment shown in Figure 3.7. This region has been analysed by RRBS with a 
depth of 67 reads and each read covers 4-7 CpGs. To estimate α and β, what is 
important is the transition from one CpG in a read to the next. This transition 
can be methylated to methylated, methylated to unmethylated, unmethylated 
to methylated or unmethylated to unmethylated. Therefore, I wrote software 
in Python that read through a SAM file and counted the number of each 
transition for all reads in each fragment. The output for this fragment (chr1: 





Chr	 Start	 End	 U-U	 U-M	 M-U	 M-M	 Total	Reads	







Table 3.3: Transition counts and genomic position for the MspI fragment 
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Figure 3.7: Schematic of methylation for an MspI fragment at chr1: 876,638-
874,696. Each line is a sequencing-read, each unfilled circle an 
unmethylated CpG and each filled circle a methylated CpG. Space between 
circles is proportionate to the distance between CpG sites. 
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This output can be used to estimate α and β for this fragment. From the 
transition matrix in Table 3.2, β is the probability of going from a U to an M 
given that we start at a U. Therefore it is the [U-M] transitions divided by all 
transitions starting with a U, which in this case is β = 38
(38+36)
= 0.514 . 
Additionally, α is the probability of going from an M to a U given that we 
start at an M, so is the [M-U] transitions divided by all transitions starting 
with an M; this is α = 47
(47+88)
= 0.348 . So to test independence we compare α 
(0.348) to 1-β (0.486); which, in this case, shows 0.348≠0.486 suggesting that 
each CpG may not be independent of the previous CpG for this fragment. 
Specifically, there appears to be a higher change of landing on an 
unmethylated CpG if the previous CpG is unmethylated. This then means 
that β≠1-α, that is  0.514≠0.652, so there is also a higher chance of landing on a 
methylated CpG if the previous CpG is methylated. 
 
Therefore, if we conclude that methylation of one CpG may be affected by the 
previous CpG the next question is the extent to which the previous CpG 
influences methylation of the current CpG. At one end of the spectrum, some 
fragments may show independence between CpGs while at the other the 
relationship may be completely deterministic. We have already defined 




Which are simply rearrangements of: 
α +β =1   
Conversely, if a previous CpG influences the methylation of the current CpG 





As α and β are probabilities (i.e., must be between 0 and 1) the maximal 
possible inequality is either 1 or -1; therefore, if the relationship is 





Which are both rearrangements of: 
α +β =1±1  
So α+β will either equal 2 or 0. In the case where α +β = 2 , both α and β must 
equal 1; therefore, an M will always follow a U and a U will always follow an 
M (refer to Figure 3.6 and Table 3.2). This gives the methylation pattern 
shown in Figure 3.8 (A). However, if α +β = 0  then both α and β are 0; thus, 
an M will never follow a U and a U will never follow an M. This gives the 
methylation pattern shown in Figure 3.8 (B). 
 
Thus, it is possible to have a value, rho, defined as ρ =1− (α +β) , which 
equals 0 at independence, -1 at perfect anticorrelation (as in 3.8 (A)) and 1 at 
perfect correlation (as in 3.8 (B)) between one CpG and the next. I wrote a 
computer script in R that used the genome wide transition counts (from a 
Python script that produced an output similar to table 2.2 for every MspI 
fragment in the genome) to estimate α, β and ρ. Figure 3.9 plots the observed 
distribution of the value of ρ (only including the 31,827 fragments where there 
were >5 examples of each of the four methylation state transitions, to enable 
some accuracy in estimating α, β and, therefore, ρ), for one RRBS library. This 
figure shows that there is a shift of the peak towards 1 and the distribution is 
also skewed towards 1. This distribution indicates that, on a genome-wide 
level, the methylation of one CpG is not independent of the previous CpG 
and that a previously methylated CpG increases the chance of the current 



























Figure 3.8: Schematic showing (A) perfect anticorrelation and (B) perfect 
correlation between adjacent CpGs within reads. 
Figure 3.9: Histogram showing the distribution of rho for the control 




However, there are some obvious issues with using a Markov chain to model 
the methylation of a stretch of DNA. Firstly and most obviously, the 
directionality of the Markov chain does not reflect the biological reality of 
DNA methylation. Methylation of the whole strand does not change as one 
jumps from one CpG to the next; instead, every CpG exists in its methylation 
state alongside every other CpG in the DNA strand. To use this model we 
have forced a changing methylation state by reading in an arbitrary direction 
along the DNA, despite the fact that there is no evidence that any biological 
mechanism ‘reads’ the methylation of a strand by jumping from CpG to CpG 
in this manner (i.e., there is no biological basis for the directionality in the 
model). Additionally, the direction in which one reads along the genome can 
(and does) affect the estimation of α, β and ρ.  
 
Furthermore, Markov chains (by definition) only allow for the methylation of 
one CpG to be affected by one other (the previous CpG in the chain); 
however, it is biologically plausible that a CpG could be affected, for example, 
by both the CpG behind and in front of it (and others), when reading in an 
arbitrary direction. 
 
As a consequence of these limitations, we decided to turn to the more flexible 
class of generalised linear models (GLMs) as an alternative technique to try to 
test for and correct for non-independence in the data set. Generalised linear 
models are an extension of regression modelling, using a linking function for 
non-normally distributed data (in our case, binomially distributed data) 
(McCulloch, 2000). In the case of binary data, the logit is used as the linking 







'  where l is the logit value and p is the 
probability of success. See Figure 3.10 for the shape of the logit linking 
function. When the logit is used as the linking function, the regression model 
is logistic regression (McCulloch, 2000). Given that we are interested in 
whether the overall methylation within a region is different between two 
samples, we are modelling the marginal probability outcome (i.e., p is the 
overall likelihood of a CpG being methylated in the sample). The logistic 
regression model for the marginal probability outcome p takes the form 
shown below, where β0  is a constant, X1  is the regression variable (in our 
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case, an identifier variable indicating whether the sample was dexamethasone 








'= β0 +β1X1  
In this equation, it is β1  that describes the effect of our variable (drug 
treatment) on the probability of methylation. As it stands, this approach is 
identical to the naïve logistic regression approach of Akalin et al. (2012) and, 
as every observation is treated as independent in this model, it does not 
correct for non-independence. However, we can consider an underlying 
model of the same form that describes the true effect of drug treatment (as 
opposed to the observed effect, which is skewed by non-independence) on the 
probability of methylation, and thus includes the true value of β1 . We then 
require a means of estimating the true value of β1  from the observed data. 
Furthermore, as we require a means of determining the confidence in our 
estimates of the effect of drug treatment, we require a method of estimating 





Happily, there exist a class of equations that allow us to estimate this value 
for generalised linear models, known as the generalised estimating equations 
















Figure 3.10: The curve of the logit value for a proportion. 
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(GEEs), developed by Liang and Zeger and originally described in two 1986 
papers (Liang and Zeger, 1986; Zeger and Liang, 1986). These were created for 
use in epidemiology to solve an analogous problem with the analysis of data 
from cohort studies. In a cohort study, one may have repeated measures from 
each study participant for a variable that one may wish to relate to outcome 
measurements (as an arbitrary example, blood pressure measurements and 
existence of a heart murmur). One would wish to use all of these repeated 
measurements to maximise power; however, there is the problem that 
repeated outcome and variable measurements would be correlated if they 
come from the same individual (e.g., an individual’s blood pressure is likely 
to be more similar to a previous reading from the same individual than a 
measurement from someone completely different). It is for this reason that 
there was a need to estimate the parameters of an explanatory model that 
links an outcome with an explanatory variable, which would hold for non-
Gaussian (normally-distributed) data (as in our example, where the presence 
or absence of a heart murmur will be a binary measurement). 
 
GEEs are based on quasi-likelihood theory, introduced by Wedderburn (1974) 
and Mccullagh (1983). Regarding notation, a '  is the transpose of a  and ∂  
denotes a partial derivative expression; additionally, vectors are considered 
column vectors unless they are explicitly noted as transposed. If a genomic 
region of interest is covered by K sequencing reads, with n  CpGs per read, 
then let yi  denote the n×1  vector of methylation observations from a single 
read and xi  be an n× p  matrix of explanatory variables (in out case presence 
or absence of drug treatment, which is constant for each observation in yi , but 
this could include additional explanatory variables). Then if µi  is the 
expectation of yi  and g( f )  is the inverse of the link function, we have the 
equation below: 
µi = g(xiβ)  
Where β  is a p×1  vector of parameters (in our case β0,β1[ ] ) that describe the 
relationship between the expected methylation and the explanatory variables. 
Furthermore, following the quasi-likelihood approach, the variance of yij  (a 
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single CpG outcome in yi ), vij , is defined as a function of the mean, with φ  as 





GEEs solve for the maximum quasi-likelihood estimator of β , β
∧
 for 



















In the expression above for Vi , Ai  is a diagonal matrix with h(µij )  on the jth 
diagonal and Ri (α)  is the ‘working’ n×n  correlation matrix for the values of 
yi . Ri (α)  is considered a ‘working’ matrix as its structure is determined by 
the user and it may not be the true correlation matrix (Zeger and Liang, 1986). 
A guess for Ri (α)  that is close to the truth is desirable, as this will increase the 
statistical efficiency for estimating β ; however, the estimates of β  are 
unbiased whatever the choice of Ri (α)  (i.e., the mean of β
∧
−β is 0) and it is 
possible to calculate the covariance matrix of β
∧
 in a way that is robust to 
misspecification of Ri (α)  using the robust or ‘sandwich’ variance estimation 
below (Liang and Zeger, 1986; Zeger and Liang, 1986). Liang and Zeger (1986) 
further show that the distribution of β
∧
 is multivariate Gaussian at large 
sample numbers, allowing the robust variance term to be used to construct 
appropriate confidence intervals or calculate p values. 





































It is this robust variance expression that is the major advantage of the GEE 
method, whereby the true correlation within reads is empirically estimated 
from the data in this expression. This is achieved by estimating the true 
covariance of y, the methylation outcomes, using the SiS 'i  outer product. Over 
many clusters, Liang and Zeger (1986) show that this is a consistent estimator 
of the true covariance. 
 
The robustness of the sandwich variance gives the GEE approach flexibility 
that a more rigid model of intra-read correlation would not. Using GEEs to 
examine each fragment allows the intra-read correlation for the fragments to 
change in both magnitude and structure across the genome, without affecting 
the validity of the analysis. 
 
Liang and Zeger (1986) provide details on how to compute β
∧
, using an 
iterative procedure. In short, β
∧
 is computed as a function of the estimates of 




) which are then re-estimated as a function of the updated value of β
∧
 and so 
on until convergence. 
 
In addition to accounting for a single level of correlation (i.e., within read) 
within the data, the robustness of the GEE approach allows for accurate 
estimates of regression coefficients and standard errors when two or more 
levels of correlation to exist within the data, provided that there are a large 
enough number of top-level clusters. This means that the approach is 
generalizable beyond my study design, where I am comparing two groups of 
cells which differ only in their exposure to dexamethasone, to other, more 
common, study designs using whole-genome bisulphite sequencing. In 
particular, it can be used for analysis of case/control studies, where the 
methylation of one group of people with an exposure of interest (e.g., a 
disease) is compared to an unexposed group. In this situation, we expect the 
methylation observations to be correlated within reads at a lower level and 
within people at a higher level. Here, the sandwich variance estimator will 
produce valid standard errors when the true correlation would be highly 
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challenging to model, provided that there are enough people in the study and 
that all reads are made up to the same number of CpGs with missing value 
placeholders (to ensure a consistent within-individual correlation structure). 
 
Unfortunately, problems begin to arise at low numbers of top-level clusters 
(reads in my case, people for a case/control study). This is because the 
method has been shown to exhibit bias at low (typically < 40) sample 
numbers, leading to increased type-1 error (Morel et al., 2003). Specifically, 
there is under coverage of the true confidence intervals, leading to type 1 
error. This has the potential to be a problem, as (due to the high cost of whole-
genome bisulphite sequencing) many studies that bisulphite sequence groups 
of individuals have quite low sample numbers. 
 
Additionally, GEEs have not been traditionally used in genome-wide studies 
such as genome-wide bisulphite sequencing, where there are many thousands 
of separate analyses across the genome and, consequently, a very low p value 
threshold for significance (to account for the multiple-testing). Up until 
recently, therefore, their performance at the levels of significance used for 
genome-wide studies was unknown. However, a recent paper by Sitlani et al. 
(2014) suggest that GEEs behave appropriately in such settings. However, at 
the increased type-1 error with low sample numbers does become more 
pronounced at these low significance thresholds (though there is not evidence 
of high type-1 error when sample sizes are appropriately large) (Sitlani et al., 
2014). To correct this source of error, Sitlani et al. (2014) propose that, instead 
of assuming a Gaussian distribution when interpreting robust standard error, 
a t distribution could be used instead. At low degrees of freedom, the t 
distribution has heavier tails than the equivalent Gaussian distribution; 
therefore, if a statistic that is truly t distributed is assumed to be Gaussian 
then there will be an inflated rate of type-1 error (see Figure 3.11). 
 
To implement a t distribution, Sitlani et al. (2014) adopt the approach of Pan 
and Wall (2002), who apply the estimate of the degrees of freedom outlined 
by Satterthwaite (1946) to GEEs, defined below. 
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In simulation studies with correlation between repeated measurements from 
the same individual, Sitlani et al. (2014) show that the estimated t distribution 










We chose to adopt this method when the number of top-level clusters was 
low (between 12 and 40). Such a technique allowing the GEEs to be extended 
to lower sample numbers is essential for RRBS studies as there are often low 
numbers of individuals in case/control studies, as mentioned. Additionally, 
two sample studies will often have a great deal of the genome covered by low 
numbers of reads, and extending the analysis will allow more of these 
genomic areas to be accurately analysed. 
















Figure 3.11: Curves of probability mass density functions for the t 
distribution and the Gaussian distribution, with probability density plotted 
against the number of standard deviations from the mean (labelled as ‘x 
value’). The Gaussian (or normal) distribution is shown as the black 
dashed line against the t distribution for (red) 1 degree of freedom, (blue) 3 
degrees of freedom, (green) 8 degrees of freedom and (yellow) 30 degrees 
of freedom. This demonstrates that there is a greater probability of 




GEE-based analysis was therefore chosen as the main analysis method for my 
RRBS results, where the top level clustering was within read. These results are 
presented in the following subsections. Furthermore, the robustness of the 
technique should theoretically allow it to be applied to the analysis of two (or 
more) groups of libraries, rather than simply to two individual libraries. In 
this scenario one would expect an extra level of correlation within-libraries, as 
well as within-reads, which the robust estimate of variance should handle. 
However, vastly different coverage between different libraries may 
complicate the GEE analysis, as the technique requires a mean to be estimated 
for each position in the outcomes vector (i.e., #i	, the mean of yi). If there are 
large variations in the coverage for each library, certain positions in #i will 
only be able to be estimated from a few libraries, making the sample mean 
less likely to reflect the true underlying mean, affecting the results of the 
method. A/Prof. Katrina Sharples (Department of Medicine) and I are 
currently working to determine how much this is likely to affect the results, 
and apply GEEs or another valid technique (such as mixed-effects modelling) 
to a two-group analysis of RRBS libraries, using libraries prepared from tissue 
from 15 pre-eclamptic and 15 normal placentas. 
 
Modelling Within-Read Correlation 
 
While the GEEs allow valid inferences about mean methylation to be made 
regardless of the intra-read correlation, it would be of biological interest to 
examine the correlation itself. It was decided to again split the genome up 
into MspI fragments and examine the correlation within reads, within each 
fragment. It was hypothesised that correlation would vary significantly across 
the genome. Furthermore, I hypothesised that biological function of a 
genomic region would affect the degree of correlation. Specifically, I wished 
to investigate whether the proximity of a fragment to a gene transcription 
start site would affect the within-read correlation. 
 
An ni ×ni  matrix can be used to represent within-read correlation, where ni  is 
the number of CpGs in each read. Each row and each column in the matrix, 
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therefore, represents a CpG locus while each position within the matrix 
represents the correlation between the row locus and the column locus. As a 
single locus is always absolutely correlated with itself, this results in a matrix 
with 1 on the main diagonal and values between -1 and 1 in every other 
position. 
 
To model the within-read correlation we proposed a simple model, where 
every CpG is correlated to the same extent with every other in the read, that is  
Cor(yij, yik ) =α , for every j ≠ k . This gives the correlation matrix the form: 
1 α … α
α 1 … α
! ! " !














In reality, this model is probably too simple to capture the true correlation 
structure within a sequencing read. One would expect that correlation would 
differ depending on how far away the two CpGs are (Park et al., 2014). 
However, CpGs within a read from the Illumina HiSeq 2500 can be a 
maximum of 100 bp apart (Illumina, 2013). Given that this is such a short 
distance, I would argue that the genomic distance between CpGs would only 
result in small differences in correlation values between closer and further-
away CpGs within the same read. Indeed, when comparing correlation 
between CpG loci (which is somewhat different to correlation within a 
sequencing read), correlation between CpGs was quite similar (and high) for 
CpGs within 100 bp of each other (Park et al., 2014). This model (known as an 
exchangeable correlation structure) can also be used as the working 
correlation structure for GEE analysis, which should increase statistical 
efficiency over the independence working correlation (though at the expense 
of much longer computation time) (Liang and Zeger, 1986). 
 
This model has the advantage of being simple to use, with the pairwise 
correlations being simple to calculate and interpret, with one value ( ) for 
each fragment. Conveniently, specifying the ‘exchangeable’ working 
correlation structure for the geepack package’s ‘geese’ GEE solver will 
calculate this model, which is how we calculated correlation (Halekoh et al., 
α
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2006). The mean correlation, using this model, was 0.06 and the distribution 







As can be seen, the figure shows a skewed distribution towards positive 
correlation; indeed the measured skewness of this distribution is (positive) 
1.68 using the definition γ1 = µ2 /µ33/2  where γ1  is the skewness, µ2  is the 
second central moment and µ3  is the third central moment.  
 
The distance of fragments to the nearest transcription start site was also 




















Figure 3.12: Histogram showing the empirical distribution of the 
exchangeable correlation within reads for each MspI fragment meeting the 
inclusion criteria for the GEE version 2.0 analysis (described later). 
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whether distance from a transcription start site was related to the degree of 
correlation within reads. This analysis did not show a significant association 
between distances to the transcription start sites and within-read correlation. 
As such, we found no evidence that transcription start sites affect the 
observed correlation in nearby genomic regions. 
 
Reanalysis of RRBS Results 
 
Using the GEE technique with the independence working correlation 
structure, my RRBS results were reanalysed. The 40-220 bp MspI fragments 
were tested as potential differentially methylated regions (DMRs), with 
fragments included in the analysis if both samples had 20 or more reads each 
with at least 3 CpG sites mapped to that fragment. Only fragments where 
both libraries had > 2% and < 98% methylation were included, as the GEEs 
will not be mathematically solvable near 0% or 100% methylation due to the 
fact that if the probability of methylation is 0 or 1 then the same result of all 
unmethylated or all methylated CpGs will be observed regardless of what the 
correlation is (therefore making it impossible to empirically estimate the 
correlation structure). Note that these are considerably more stringent 
inclusion criteria than used for the DMAP analysis. 
 
Using a significance cut-off of p < 1.10e-6 (the p < 0.05 Bonferroni correction 
for 45,628 included fragments), 332 fragments were found to be significant 
when the 2014 libraries were reanalysed. This suggests that the analyses that 
assume independence (such as the original Chi-squared analysis) 
considerably overestimated the number of significantly different fragments. 
The p values and methylation differences for this reanalysis are shown in 
Figure 3.13. Of the 332 significantly different fragments, 298 show higher 
methylation in the dexamethasone treated library (89.8% of fragments; 95% 
CI=86.0-92.8%). To show how the GEE approach handles within read 
correlation, the same fragments are analysed assuming independence in 





















Figure 3.13: Methylation difference (dexamethasone treated minus 
control) and p value for difference for all 45,628 fragments 
included in the GEE analysis. The dashed horizontal line indicates 






These results were analysed using version 1.1 of the R package (MPBSgee) 
that I wrote to perform whole-genome methylation analyses using GEEs. 
They are presented here because version 1.1 was used to select areas of the 
genome to be validated by Sequenom. As mentioned in Chapter 2, the areas 
chosen were near the transcription start sites of LY6E, CRSPLD1, CTHRC1, IL-
15, PTPRS and CEP70. 
 
There are a few points that should be made about the version 1.1 results; 
firstly, the stringent inclusion criteria used mean that a minority of MspI 
fragments covered by RRBS could be included (as there needed to be > 20 


















Figure 3.14: Same fragments as figure 3.13 analysed assuming 
independence of CpGs within reads. 
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reads from each library, each with > 3 CpGs, for inclusion). Secondly, there 
are a few (~20) fragments with extremely small p values as can be clearly seen 
in Figure 3.7. These fragments show such low p values because they all have > 
5000 total reads mapping to the fragments, and typically > 10,000 reads. This 
raises the possibility that they represent repetitive areas of the genome that 
have mapped to the same place (by escaping the Bismark program’s filters), 
especially as most of the fragments come from small areas of chromosomes 1 
and 21. These fragments were ignored when selecting regions for Sequenom 
validation. 
 
MPBSgee was extensively rewritten for version 2.0 (though this was after 
Sequenom experiments were carried out). The features of version 2.0 will be 
briefly presented later in this document; however, it incorporates the degrees 
of freedom estimation of Satterthwaite (1946) for low coverage fragments, 
following the approach of Sitlani et al. (2014). This allows a much greater 
proportion of the genome to be analysed. Additionally, it imposes a cut off of 
4,000 mapped reads, above which a fragment is discarded, to deal with the 
concerns with mapped reads from repetitive regions. 
 
Version 2.0 has much more sophisticated inclusion criteria for analysis. A 
fragment can be included if greater than 7 reads from each library are 
mapped to the fragment. If fewer than 60 reads in total are mapped to a 
fragment, the degrees of freedom approximation is calculated and a t test is 
used, otherwise the standard Z test is applied. If more than 4,000 reads map 
to a fragment it is discarded. Using these criteria, 91,010 fragments could be 
included in the analysis, almost double the number that version 1.1 analysed. 
With a p value cut-off of p < 5.49e-7 (the p < 0.05 Bonferroni correction for 
91,010 fragments) 281 fragments showed a significant difference (this is lower 
than the version 1.1 results because of the upper read limit and the lower 
significance cut-off required when analysing more fragments). These results 





This list of 281 significant fragments, along with the distance to the nearest 
transcription start site (with the gene name) is presented in Table 3.4. 
 
  















Figure 3.15: Analysis of 2014 libraries using version 2.0 of the analysis 
package. Layout is as in Figure 3.13. 
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Table 3.4: List of fragments with statistically significant methylation differences by GEE, with position information, absolute 
methylation differences, coefficient estimate, p value and nearby TSS information. 
Chr	 Start	 End	 MethDif	 Beta	 Robust.Z	 pVal	 Test	 DoF	 Gene.Name	 TSS	 Dist	
1	 10497	 10588	 0.0705	 1.19e+00	 6.26e+00	 3.77e-10	 Z	 NA	 DDX11L1	 11873	 -1330.5	
1	 2135960	 2136043	 0.3798	 1.61e+00	 6.15e+00	 7.78e-10	 Z	 NA	 C1orf86	 2123333	 12668.5	
1	 5805254	 5805384	 0.2970	 1.23e+00	 7.08e+00	 1.45e-12	 Z	 NA	 MIR4689	 5922731	 -117412.0	
1	 16339746	 16339795	 0.4301	 3.46e+00	 5.04e+00	 4.69e-07	 Z	 NA	 HSPB7	 16340522	 -751.5	
1	 22970216	 22970338	 0.2389	 9.79e-01	 5.35e+00	 8.76e-08	 Z	 NA	 C1QC	 22970117	 160.0	
1	 45249967	 45250020	 0.2395	 1.24e+00	 5.36e+00	 8.33e-08	 Z	 NA	 BEST4	 45249256	 737.5	
1	 46860147	 46860206	 0.5057	 2.25e+00	 5.19e+00	 2.13e-07	 Z	 NA	 FAAH	 46859938	 238.5	
1	 100253707	 100253799	 0.2027	 8.38e-01	 1.04e+01	 1.70e-25	 Z	 NA	 AGL	 100315639	 -61886.0	
1	 108113100	 108113260	 0.3755	 1.78e+00	 6.01e+00	 1.81e-09	 Z	 NA	 VAV3	 108113781	 -601.0	
1	 117209844	 117209915	 0.3770	 1.99e+00	 5.96e+00	 2.54e-09	 Z	 NA	 MIR320B1	 117214370	 -4490.5	
1	 121261077	 121261156	 0.3318	 2.36e+00	 5.28e+00	 1.30e-07	 Z	 NA	 EMBP1	 121260909	 207.5	
1	 148556709	 148556808	 0.2261	 1.59e+00	 5.68e+00	 1.32e-08	 Z	 NA	 NBPF15	 148558187	 -1428.5	
1	 180199114	 180199166	 0.2628	 1.27e+00	 5.03e+00	 4.93e-07	 Z	 NA	 LHX4	 180199432	 -292.0	
1	 185287131	 185287207	 0.3934	 2.03e+00	 6.09e+00	 1.10e-09	 Z	 NA	 GS1-279B7.1	 185292978	 -5809.0	
1	 194087394	 194087486	 0.1338	 1.78e+00	 5.55e+00	 2.93e-08	 Z	 NA	 LINC01031	 193273874	 813566.0	
1	 202611641	 202611729	 0.1547	 8.60e-01	 5.09e+00	 3.63e-07	 Z	 NA	 SYT2	 202559724	 51961.0	
1	 204042601	 204042660	 0.3869	 2.49e+00	 5.11e+00	 3.15e-07	 Z	 NA	 SOX13	 204042245	 385.5	
1	 204121146	 204121205	 0.3537	 2.29e+00	 5.36e+00	 8.18e-08	 Z	 NA	 REN	 204123943	 -2767.5	
1	 236273296	 236273387	 0.1787	 7.60e-01	 6.59e+00	 4.52e-11	 Z	 NA	 GPR137B	 236305831	 -32489.5	
2	 11925187	 11925240	 0.2693	 2.01e+00	 5.07e+00	 4.06e-07	 Z	 NA	 LPIN1	 11886721	 38492.5	
2	 38152622	 38152674	 0.3534	 1.61e+00	 5.05e+00	 4.45e-07	 Z	 NA	 RMDN2	 38152461	 187.0	
2	 46768938	 46769017	 0.2152	 1.07e+00	 5.69e+00	 1.30e-08	 Z	 NA	 RHOQ	 46769866	 -888.5	
2	 61991598	 61991722	 0.3258	 2.24e+00	 5.26e+00	 1.47e-07	 Z	 NA	 FAM161A	 62051982	 -60322.0	
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2	 70529006	 70529066	 0.0959	 1.29e+00	 5.20e+00	 2.04e-07	 Z	 NA	 FAM136A	 70523107	 5929.0	
2	 89504750	 89504860	 -0.4207	 -2.32e+00	 -7.59e+00	 3.14e-14	 Z	 NA	 MIR4436A	 89111883	 392922.0	
2	 90449764	 90449826	 0.2715	 1.16e+00	 6.39e+00	 1.63e-10	 Z	 NA	 MIR4436A	 89111883	 1337912.0	
2	 96780503	 96780584	 0.4097	 2.46e+00	 5.23e+00	 1.71e-07	 Z	 NA	 ADRA2B	 96778622	 1921.5	
2	 103098470	 103098597	 -0.0932	 -4.41e-01	 -6.79e+00	 1.13e-11	 Z	 NA	 SLC9A4	 103089761	 8772.5	
2	 109744863	 109744924	 0.5131	 2.33e+00	 5.03e+00	 4.85e-07	 Z	 NA	 SH3RF3	 109745996	 -1102.5	
2	 131129914	 131130012	 -0.5755	 -3.29e+00	 -9.56e+00	 1.18e-21	 Z	 NA	 PTPN18	 131113579	 16384.0	
2	 172967338	 172967421	 0.2872	 1.89e+00	 5.43e+00	 5.79e-08	 Z	 NA	 DLX2-AS1	 172967733	 -353.5	
2	 206790806	 206790944	 0.3075	 1.43e+00	 7.73e+00	 1.06e-14	 Z	 NA	 INO80D	 206858444	 -67569.0	
2	 216877940	 216878069	 0.5001	 2.44e+00	 6.20e+00	 5.77e-10	 Z	 NA	 PECR	 216903110	 -25105.5	
2	 220306756	 220306815	 0.5414	 2.87e+00	 5.16e+00	 2.49e-07	 Z	 NA	 SPEG	 220299699	 7086.5	
2	 233312570	 233312627	 -0.1475	 -1.68e+00	 -5.52e+00	 3.38e-08	 Z	 NA	 ALPI	 233320832	 -8233.5	
2	 236406331	 236406449	 -0.2070	 -1.51e+00	 -5.89e+00	 3.82e-09	 Z	 NA	 AGAP1	 236402732	 3658.0	
3	 12838028	 12838192	 0.3133	 2.50e+00	 5.62e+00	 1.43e-07	 t	 112.2	 CAND2	 12838170	 -60.0	
3	 45883334	 45883399	 0.3636	 1.66e+00	 5.13e+00	 2.82e-07	 Z	 NA	 LZTFL1	 45864809	 18557.5	
3	 49690520	 49690613	 0.2626	 1.30e+00	 5.82e+00	 5.97e-09	 Z	 NA	 APEH	 49711434	 -20867.5	
3	 73144411	 73144493	 0.3617	 1.65e+00	 5.42e+00	 6.09e-08	 Z	 NA	 EBLN2	 73110809	 33643.0	
3	 123303919	 123303988	 0.3205	 1.82e+00	 9.52e+00	 1.66e-21	 Z	 NA	 MYLK-AS1	 123304359	 -405.5	
3	 125551268	 125551381	 0.1749	 7.23e-01	 1.40e+01	 1.60e-44	 Z	 NA	 LOC101927056	 125546079	 5245.5	
3	 131221699	 131221786	 0.4636	 2.73e+00	 5.06e+00	 4.11e-07	 Z	 NA	 SNORA58	 131197841	 23901.5	
3	 138313075	 138313135	 0.6007	 2.90e+00	 5.03e+00	 4.92e-07	 Z	 NA	 FAIM	 138327541	 -14436.0	
3	 179371858	 179371924	 0.3746	 2.05e+00	 5.13e+00	 2.92e-07	 Z	 NA	 USP13	 179370932	 959.0	
3	 194040203	 194040258	 0.3492	 1.82e+00	 5.35e+00	 8.60e-08	 Z	 NA	 CPN2	 194060493	 -20262.5	
3	 195373887	 195374027	 0.1313	 8.98e-01	 5.13e+00	 2.89e-07	 Z	 NA	 SDHAP2	 195384909	 -10952.0	
3	 195929581	 195929661	 0.4025	 2.08e+00	 5.07e+00	 4.07e-07	 Z	 NA	 ZDHHC19	 195924322	 5299.0	
3	 197355101	 197355225	 0.2100	 1.90e+00	 5.62e+00	 1.93e-08	 Z	 NA	 LOC220729	 197340897	 14266.0	
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4	 1526168	 1526260	 0.0898	 7.67e-01	 5.65e+00	 1.63e-08	 Z	 NA	 FAM53A	 1641607	 -115393.0	
4	 2933322	 2933420	 -0.0690	 -2.97e-01	 -5.42e+00	 5.85e-08	 Z	 NA	 MFSD10	 2932287	 1084.0	
4	 10020732	 10020792	 0.4385	 2.06e+00	 5.16e+00	 2.44e-07	 Z	 NA	 WDR1	 10075962	 -55200.0	
4	 109316308	 109316359	 0.0000	 -3.94e-16	 -6.63e+00	 5.37e-11	 t	 976.5	 RPL34-AS1	 109459345	 -143011.5	
4	 141013584	 141013676	 0.2675	 1.11e+00	 5.54e+00	 3.09e-08	 Z	 NA	 SCOC	 141178439	 -164809.0	
4	 142557614	 142557713	 0.5892	 3.05e+00	 6.07e+00	 1.29e-09	 Z	 NA	 IL15	 142557748	 -84.5	
4	 146953763	 146953850	 -0.2252	 -9.44e-01	 -5.22e+00	 1.76e-07	 Z	 NA	 LINC01095	 147030606	 -76799.5	
4	 154073409	 154073509	 0.2895	 1.77e+00	 5.20e+00	 2.04e-07	 Z	 NA	 TRIM2	 154074269	 -810.0	
4	 185746744	 185746789	 0.3176	 1.64e+00	 5.10e+00	 3.35e-07	 Z	 NA	 LOC731424	 185764449	 -17682.5	
5	 64399099	 64399177	 0.4508	 2.00e+00	 5.95e+00	 2.64e-09	 Z	 NA	 ADAMTS6	 64444562	 -45424.0	
5	 68628568	 68628644	 0.5383	 2.68e+00	 6.20e+00	 5.73e-10	 Z	 NA	 AK6	 68647552	 -18946.0	
5	 114505305	 114505376	 0.4454	 2.02e+00	 5.52e+00	 3.46e-08	 Z	 NA	 TRIM36	 114506798	 -1457.5	
5	 114505377	 114505499	 0.4644	 2.30e+00	 5.09e+00	 3.52e-07	 Z	 NA	 TRIM36	 114506798	 -1360.0	
5	 131563904	 131563982	 0.3218	 1.61e+00	 5.18e+00	 2.22e-07	 Z	 NA	 MIR6830	 131553541	 10402.0	
5	 139045285	 139045334	 0.2736	 1.65e+00	 7.02e+00	 2.21e-12	 Z	 NA	 CXXC5	 139028300	 17009.5	
5	 169064208	 169064320	 0.5477	 2.79e+00	 5.08e+00	 3.86e-07	 Z	 NA	 DOCK2	 169064250	 14.0	
5	 172710973	 172711060	 0.5577	 2.72e+00	 7.04e+00	 1.92e-12	 Z	 NA	 STC2	 172741725	 -30708.5	
5	 177519838	 177519971	 0.0242	 1.65e-01	 7.54e+00	 1.28e-07	 t	 22.7	 N4BP3	 177540555	 -20650.5	
5	 180286037	 180286169	 -0.1399	 -6.77e-01	 -5.43e+00	 1.35e-07	 t	 251.1	 ZFP62	 180274610	 11493.0	
6	 37664443	 37664537	 0.3044	 1.54e+00	 5.33e+00	 1.00e-07	 Z	 NA	 MDGA1	 37600283	 64207.0	
6	 37723418	 37723520	 0.1692	 6.83e-01	 5.60e+00	 2.12e-08	 Z	 NA	 ZFAND3	 37787306	 -63837.0	
6	 53409214	 53409264	 0.3684	 1.71e+00	 5.01e+00	 5.31e-07	 Z	 NA	 LOC101927136	 53426086	 -16847.0	
6	 87748852	 87748947	 0.0920	 4.44e-01	 7.80e+00	 6.42e-15	 Z	 NA	 CGA	 87795215	 -46315.5	
6	 130340641	 130340705	 0.3934	 2.18e+00	 5.11e+00	 3.14e-07	 Z	 NA	 L3MBTL3	 130339727	 946.0	
6	 157041257	 157041307	 0.3414	 1.75e+00	 5.04e+00	 4.75e-07	 Z	 NA	 ARID1B	 157099063	 -57781.0	
7	 596269	 596361	 0.1499	 1.02e+00	 5.02e+00	 5.22e-07	 Z	 NA	 PRKAR1B	 588833	 7482.0	
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7	 1468715	 1468847	 0.2949	 1.75e+00	 6.29e+00	 3.23e-10	 Z	 NA	 MICALL2	 1473994	 -5213.0	
7	 5633860	 5633909	 0.4545	 1.96e+00	 5.37e+00	 7.91e-08	 Z	 NA	 FSCN1	 5632435	 1449.5	
7	 6769180	 6769300	 0.2961	 1.28e+00	 5.16e+00	 2.51e-07	 Z	 NA	 PMS2CL	 6774935	 -5695.0	
7	 25219434	 25219496	 0.3965	 2.01e+00	 5.31e+00	 1.13e-07	 Z	 NA	 NPVF	 25264190	 -44725.0	
7	 78394825	 78394957	 0.1321	 6.18e-01	 5.49e+00	 4.06e-08	 Z	 NA	 MAGI2-AS2	 78638303	 -243412.0	
7	 101361425	 101361526	 0.3714	 1.80e+00	 5.02e+00	 5.26e-07	 Z	 NA	 CUX1	 101459183	 -97707.5	
7	 127225457	 127225560	 0.2473	 1.23e+00	 5.69e+00	 1.24e-08	 Z	 NA	 ARF5	 127228405	 -2896.5	
7	 132299552	 132299671	 0.4507	 2.43e+00	 5.99e+00	 2.15e-09	 Z	 NA	 FLJ40288	 132333552	 -33940.5	
7	 140098262	 140098331	 0.4772	 2.61e+00	 5.53e+00	 3.13e-08	 Z	 NA	 RAB19	 140103842	 -5545.5	
7	 148982426	 148982496	 0.5389	 2.41e+00	 6.55e+00	 5.70e-11	 Z	 NA	 LOC155060	 148982371	 90.0	
7	 149157545	 149157590	 0.5860	 3.55e+00	 5.30e+00	 1.17e-07	 Z	 NA	 ZNF746	 149169883	 -12315.5	
7	 149157627	 149157747	 0.4883	 2.27e+00	 5.36e+00	 8.20e-08	 Z	 NA	 ZNF746	 149169883	 -12196.0	
7	 149157944	 149158072	 0.1966	 1.31e+00	 5.01e+00	 5.41e-07	 Z	 NA	 ZNF746	 149169883	 -11875.0	
7	 151329131	 151329187	 0.3403	 1.73e+00	 5.30e+00	 1.13e-07	 Z	 NA	 PRKAG2	 151253200	 75959.0	
7	 158059251	 158059359	 0.1915	 1.17e+00	 5.09e+00	 3.58e-07	 Z	 NA	 MIR595	 158325409	 -266104.0	
8	 1792592	 1792699	 -0.2690	 -1.14e+00	 -8.75e+00	 2.18e-18	 Z	 NA	 ARHGEF10	 1772148	 20497.5	
8	 9424279	 9424412	 -0.0803	 -1.01e+00	 -5.80e+00	 6.74e-09	 Z	 NA	 TNKS	 9413444	 10901.5	
8	 11759902	 11760024	 0.2591	 1.47e+00	 5.77e+00	 8.04e-09	 Z	 NA	 CTSB	 11700033	 59930.0	
8	 38757785	 38757877	 0.3157	 1.70e+00	 5.10e+00	 3.33e-07	 Z	 NA	 PLEKHA2	 38758752	 -921.0	
8	 75897025	 75897106	 0.5402	 2.74e+00	 5.80e+00	 6.49e-09	 Z	 NA	 CRISPLD1	 75896707	 358.5	
8	 75897297	 75897450	 0.4504	 1.94e+00	 5.63e+00	 1.78e-08	 Z	 NA	 CRISPLD1	 75896707	 666.5	
8	 93115568	 93115617	 0.2896	 2.01e+00	 5.20e+00	 2.04e-07	 Z	 NA	 RUNX1T1	 92967194	 148398.5	
8	 94712460	 94712580	 0.3994	 2.64e+00	 6.87e+00	 6.30e-12	 Z	 NA	 FAM92A1	 94712734	 -214.0	
8	 94713315	 94713366	 0.2251	 1.11e+00	 5.54e+00	 3.06e-08	 Z	 NA	 FAM92A1	 94712734	 606.5	
8	 95274443	 95274493	 0.2168	 1.25e+00	 5.12e+00	 3.00e-07	 Z	 NA	 GEM	 95261484	 12984.0	
8	 95960814	 95960867	 0.1949	 8.19e-01	 5.08e+00	 3.80e-07	 Z	 NA	 TP53INP1	 95938199	 22641.5	
8	 104383715	 104383869	 0.4847	 2.60e+00	 5.22e+00	 1.76e-07	 Z	 NA	 CTHRC1	 104383742	 50.0	
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8	 109799763	 109799825	 0.4716	 2.21e+00	 6.82e+00	 8.89e-12	 Z	 NA	 TMEM74	 109795345	 4449.0	
8	 124171062	 124171114	 0.3275	 1.58e+00	 5.21e+00	 1.93e-07	 Z	 NA	 FAM83A	 124191286	 -20198.0	
8	 134564496	 134564575	 0.3281	 1.41e+00	 5.67e+00	 1.43e-08	 Z	 NA	 ST3GAL1	 134467090	 97445.5	
8	 142010797	 142010886	 0.2406	 1.08e+00	 5.03e+00	 4.81e-07	 Z	 NA	 DENND3	 142138719	 -127877.5	
8	 144100132	 144100200	 0.6150	 3.04e+00	 5.05e+00	 4.37e-07	 Z	 NA	 LY6E	 144099901	 265.0	
8	 144329118	 144329200	 0.2635	 2.47e+00	 5.49e+00	 3.94e-08	 Z	 NA	 ZFP41	 144329097	 62.0	
8	 144349243	 144349308	 -0.0654	 -9.58e-01	 -5.49e+00	 3.99e-08	 Z	 NA	 GLI4	 144349606	 -330.5	
8	 144373564	 144373625	 0.1499	 1.60e+00	 6.13e+00	 8.72e-10	 Z	 NA	 ZNF696	 144373558	 36.5	
8	 145009069	 145009162	 0.1053	 1.63e+00	 5.03e+00	 4.86e-07	 Z	 NA	 MIR661	 145019358	 -10242.5	
8	 145027482	 145027555	 0.1656	 1.45e+00	 5.54e+00	 3.09e-08	 Z	 NA	 MIR661	 145019358	 8160.5	
8	 145180713	 145180772	 0.1799	 1.11e+00	 6.18e+00	 6.26e-10	 Z	 NA	 HGH1	 145192671	 -11928.5	
8	 145239580	 145239700	 0.1364	 5.80e-01	 7.89e+00	 2.95e-15	 Z	 NA	 MROH1	 145203547	 36093.0	
9	 68298787	 68298864	 0.0000	 -4.16e-16	 -5.83e+00	 1.10e-07	 t	 80.6	 LOC642236	 68427782	 -128956.5	
9	 97767092	 97767134	 0.6680	 3.42e+00	 5.01e+00	 5.43e-07	 Z	 NA	 MIR6081	 97827631	 -60518.0	
9	 128171151	 128171291	 -0.3669	 -2.79e+00	 -7.16e+00	 7.98e-13	 Z	 NA	 MAPKAP1	 128199672	 -28451.0	
9	 131939023	 131939091	 0.4651	 2.14e+00	 5.96e+00	 2.55e-09	 Z	 NA	 IER5L	 131937830	 1227.0	
9	 133942801	 133942883	 0.0000	 -5.23e-16	 -6.54e+00	 7.37e-10	 t	 163.2	 AIF1L	 133971862	 -29020.0	
9	 137030405	 137030454	 0.3222	 1.45e+00	 5.06e+00	 4.10e-07	 Z	 NA	 RNU6ATAC	 137029561	 868.5	
9	 139948503	 139948548	 -0.1833	 -1.39e+00	 -6.65e+00	 2.84e-11	 Z	 NA	 ENTPD2	 139942550	 5975.5	
9	 140094368	 140094466	 0.1462	 1.30e+00	 5.05e+00	 4.51e-07	 Z	 NA	 TMEM203	 140098534	 -4117.0	
10	 1549032	 1549179	 -0.1754	 -1.66e+00	 -5.61e+00	 2.05e-08	 Z	 NA	 ADARB2-AS1	 1568824	 -19718.5	
10	 13570643	 13570708	 0.4018	 2.70e+00	 5.55e+00	 2.91e-08	 Z	 NA	 PRPF18	 13628938	 -58262.5	
10	 13571065	 13571116	 0.3881	 1.94e+00	 5.09e+00	 3.57e-07	 Z	 NA	 PRPF18	 13628938	 -57847.5	
10	 61122470	 61122621	 -0.1476	 -1.22e+00	 -5.35e+00	 8.72e-08	 Z	 NA	 FAM13C	 61005888	 116657.5	
10	 72968947	 72969053	 0.2016	 1.89e+00	 5.54e+00	 3.08e-08	 Z	 NA	 UNC5B	 72972291	 -3291.0	
10	 92980602	 92980691	 0.0912	 1.57e+00	 5.07e+00	 4.06e-07	 Z	 NA	 PCGF5	 92980358	 288.5	
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10	 122610794	 122610850	 0.4420	 1.91e+00	 5.25e+00	 1.51e-07	 Z	 NA	 WDR11	 122610686	 136.0	
10	 127584386	 127584518	 0.2782	 1.32e+00	 5.70e+00	 1.19e-08	 Z	 NA	 FANK1	 127585107	 -655.0	
10	 127584600	 127584705	 0.1999	 8.11e-01	 5.55e+00	 2.83e-08	 Z	 NA	 FANK1	 127585107	 -454.5	
10	 127584720	 127584769	 0.3506	 1.51e+00	 5.57e+00	 2.59e-08	 Z	 NA	 FANK1	 127585107	 -362.5	
10	 127584829	 127584966	 0.7113	 3.76e+00	 8.46e+00	 2.57e-17	 Z	 NA	 FANK1	 127585107	 -209.5	
10	 127585282	 127585426	 0.3938	 1.67e+00	 6.42e+00	 1.37e-10	 Z	 NA	 FANK1	 127585107	 247.0	
10	 132100019	 132100094	 0.4874	 2.22e+00	 5.91e+00	 3.40e-09	 Z	 NA	 GLRX3	 131934638	 165418.5	
10	 134756278	 134756326	 0.2852	 2.25e+00	 5.04e+00	 4.55e-07	 Z	 NA	 LINC01166	 134757470	 -1168.0	
11	 403483	 403585	 0.0000	 -5.97e-16	 -7.94e+00	 9.52e-15	 t	 615.9	 SIGIRR	 405715	 -2181.0	
11	 2337156	 2337216	 -0.2961	 -1.39e+00	 -5.79e+00	 6.98e-09	 Z	 NA	 CD81-AS1	 2349978	 -12792.0	
11	 46369240	 46369295	 0.2786	 1.23e+00	 5.48e+00	 4.14e-08	 Z	 NA	 DGKZ	 46368955	 312.5	
11	 46722992	 46723070	 0.3099	 1.62e+00	 5.72e+00	 1.04e-08	 Z	 NA	 ZNF408	 46722643	 388.0	
11	 59333340	 59333420	 0.4680	 2.16e+00	 5.66e+00	 1.47e-08	 Z	 NA	 OSBP	 59341870	 -8490.0	
11	 61511890	 61511982	 0.2441	 1.46e+00	 7.98e+00	 1.51e-15	 Z	 NA	 MYRF	 61520120	 -8184.0	
11	 66494785	 66494855	 0.3988	 1.80e+00	 6.21e+00	 5.32e-10	 Z	 NA	 C11orf80	 66512206	 -17386.0	
11	 67723205	 67723365	 0.5343	 2.90e+00	 6.99e+00	 2.85e-12	 Z	 NA	 UNC93B1	 67758570	 -35285.0	
11	 92931236	 92931310	 0.3320	 1.80e+00	 5.28e+00	 1.31e-07	 Z	 NA	 SLC36A4	 92877336	 53937.0	
11	 107730519	 107730636	 0.3692	 1.81e+00	 5.24e+00	 1.59e-07	 Z	 NA	 RAB39A	 107799276	 -68698.5	
11	 119725453	 119725536	 -0.2612	 -1.07e+00	 -6.80e+00	 1.01e-11	 Z	 NA	 LOC102724301	 119600292	 125202.5	
11	 120894932	 120894989	 0.3803	 1.82e+00	 5.01e+00	 5.41e-07	 Z	 NA	 TBCEL	 120894812	 148.5	
11	 123172442	 123172533	 0.2447	 1.13e+00	 5.98e+00	 2.19e-09	 Z	 NA	 MIR4493	 123252147	 -79659.5	
12	 3186933	 3187046	 0.5449	 2.57e+00	 8.08e+00	 6.40e-16	 Z	 NA	 TSPAN9	 3186520	 469.5	
12	 12849181	 12849228	 0.3823	 2.82e+00	 5.35e+00	 8.88e-08	 Z	 NA	 CDKN1B	 12870203	 -20998.5	
12	 28995684	 28995759	 0.0000	 -5.42e-16	 -6.29e+00	 4.26e-09	 t	 133.6	 FAR2	 29301935	 -306213.5	
12	 51632344	 51632443	 0.1770	 1.41e+00	 5.80e+00	 6.57e-09	 Z	 NA	 DAZAP2	 51632507	 -113.5	
12	 59990453	 59990589	 0.6349	 4.11e+00	 6.03e+00	 1.37e-07	 t	 55.8	 SLC16A7	 59989820	 701.0	
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12	 72080122	 72080169	 0.3574	 1.62e+00	 5.03e+00	 4.91e-07	 Z	 NA	 TMEM19	 72079877	 268.5	
12	 117463411	 117463570	 0.2423	 1.94e+00	 5.29e+00	 1.23e-07	 Z	 NA	 TESC	 117476727	 -13236.5	
12	 117627487	 117627665	 -0.2500	 -1.49e+00	 -5.39e+00	 3.82e-07	 t	 115.3	 NOS1	 117645946	 -18370.0	
12	 120763625	 120763749	 0.2511	 2.46e+00	 5.60e+00	 2.18e-08	 Z	 NA	 PLA2G1B	 120759913	 3774.0	
12	 127650615	 127650654	 0.3855	 1.64e+00	 1.23e+01	 1.01e-34	 Z	 NA	 LOC101927616	 127808699	 -158064.5	
12	 133067067	 133067130	 0.3782	 1.60e+00	 5.81e+00	 6.20e-09	 Z	 NA	 FBRSL1	 133067156	 -57.5	
13	 28534890	 28534963	 0.2855	 1.52e+00	 5.71e+00	 1.11e-08	 Z	 NA	 CDX2	 28536204	 -1277.5	
13	 75794002	 75794074	 0.2203	 1.17e+00	 5.19e+00	 2.08e-07	 Z	 NA	 CTAGE11P	 75811888	 -17850.0	
14	 19888879	 19888970	 0.1199	 1.31e+00	 5.02e+00	 5.27e-07	 Z	 NA	 LINC01296	 19891096	 -2171.5	
14	 55033344	 55033413	 0.4169	 1.82e+00	 5.03e+00	 5.03e-07	 Z	 NA	 SAMD4A	 55034329	 -950.5	
14	 71108776	 71108831	 0.4208	 2.02e+00	 5.17e+00	 2.34e-07	 Z	 NA	 TTC9	 71108503	 300.5	
14	 78108285	 78108421	 0.4327	 1.98e+00	 5.08e+00	 3.74e-07	 Z	 NA	 ALKBH1	 78138748	 -30395.0	
14	 101133957	 101134089	 0.3576	 1.75e+00	 6.27e+00	 3.59e-10	 Z	 NA	 LINC00523	 101123604	 10419.0	
14	 105066616	 105066733	 0.2046	 1.05e+00	 5.10e+00	 3.46e-07	 Z	 NA	 TMEM179	 105060417	 6257.5	
15	 20210191	 20210284	 0.2206	 1.27e+00	 5.82e+00	 2.23e-08	 t	 202.1	 CHEK2P2	 20487996	 -277758.5	
15	 31693498	 31693593	 0.0640	 3.17e-01	 6.29e+00	 3.25e-10	 Z	 NA	 KLF13	 31619057	 74488.5	
15	 40571738	 40571801	 0.2945	 2.23e+00	 6.09e+00	 1.16e-09	 Z	 NA	 ANKRD63	 40573644	 -1874.5	
15	 53096236	 53096327	 0.4061	 1.87e+00	 5.22e+00	 1.77e-07	 Z	 NA	 ONECUT1	 53049159	 47122.5	
15	 62683367	 62683448	 0.2892	 1.46e+00	 5.33e+00	 9.95e-08	 Z	 NA	 MIR6085	 62635227	 48180.5	
15	 62683455	 62683546	 0.4666	 2.20e+00	 6.08e+00	 1.18e-09	 Z	 NA	 MIR6085	 62635227	 48273.5	
15	 65904008	 65904142	 -0.1439	 -5.86e-01	 -5.22e+00	 1.77e-07	 Z	 NA	 SLC24A1	 65903742	 333.0	
15	 72069756	 72069849	 0.2746	 1.81e+00	 5.05e+00	 4.31e-07	 Z	 NA	 NR2E3	 72102887	 -33084.5	
16	 790212	 790318	 0.2740	 1.15e+00	 6.29e+00	 3.22e-10	 Z	 NA	 NARFL	 779768	 10497.0	
16	 1107535	 1107666	 0.4576	 2.32e+00	 6.20e+00	 5.79e-10	 Z	 NA	 SSTR5-AS1	 1114081	 -6480.5	
16	 1858716	 1858876	 0.2988	 1.53e+00	 5.66e+00	 8.03e-08	 t	 141.1	 HAGH	 1859103	 -307.0	
16	 3029775	 3029847	 0.2989	 1.64e+00	 5.26e+00	 1.48e-07	 Z	 NA	 PKMYT1	 3022791	 7020.0	
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16	 3551191	 3551247	 0.3389	 1.65e+00	 5.20e+00	 1.98e-07	 Z	 NA	 CLUAP1	 3550944	 275.0	
16	 10856323	 10856410	 -0.0600	 -3.05e-01	 -7.50e+00	 1.05e-07	 t	 23.7	 TVP23A	 10860532	 -4165.5	
16	 19897062	 19897154	 0.1198	 1.54e+00	 5.10e+00	 3.42e-07	 Z	 NA	 GPRC5B	 19870292	 26816.0	
16	 32830249	 32830383	 0.2671	 2.08e+00	 6.05e+00	 1.49e-09	 Z	 NA	 SLC6A10P	 32888796	 -58480.0	
16	 33964843	 33964901	 0.4540	 1.99e+00	 1.76e+01	 4.00e-69	 Z	 NA	 LINC00273	 33961051	 3821.0	
16	 66982435	 66982521	 -0.1147	 -4.73e-01	 -5.14e+00	 2.80e-07	 Z	 NA	 CES3	 66995131	 -12653.0	
16	 67189271	 67189347	 0.5043	 2.94e+00	 6.50e+00	 2.52e-10	 t	 372.2	 TRADD	 67188088	 1221.0	
16	 83932383	 83932461	 -0.3635	 -1.62e+00	 -5.54e+00	 3.08e-08	 Z	 NA	 MLYCD	 83932729	 -307.0	
16	 84651489	 84651548	 0.3357	 1.41e+00	 6.03e+00	 1.65e-09	 Z	 NA	 KLHL36	 84682130	 -30611.5	
16	 85316107	 85316208	 0.1703	 8.87e-01	 6.62e+00	 3.51e-11	 Z	 NA	 LINC00311	 85316563	 -405.5	
17	 4853764	 4853855	 0.4215	 1.90e+00	 6.30e+00	 2.98e-10	 Z	 NA	 ENO3	 4854383	 -573.5	
17	 5404486	 5404600	 0.4302	 1.91e+00	 5.46e+00	 4.82e-08	 Z	 NA	 NLRP1	 5404718	 -175.0	
17	 7835032	 7835115	 0.2473	 1.24e+00	 5.68e+00	 1.33e-08	 Z	 NA	 CNTROB	 7835441	 -367.5	
17	 13504903	 13504959	 0.4273	 1.91e+00	 5.68e+00	 1.32e-08	 Z	 NA	 HS3ST3A1	 13399005	 105926.0	
17	 16492725	 16492798	 0.5481	 2.54e+00	 6.70e+00	 2.04e-11	 Z	 NA	 ZNF624	 16524047	 -31285.5	
17	 21219992	 21220075	 0.2615	 2.19e+00	 5.05e+00	 4.36e-07	 Z	 NA	 MAP2K3	 21191347	 28686.5	
17	 21221395	 21221523	 0.4829	 2.13e+00	 5.62e+00	 1.92e-08	 Z	 NA	 MAP2K3	 21191347	 30112.0	
17	 21221645	 21221780	 0.3827	 1.62e+00	 5.55e+00	 2.92e-08	 Z	 NA	 MAP2K3	 21191347	 30365.5	
17	 21561584	 21561690	 -0.1742	 -7.66e-01	 -5.13e+00	 2.90e-07	 Z	 NA	 C17orf51	 21431570	 130067.0	
17	 31149797	 31149836	 0.2702	 1.11e+00	 1.08e+01	 4.82e-27	 Z	 NA	 TMEM98	 31254927	 -105110.5	
17	 37719830	 37719912	 0.4696	 2.47e+00	 5.81e+00	 6.22e-09	 Z	 NA	 NEUROD2	 37760020	 -40149.0	
17	 41401006	 41401090	 0.1326	 1.18e+00	 6.00e+00	 1.99e-09	 Z	 NA	 LINC00854	 41373436	 27612.0	
17	 47987899	 47987980	 0.2348	 1.30e+00	 5.83e+00	 5.63e-09	 Z	 NA	 DLX4	 48046561	 -58621.5	
17	 56296561	 56296618	 0.4353	 2.39e+00	 5.46e+00	 4.85e-08	 Z	 NA	 MKS1	 56282796	 13793.5	
17	 57785176	 57785328	 0.2280	 1.99e+00	 5.31e+00	 1.11e-07	 Z	 NA	 VMP1	 57784862	 390.0	
17	 64831320	 64831376	 0.4468	 1.94e+00	 6.07e+00	 1.29e-09	 Z	 NA	 CACNG5	 64873390	 -42042.0	
17	 71161134	 71161227	 0.0958	 1.12e+00	 5.64e+00	 1.73e-08	 Z	 NA	 SSTR2	 71161159	 21.5	
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17	 76349220	 76349282	 0.4263	 2.59e+00	 5.62e+00	 1.88e-08	 Z	 NA	 SOCS3	 76352857	 -3606.0	
17	 76879642	 76879714	 0.3506	 1.74e+00	 6.28e+00	 3.42e-10	 Z	 NA	 KIAA1731NL	 76886661	 -6983.0	
17	 77674065	 77674215	 0.3338	 1.40e+00	 5.04e+00	 4.60e-07	 Z	 NA	 MIR4739	 77680984	 -6844.0	
17	 79268405	 79268474	 0.1931	 9.62e-01	 5.90e+00	 3.62e-09	 Z	 NA	 LINC00482	 79276623	 -8183.5	
17	 79268475	 79268534	 0.0856	 1.09e+00	 5.37e+00	 7.99e-08	 Z	 NA	 LINC00482	 79276623	 -8118.5	
17	 79958685	 79958798	 0.2511	 1.61e+00	 5.33e+00	 9.97e-08	 Z	 NA	 STRA13	 79976578	 -17836.5	
17	 80009052	 80009148	 0.1793	 7.37e-01	 5.60e+00	 2.09e-08	 Z	 NA	 GPS1	 80009762	 -662.0	
17	 80454899	 80454942	 0.1318	 1.90e+00	 5.37e+00	 7.97e-08	 Z	 NA	 FOXK2	 80477593	 -22672.5	
17	 80710534	 80710620	 0.2692	 1.70e+00	 5.38e+00	 7.34e-08	 Z	 NA	 TBCD	 80709939	 638.0	
18	 8706505	 8706545	 0.1962	 1.16e+00	 5.30e+00	 1.19e-07	 Z	 NA	 GACAT2	 8695853	 10672.0	
18	 9708788	 9708889	 0.5302	 2.68e+00	 6.08e+00	 1.17e-09	 Z	 NA	 RAB31	 9708227	 611.5	
18	 21520209	 21520328	 0.3877	 1.65e+00	 5.53e+00	 3.20e-08	 Z	 NA	 TTC39C	 21572736	 -52467.5	
18	 30050300	 30050382	 0.4731	 2.15e+00	 5.96e+00	 2.46e-09	 Z	 NA	 WBP11P1	 30091625	 -41284.0	
18	 45936836	 45937018	 0.4433	 1.93e+00	 6.33e+00	 9.37e-08	 t	 45.8	 CTIF	 46065426	 -128499.0	
18	 55253930	 55253979	 0.4229	 2.07e+00	 5.63e+00	 1.77e-08	 Z	 NA	 NARS	 55267893	 -13938.5	
18	 77247051	 77247144	 0.1030	 1.64e+00	 5.42e+00	 5.97e-08	 Z	 NA	 NFATC1	 77160273	 86824.5	
18	 77483839	 77483947	 0.0393	 2.00e-01	 5.09e+00	 3.50e-07	 Z	 NA	 CTDP1	 77441429	 42464.0	
18	 77552544	 77552759	 -0.4915	 -2.82e+00	 -5.93e+00	 7.99e-09	 t	 305.1	 KCNG2	 77623667	 -71015.5	
18	 77569158	 77569217	 -0.0833	 -4.05e-01	 -1.64e+15	 0.00e+00	 t	 1336.4	 KCNG2	 77623667	 -54479.5	
19	 1745015	 1745157	 0.3128	 1.75e+00	 5.83e+00	 2.49e-08	 t	 183.2	 ONECUT3	 1753661	 -8575.0	
19	 1763084	 1763218	 -0.0833	 -4.05e-01	 -7.23e+15	 0.00e+00	 t	 635.9	 ONECUT3	 1753661	 9490.0	
19	 2561967	 2562103	 0.5433	 2.44e+00	 5.55e+00	 2.93e-08	 Z	 NA	 GNG7	 2511217	 50818.0	
19	 2622830	 2622927	 0.4141	 1.85e+00	 5.20e+00	 2.03e-07	 Z	 NA	 DIRAS1	 2714564	 -91685.5	
19	 3285038	 3285130	 0.1616	 9.56e-01	 5.72e+00	 1.04e-08	 Z	 NA	 CELF5	 3225482	 59602.0	
19	 5340926	 5340970	 0.7449	 3.89e+00	 5.17e+00	 2.32e-07	 Z	 NA	 ZNRF4	 5455425	 -114477.0	
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19	 5711971	 5712067	 0.0452	 2.29e-01	 6.24e+00	 1.24e-08	 t	 95.0	 CATSPERD	 5720687	 -8668.0	
19	 5885918	 5885984	 0.2174	 1.04e+00	 5.37e+00	 7.67e-08	 Z	 NA	 NDUFA11	 5891286	 -5335.0	
19	 7991198	 7991358	 -0.3589	 -1.75e+00	 -6.61e+00	 3.82e-11	 Z	 NA	 TIMM44	 7991602	 -324.0	
19	 14184108	 14184181	 0.2775	 1.26e+00	 5.11e+00	 3.19e-07	 Z	 NA	 MIR1199	 14184172	 -27.5	
19	 14676764	 14676815	 0.3260	 1.46e+00	 5.61e+00	 2.00e-08	 Z	 NA	 NDUFB7	 14676889	 -99.5	
19	 15334539	 15334675	 -0.1459	 -9.48e-01	 -5.65e+00	 1.59e-08	 Z	 NA	 EPHX3	 15337729	 -3122.0	
19	 17356596	 17356705	 0.0689	 1.29e+00	 5.09e+00	 3.54e-07	 Z	 NA	 USHBP1	 17360829	 -4178.5	
19	 19932219	 19932308	 0.4686	 2.18e+00	 6.00e+00	 2.00e-09	 Z	 NA	 ZNF506	 19903519	 28744.5	
19	 28293221	 28293328	 -0.1281	 -6.32e-01	 -9.50e+00	 2.20e-21	 Z	 NA	 LOC101927151	 28284802	 8472.5	
19	 38720377	 38720469	 0.5108	 2.96e+00	 5.12e+00	 3.10e-07	 Z	 NA	 DPF1	 38701645	 18778.0	
19	 51843546	 51843615	 0.3454	 1.90e+00	 5.30e+00	 1.18e-07	 Z	 NA	 ETFB	 51848408	 -4827.5	
19	 53038972	 53039128	 0.4187	 2.42e+00	 5.13e+00	 2.94e-07	 Z	 NA	 ZNF808	 53030908	 8142.0	
19	 53104655	 53104748	 0.4170	 2.24e+00	 6.04e+00	 1.55e-09	 Z	 NA	 ZNF137P	 53099936	 4765.5	
19	 55574538	 55574670	 0.4097	 2.95e+00	 5.18e+00	 2.20e-07	 Z	 NA	 EPS8L1	 55587220	 -12616.0	
19	 58962612	 58962755	 0.4021	 2.01e+00	 7.05e+00	 1.84e-12	 Z	 NA	 ZNF324B	 58962970	 -286.5	
19	 59050051	 59050141	 0.2982	 1.63e+00	 5.08e+00	 3.72e-07	 Z	 NA	 TRIM28	 59055835	 -5739.0	
20	 626206	 626305	 0.2171	 1.01e+00	 5.84e+00	 5.09e-09	 Z	 NA	 SRXN1	 627267	 -1011.5	
20	 3220014	 3220066	 0.5392	 2.78e+00	 6.02e+00	 1.74e-09	 Z	 NA	 C20orf194	 3229947	 -9907.0	
20	 17485811	 17485957	 0.3115	 2.07e+00	 5.32e+00	 1.01e-07	 Z	 NA	 BFSP1	 17474549	 11335.0	
20	 17628781	 17628840	 0.2419	 2.57e+00	 5.97e+00	 2.37e-09	 Z	 NA	 RRBP1	 17594322	 34488.5	
20	 26188685	 26188756	 0.1579	 6.49e-01	 5.95e+00	 2.76e-09	 Z	 NA	 MIR663A	 26188821	 -100.5	
20	 26189308	 26189353	 0.3620	 2.12e+00	 6.62e+00	 3.53e-11	 Z	 NA	 MIR663A	 26188821	 509.5	
20	 26190118	 26190176	 0.2308	 1.23e+00	 9.90e+00	 4.37e-23	 Z	 NA	 MIR663A	 26188821	 1326.0	
20	 46524080	 46524239	 0.3683	 2.18e+00	 6.66e+00	 2.79e-11	 Z	 NA	 LINC01522	 46608836	 -84676.5	
20	 49208888	 49209034	 0.4081	 2.44e+00	 6.67e+00	 7.52e-10	 t	 124.2	 FAM65C	 49202644	 6317.0	
20	 57607236	 57607350	 0.0795	 1.26e+00	 5.08e+00	 3.73e-07	 Z	 NA	 SLMO2	 57608199	 -906.0	
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20	 60942382	 60942421	 0.4890	 2.23e+00	 6.30e+00	 3.02e-10	 Z	 NA	 LAMA5-AS1	 60928065	 14336.5	
20	 60985903	 60985998	 -0.3962	 -1.79e+00	 -7.13e+00	 1.16e-09	 t	 63.6	 RBBP8NL	 60985292	 658.5	
20	 61371667	 61371741	 0.4281	 2.87e+00	 5.06e+00	 4.09e-07	 Z	 NA	 NTSR1	 61340188	 31516.0	
21	 9439599	 9439739	 -0.0974	 -7.98e-01	 -5.20e+00	 1.97e-07	 Z	 NA	 MIR3648-1	 9825831	 -386162.0	
21	 9826386	 9826448	 0.1225	 5.31e-01	 7.44e+00	 9.78e-14	 Z	 NA	 MIR3687-1	 9826202	 215.0	
21	 9826840	 9826933	 0.3042	 1.28e+00	 1.42e+01	 8.20e-46	 Z	 NA	 MIR3687-1	 9826202	 684.5	
21	 27302589	 27302652	 0.0000	 -8.22e-16	 -5.31e+00	 1.40e-07	 t	 791.6	 APP	 27252860	 49760.5	
21	 35987232	 35987291	 0.3378	 1.54e+00	 5.64e+00	 7.60e-08	 t	 159.4	 CLIC6	 36041687	 -54425.5	
21	 43373903	 43373953	 0.5051	 2.24e+00	 5.06e+00	 4.29e-07	 Z	 NA	 ZBTB21	 43406939	 -33011.0	
21	 45660012	 45660209	 -0.3073	 -1.30e+00	 -5.40e+00	 6.83e-08	 Z	 NA	 DNMT3L	 45666221	 -6110.5	
21	 47537232	 47537364	 -0.2726	 -1.13e+00	 -6.16e+00	 7.44e-10	 Z	 NA	 FTCD	 47556175	 -18877.0	
21	 48087968	 48088071	 0.4111	 2.69e+00	 5.29e+00	 1.20e-07	 Z	 NA	 PRMT2	 48055506	 32513.5	
22	 34554086	 34554219	 0.3296	 1.37e+00	 6.70e+00	 1.16e-08	 t	 55.2	 LARGE-AS1	 34120971	 433181.5	
22	 37505513	 37505565	 0.0000	 3.91e-16	 5.75e+00	 1.05e-08	 t	 1600.2	 IL2RB	 37521879	 -16340.0	
22	 37599434	 37599550	 -0.1184	 -7.88e-01	 -5.28e+00	 5.27e-07	 t	 129.0	 SSTR3	 37600276	 -784.0	
22	 43698931	 43699007	 0.4914	 2.63e+00	 5.58e+00	 1.74e-07	 t	 109.8	 SCUBE1	 43599228	 99741.0	
22	 46450034	 46450096	 0.4910	 2.33e+00	 5.35e+00	 8.56e-08	 Z	 NA	 PRR34-AS1	 46449725	 340.0	
22	 49496226	 49496341	 0.2582	 1.38e+00	 5.72e+00	 1.09e-08	 Z	 NA	 LINC01310	 49262581	 233702.5	
22	 50498034	 50498137	 -0.2831	 -1.17e+00	 -6.12e+00	 9.35e-10	 Z	 NA	 MLC1	 50497819	 266.5	
X	 995974	 996141	 0.2045	 9.16e-01	 1.20e+01	 1.10e-12	 t	 28.8	 CRLF2	 1314893	 -318835.5	
X	 1717151	 1717192	 0.6525	 3.33e+00	 6.83e+00	 8.45e-12	 Z	 NA	 ASMT	 1714347	 2824.5	
X	 125715240	 125715319	 0.3731	 1.60e+00	 2.27e+01	 4.63e-114	 Z	 NA	 DCAF12L1	 125683365	 31914.5	
X	 151628704	 151628839	 -0.2803	 -1.16e+00	 -7.30e+00	 6.12e-09	 t	 41.1	 MIR105-2	 151562883	 65888.5	
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Given that this table presents many fragments that were not previously 
identified in the 2013 RRBS experiment of Foster (2014), and given that this 
RRBS experiment identified many fragments not previously implicated in 
ALL biology, it was considered prudent to attempt to independently validate 
these findings before further analysing this list of fragments. 
 
As a comparison, the 2013 libraries were also reanalysed using the GEE 
method (version 2.0), with the independence ‘working’ correlation structure. 
Of the 37,660 fragments included in the reanalysis, 143 met the significance 
threshold of p < 1.33e-6 (the p < 0.05 Bonferroni correction for 37,660 
fragments). The absolute methylation differences and p values for this 
reanalysis are shown in Figure 3.16. As can be seen, the vast majority of these 
results are very close to the threshold for significance. This, along with the 
relatively low number of significant fragments, suggests that this experiment 
was relatively poorly powered (in keeping with the fact that these libraries 




Comparison with Assumed-Independence Techniques 
 
As described, the GEE reanalysis substantially reduced the number of 
fragments displaying significant methylation differences compared with 
DMAP. However, for this difference to be meaningful for downstream 
applications, it would need to change the rankings of the most significant 
results. Otherwise, if the GEEs simply made the p values from a chi squared 
test proportionally bigger (which would be the case if correlation were 
consistent across the genome), a simple multiplicative correction could be 
applied to the Chi-squared results. 















Figure 3.16: The absolute methylation difference (dexamethasone 
treated minus control) and p values for all fragments included in the 




For comparison, I applied a GEE analysis, a chi squared test (used by the 
DMAP package) and naïve logistic regression (used by methylkit) to the 
90,010 fragments included in the version 2.0 GEE analysis (Akalin et al., 2012; 
Stockwell, 2013). Using a p value cut-off of p < 5.49e-7 (the p < 0.05 Bonferroni 
correction for 91,010 fragments), 2,695 fragments were significantly different 
by Chi-squared, 2,645 fragments by logistic regression and (as mentioned) 281 
fragments by GEE.  
 
To simply compare rankings, I compared the 300 most significant fragments 
from each of the three methods (chosen arbitrarily because approximately 300 
significant results were found by GEE). If the rankings were conserved 
between the tests, one would expect the vast majority of fragments to be the 
same in each of the top 300s. This is the case between logistic regression and 
Chi-squared, with 282 of 300 fragments in common; however, between GEE 
and Chi-squared only 95 fragments are in common and between GEE and 
logistic regression only 93 fragments were in common. When intra-read 
correlation was modelled using an exchangeable correlation structure 
(described earlier), there was very high mean intra-read correlation for both 
Chi-squared and logistic regression, at 0.761 and 0.760 respectively, compared 
with 0.349 for the GEE top 300 (all of which are higher than the average for 
the libraries). This would suggest that it is the degree of correlation that is the 
cause of the different rankings, as one would expect. Given that these tests are 
unable to handle within-read correlation, the high correlation values for the 
top 300 results by Chi-squared test and logistic regression also add further 
weight to the argument that these are inappropriate analysis methods for 
RRBS. 
 
MPBSgee: R package for Genome-Wide Methylation Analyses with GEEs 
 
As previously alluded to, using GEEs for genome-wide methylation analysis 
required the development of custom software. Therefore, I wrote a number of 
functions that allowed previously available analysis tools to be applied to 
RRBS and other genome-wide bisulphite sequencing libraries. These 
functions allowed the geese function of the ‘geepack’ R package (Halekoh et 
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al., 2006) to fit GEEs to hundreds of thousands of defined small genomic 
regions for differentially-methylated-regions analysis. Calculation of the 
degrees of freedom approximation of Satterthwaite (1946) was carried out by 
incorporating code from the ‘boss’ package of Voorman et al. (2012) and 
Sitlani et al. (2014). 
 
The genome-wide GEE analysis was incorporated into a single function 
within the MPBSgee R package, BS.DMR. Additionally, the lollypop plot 
software outlined earlier was written into the package as a function called 
lolly.plot. A gene location function was also written to give the distance to the 
nearest transcription start site and the name of the transcribed gene, for each 
of a list of genomic regions (using the distance from the middle of the region), 
called tss.dist. Lastly, the MspI fragment positions were provided for use as 
default genomic regions for differentially-methylated-regions detection. R 
package development was carried out as outlined in Chapter 2. The current 
package version is 2.0 and is available on request along with a package 
vignette. 
 
This package critically depends on the geepack, data.table and boss R 
packages, which must be installed for MPBSgee to run. After installation of 
the package dependencies, MPBSgee can be installed from the directory 




3.4 Validation by Sequenom MassArray 
 
Regions near or within Msp1 fragments that were near the start of the LY6E, 
IL15, RAB31, CRISPLD1 or CEP70, which displayed significant methylation 
changes by RRBS, were analysed by Sequenom MassArray. Results came 
from either three or four pairs of samples (each pair representing a side-by-
side cell culture experiment with and without dexamethasone), dictated by 
sample availability. For LYSE two independent PCR amplicons were assessed 
by Sequenom MassArray. Per cent methylation was returned for each of the 
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CpGs in the amplicon for each sample. As samples were paired, I worked 
with the pairwise differences in methylation proportions at each CpG site, 
which were analysed over the whole amplicon using the paired t test. The 
results are summarised in Figure 3.17, with RAB31 excluded as the sample 
failed in the Sequenom run. This shows that there is a considerable spread in 
the results from each pair; the IL15 results, for example, show that the 95% 
confidence intervals from the individual pairs are compatible with 10% 
greater or 20% less methylation in the control library (compared to the 
dexamethasone treated library). Furthermore, only amplicon 2 from LY6E 
shows a significant change, and the effect estimate is only a 2.6% (4.3% - 0.9%, 
p = 0.0036 by paired t test) difference in methylation.  
 
As such, these results cannot be said to validate the differences found by 
RRBS. However, there does appear to be evidence of considerable variation. 
Picking the most extreme example, there is a difference of 19.6% (11.9% - 
27.4%, p = 1.44e-5 by Student’s t test) between the estimated differences of the 
first and third pairs for the IL15 amplicon. All of the amplicons have examples 




Gene	 Chrom	 Frag	Start	 Frag	End	 RRBS	P	
Value	
Seq	Dif	 Seq	P	Value	
LY6E	2	 8	 144100132	 144100200	 4.37E-07	 -0.02714286	 0.003518	
LY6E	1	 8	 144100132	 144100200	 4.37E-07	 -0.0172549	 0.2266	
IL15	 4	 142557614	 142557713	 1.29E-09	 -0.02655738	 0.1001	
CEP70	 3	 138313075	 138313135	 4.92E-07	 0.015	 0.2372	
CRISPLD1	 8	 75897025	 75897106	 6.49E-09	 -0.01636364	 0.3061	
 






























Figure 3.17: LY6E amplicon 1 methylation differences (control – 
dexamethasone treated) by pairs (blue) and the mean (black). Pair 1 


































Figure 3.18: LY6E amplicon 2 methylation differences (control – 
dexamethasone treated) by pairs (blue) and overall (black). Pair 1 was 





































Figure 3.19: IL15 amplicon methylation differences (control – 
dexamethasone treated) by pairs (blue) and overall (black). Error bars 





























Figure 3.20: CEP70 amplicon methylation differences (control – 
dexamethasone treated) by pairs (blue) and overall (black). Error bars 






























Figure 3.21: CRISPLD1 amplicon methylation differences (control – 
dexamethasone treated) by pairs (blue) and overall (black). Error bars 
are the 95% confidence intervals. 
Pair Num  
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4. Conclusions and Discussion 
 




As discussed, the analysis technique used in this project was different from 
the standard analyses used in the field in that within-read correlation was 
taken into account. There are two primary advantages to this GEE approach 
over the standard techniques. Firstly, the GEE approach does not require the 
user to correctly specify how the CpGs are correlated within a read and 
instead empirically estimates the effect of correlation in a highly consistent 
manner, if read coverage is high (Liang and Zeger, 1986; Zeger and Liang, 
1986). Therefore, at high read numbers (typically > 40 reads) it does not 
matter whether every CpG observation is completely independent, 
completely dependent or anywhere in between, the estimates of the p values 
will be approximately true. In contrast, the standard techniques do not give 
accurate p values if CpGs within reads are correlated. The empirical 
estimation of the effect of correlation for each fragment also allows that the 
degree of correlation and the correlation structure within reads may change 
across the genome. Secondly, the GEE approach makes weak assumptions 
about the underlying distribution of the modelled variables by defining the 
variance as a function of the mean, meaning that estimates of regression 
coefficients and their variances will be approximately true as long as it is 
sensible to use a quasi-likelihood approximation (which is accepted to be the 
case for binary data) (Liang and Zeger, 1986; Mccullagh, 1983; Zeger and 
Liang, 1986). 
 
 As can be seen by the results in Chapter 3, when within-read correlation is 
appropriately handled there are considerably fewer significant differentially-
methylated-regions detected than if one of the standard analyses in the field 
were used. This is what one would expect, given that the standard techniques 
make an assumption of independence that does not hold for RRBS data; 
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however, this is an important observation as it suggests that the current 
literature incorrectly overestimates the significance of methylation differences 
detected by RRBS. Therefore, it is strongly recommended that future RRBS 
studies analyse their results using GEEs or some other technique that can 
account for intra-read correlation. 
 
There are, however, several limitations to the GEE method. The first of these 
is that relatively high read depth is required for the ‘robust’ estimator to be 
accurate. It is reported that a minimum number of clusters (reads in our case) 
for accurate calculation of the empirically derived (robust) variance of β
^
R  is 
at least 40 (Morel et al., 2003). This requirement for relatively high read depth 
does mean that many covered fragments in a library may not reach the 
inclusion criteria required, reducing the power of the technique. Additionally, 
GEEs are unable to calculate the robust variance of β
^
R  for a genomic area if 
one of the libraries is very close to 0% or 100% methylation (typically > 98% or 
< 2%). The reason for this can be logically explained if we consider a fragment 
with an underlying probability of methylation of 1 (i.e., there is complete 
methylation in all cells). As such, if every CpG were completely independent 
of every other CpG in the same read we would observe that all CpGs from all 
reads were methylated; equally, if every CpG were completely correlated 
with every other CpG in the same read we would still observe that all CpGs 
in all reads were methylated. Therefore, there is no empirical way to estimate 
within-read correlation from the observed data in such a scenario (it also 
follows that the corollary is true when the probability of methylation is 0 and 
all observed CpGs are unmethylated). As such, standard (independence 
based) techniques may have to be used to analyse differential methylation 
when there is very high or very low methylation, with the caveat that these 
techniques give the ‘minimum’ p values for any differences. In our GEE 
analysis, presented in Chapter 3, fragments with this very high or very low 
methylation were excluded from the analysis; however, this is an undesirable 
state of affairs (as we are missing areas of the genome that have been covered 
by RRBS). This said, changes from 0% methylation or 100% methylation that 
are in the range of what is often considered ‘biologically meaningful’ (> 10% 
change seems reasonable) are almost certain to be statistically significant, 
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given the very low variance in binary data near 0% or 100% (as variance is 
given by v = p(1− p) , where p  is the proportion methylated). As such, we 
suggest that all fragments where one sample shown near 0% or near 100% 
methylation, and the other shows a change of > 10-15% away from 0% or 
100% be considered significant, if the fragment meets the minimum read 
threshold. 
 
Additionally, the inclusion criteria of > 20 reads from each library each with 
at least 3 CpGs is highly stringent, and discards many fragments with low 
coverage (that may show true methylation differences). This is done to avoid 
the bias in the robust (or sandwich) variance estimate (see page 88) at low 
sample numbers, 20 was chosen as a read threshold to give > 40 clusters in 
total as this seems to be about the point where bias in the GEE method 
becomes apparent (Li and Redden, 2015). However, it does appear that the 
issues of low sample sizes can be at least partially overcome by using the t 
distribution approximation of Sitlani et al. (2014). This technique performed 
well in simulation studies and should allow GEEs to be used to analyse 
genome wide methylation in the majority of case/control studies as well as 
allowing read thresholds to be relaxed in two sample studies, as 
demonstrated in Chapter 3. As presented in Chapter 3, I am implementing 
this approach to analyse the RRBS data of Hester Roberts, Ingrid Knarston 
and Erin Macaulay (Department of Pathology, University of Otago). Their 
study involves the use of RRBS to study the genome-wide methylation of 15 
placentas with pre-eclampsia against 15 controls. While it has not been 
implemented at this stage for my dexamethasone treated vs. control RRBS 
libraries, this approach should also be a feasible way of analysing low-
coverage fragments. This should markedly increase power over the current 
GEE approach, where much of the data collected can’t be used in the analysis. 
Therefore, the use of the estimated t distribution or some other technique that 
is effective at reducing the type-1 error at low sample numbers is 
recommended when analysing genome-wide bisulphite sequencing data with 
GEEs. 
 
Overall, I argue that the use of GEEs in the analyses presented in this thesis 
represents a considerable improvement in the analysis of RRBS data. 
 125 
Furthermore, this technique will now be used as the standard differential 
methylation analysis for RRBS data in the Morison lab, and is currently being 
used to analyse genome-wide methylation differences between pre-eclamptic 
and normal placentas in an on-going project. 
 
Within Read Correlation 
 
As demonstrated, while many fragments broadly showed independence of 
CpGs within reads, a significant number of fragments showed highly positive 
correlation, skewing the distribution (Figure 3.12). Furthermore, the 
fragments showing the 300 most significant differences by Chi-squared test, 
naïve logistic regression and GEE had significantly higher correlation than the 
overall average. This demonstrates that, for valid inferences to be made about 
the mean, a technique that can deal with highly variable correlation across the 
genome is necessary; hence the use of GEEs. 
 
Why there is so much higher correlation in the top 300 most significant 
differences is not immediately clear. For naïve logistic regression and Chi-
squared this would be expected, as correlation will increase type-1 error with 
these methods; however, higher correlation was also observed in the GEE top 
300 (albeit to a lesser extent). It may be that the most significant differences 
are most likely to occur in areas of active genomic regulation, and that these 
areas of active regulation are likely to have an active methylation machinery 
keeping neighbouring CpGs within a cell either methylated or unmethylated 
and thus leading to high observed correlation. Equally, it could be that at, a 
single-cell level, epigenetic response to dexamethasone is an all or nothing 
event, leading to almost all the CpGs in a responding cell becoming 
methylated or demethylated. Differences in methylation, therefore, would be 
due to the proportion of cells that responded and display all methylated or all 
unmethylated CpGs against a background of unresponsive cells. This would 
‘concentrate’ the methylation change in a certain proportion of the cells, and 
this would mean that we would observe correlation between CpGs in the 
same cell (as to maintain no correlation would require a diffuse change in 
methylation across all cells). 
 
 126 
Unfortunately, there are no data from the RRBS libraries alone that can 
support either of these hypotheses or another hypothesis. Further 
experiments would need to be carried out to determine why this result was 
observed. For example, if the observation is due to the changes in methylation 
occurring in areas of constitutively high regulation, we might expect to see 
high hydroxymethylation in these areas in both libraries (as 
hydroxymethylation is a mark of active methylation regulation) (Ficz et al., 
2011). Alternatively, if dexamethasone is inducing an all or nothing response, 
we might expect to see high hydroxymethylation only in those cells 
responding to dexamethasone. 
 
Power, Bias, Type 1 Error and Type 2 Error 
 
The purpose of using GEEs to analyse my RRBS results was to control the 
potential for type 1 error due to within-read correlation. However, other 
sources of type 1 error must also be considered, which could also affect the 
ability to draw conclusions from the DMR analysis. Importantly, the GEEs 
make an assumption that each cluster (read) is independent of every other; 
however, it is theoretically possible that this assumption could be violated if 
the technique repeatedly sequenced PCR products originating from the same 
cell. Furthermore, this would skew the methylation estimate towards the 
methylation status of that particular cell. This scenario is known as ‘PCR bias’ 
and must be taken into account as a potential explanation for the observation 
of significantly differentially methylated regions as, if it were to occur, it 
would substantially increase the type-1 error rate even when using GEE 
analysis. It is hypothesised that PCR bias could occur if certain DNA 
sequences were preferentially amplified in the PCR stage of library 
preparation. 
 
Additionally, while it has not been discussed in as much detail as type-1 
error, the potential for type-2 error is an important consideration in a genome-
wide study design such as this one. Furthermore, the correlation of CpGs 
within reads complicates the power calculations presented in Chapter 1, 
which quantify the potential for type-2 error in the dataset. If zx is the x 
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quantile of the standard normal distribution, P is the power at one fragment, 
ρ  is the (assumed exchangeable) correlation within reads, n is the number of 
CpGs per read, pA is the methylation in the first sample and pB  is the 
methylation in the second sample, then the required number of reads, m, for 
each library at that fragment to achieve a power of P at significance level α is 











p = pA + pB
2
 
q =1− p  
d = pA − pB  
Q =1−P  
One of the major considerations when interpreting this equation is that, at the 
significance level used with multiple testing corrections in genome-wide 
studies, a very high number of reads is required at each fragment to achieve a 
given power. This means that, at the coverage level for much of the genome, 
typical RRBS studies are only powered to detect very large differences in 
methylation. Consequently, it is highly likely that my study has missed a 
large number of real methylation differences between the dexamethasone 
treated and control libraries and my results are likely only to include 
relatively big differences. Additionally, more reads are required to achieve a 
given power as the correlation within reads increases. Consequently, RRBS or 
WGBS studies must consider correlation within reads when determining read 
depth requirements (which, in turn, will affect the number of sequencing 
lanes a study will need). 
 
While increasing read depth is the best (but also most expensive) way to 
increase power for DMR analyses such as this one, it is also possible to reduce 
type-2 error by making a trade-off with increased type-1 error. The most 
obvious way to do this would be to alter the multiple testing corrections used. 
This study used the conservative Bonferroni correction, as we were primarily 
concerned with controlling type-1 error. However, less stringent corrections 
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such as the false discovery rate method can be used, which have the potential 
to substantially reduce type-2 error in exchange for a modest increase in type 
1 error (Benjamini and Hochberg, 1995). The trade-off between type-1 and 
type-2 error will depend on the primary aims of the whole-genome 
differential-methylation studies in question. 
 
Additionally, it should be possible to increase power when using GEEs by 
choosing a working correlation structure that is close to the truth. While we 
selected the independence working structure for the analysis, due to the 
minimal assumptions that are made under this structure and the 
computational speed of its application, it is probable that the true correlation 
structure is much closer to an exchangeable structure (the structure used to 
model correlation within reads). Choosing an appropriate correlation 
structure was shown to increase power in the genome-wide context 
(Voorman et al., 2012) and the re-write of version 2.0 of the analysis software 
gave increased performance such that it should be computationally feasible to 




This section has focussed on deriving internally valid results from RRBS data. 
However, it should be noted that the issue of external validity or 
generalizability is also important. Generalizability is one of the major 
weaknesses of this project’s study design, as all experiments were carried out 
using the NALM-6 ALL cell line. Therefore, any differences between 
dexamethasone treated and untreated cells can strictly only be applied to the 
NALM-6 cell-line, and not to ALL cells in general. This said, NALM-6 cells 
are ALL cells, and they respond to dexamethasone in a manner that would be 
expected of glucocorticoid-sensitive ALL cells (see subsequent subsection). 
Therefore, any differences found in NALM-6 cells can be reasonably thought 
to provide clues about the ALL response to glucocorticoids in general. 
However, subsequent experiments using other ALL cell lines and (if possible) 
patient blasts will be required to demonstrate that any results that apply to 
NALM-6 cells apply to ALL cells in general. 
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4.2 Phenotypic Effects of Dexamethasone of NALM-6 Cells 
 
Overview of Conclusions from Cell Culture Experiments 
 
Overall, it can be concluded that exposure to dexamethasone both reduces 
NALM-6 cell proliferation and increases cell death over 72 hours, consistent 
with previous results in the literature (Bachmann et al., 2007; Juarez et al., 
2003). The main weakness in these results is the lack of reproduction in the 
proliferation experiment, with only one cell-culture experiment done to 
measure proliferation by CFSE fluorescence. However, given that these 
results match results previously published in the literature Juarez et al. (2003), 
and given that it matches the observation of reduced cell numbers in cell 
culture (an observation that was replicated multiple times by myself, Ben 
Stegmann and Bachmann et al. (2007)), I would conclude that this is likely to 
be a real result. Additionally, the very large difference between treated and 
untreated cells in CFSE fluorescence at 72 hours (well beyond the 95% 
confidence intervals for the mean) adds weight to this conclusion. As 
mentioned the observation of reduced cell numbers in dexamethasone-
exposed cell NALM-6 cultures was replicated several times; thus, this is a 
convincing result. 
 
It is worth pointing out that, as the proliferation experiment was carried out 
once, the error bars in Figure 3.3 indicate that the mean fluorescence for the 
50,000 measured dexamethasone-treated cells was significantly different to 
the mean fluorescence of the 50,000 control cells, and does not necessarily 
mean that the result is generalizable (i.e., repeated measurements would be 
required to say that dexamethasone treatment always causes this result in 
NALM-6 cells). However, this result is concordant with that of Juarez et al. 
(2003), giving replication of the result from the literature.  
 
The main importance of these findings is that they show that dexamethasone 
has a strong measureable effect on the NALM-6 phenotype, consistent with 
the cell-of origin of NALM-6 being a corticosteroid sensitive leukaemia blast 
(Bachmann et al., 2007). As such, any methylation changes detected after 
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dexamethasone exposure can be associated (though not necessarily causally 
associated) with a cellular phenotype, which includes increased death and 
reduced proliferation.  
 
4.3 Methylation Effects of Dexamethasone of NALM-6 Cells 
 
As presented in Chapter 3, RRBS was used to determine if the genome-wide 
methylation of NALM-6 cells changed in response to dexamethasone. This 
technique yielded a large number of significant differences between the 
dexamethasone-treated library and control library, using the GEE technique 
to assess significance (which we believe is more robust). These differences are 
statistically significant when accounting for multiple testing using the 
(conservative) Bonferroni correction and many show very large absolute 
differences in methylation of up to 50%. These differences included fragments 
near the beginning of biologically interesting genes, such as IL15, which 
promotes proliferation of lymphocytes and prevents apoptosis (Mishra et al., 
2014; Bulphone-Paus et al., 1997), RAB31 which has been implicated in several 
cancers (Chua et al., 2015) and CTHRC1 which has been implicated in lung 
cancer (Ke et al., 2014). 
 
However, there was a clear lack of validation by Sequenom MassArray for 
those genomic areas. This is similar to the relatively poor validation seen in 
placental samples examined by RRBS and Sequenom, even for those samples 
with more than 50 reads (see Figure 1.4). While one amplicon (LY6E2) did 
show a significant change in the expected direction, it was a much smaller 
change than would be expected based on the RRBS results. This raises 
considerable concern over the RRBS results in general. If the changes detected 
by RRBS are not reproducible, then one cannot say with certainty that they 
are real changes at all. The results also beg the question of why there was 
such poor validation between the results, even when using a discovery 
technique (GEE) that could account for correlation within the dataset and 
return suitably conservative results. 
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One possible explanation for these results is that the RRBS results are 
unreliable and most of the differences detected by RRBS are artefactual. This 
would lead to the conclusion that there is no evidence that dexamethasone 
treatment affects the methylation of NALM-6 cells. This conclusion would 
raise the question as to why the RRBS results are unreliable, particularly 
when an effort has been made to use a relatively conservative statistical 
technique (though one that may not be entirely free of type-1 error). 
Furthermore, RRBS has been previously shown to show concordance with 
Sequenom results (see Figures 1.4 and 1.5), and it therefore seems unlikely 
that the RRBS results are completely unrelated to the true methylation value. 
That said, Figures 1.4 and 1.5 show that very large differences between 
Sequenom and RRBS are possible and, indeed, common. Therefore, it is 
possible that the RRBS results have detected differences that are not 
reproducible (and which have clearly failed to be reproduced with a single 
Sequenom experiment). Given that the available data cannot rule out this 
possibility, it is not possible to conclude that there is definitive evidence for 
changes in methylation associated with dexamethasone exposure (based on 
the data presented in this report). 
 
However, there are other possible explanations that could account for that 
lack of validation of the RRBS results. Firstly, time and resources limited the 
number of differences that could be validated by Sequenom. It is therefore 
possible that regions that had poor reproducibility were chosen by chance, 
given that Figures 1.4 and 1.5 show that there is considerable variation in how 
well RRBS results agree with Sequenom results (ranging from very tight to 
very poor validation). This said, the fact that such large differences were not 
reproduced across all the regions chosen for validation does suggest that 
there is a systemic problem with reproducing the methylation differences 
from RRBS using Sequenom. 
 
The variability in the Sequenom results provides an alternative explanation 
for the lack of reproducibility for the RRBS results. All of the amplicons have 
at least one pair where there is significantly higher methylation in the 
dexamethasone treated sample compared with the untreated sample (see 
Figures 3.17-3.21), which would be considered to have validated the RRBS 
 132 
results. However, significant variations between the estimated differences 
across the pairs lead to no overall validation of the RRBS results. The 95% 
confidence intervals shown in Figures 3.17-3.21 show that many of the 
differences between pairs are highly significant, with the individual 
confidence intervals being compatible with considerably different estimates of 
the mean difference in methylation. This raises the possibility that these 
regions show variable methylation, possibly associated with dynamically 
varying gene expression. It is plausible that regions of variable methylation 
could undergo considerable changes in methylation over short time periods, 
as such changes have been previously observed (Kress et al., 2001; Wiench et 
al., 2011). Therefore, isolated cell cultures could display differences in such 
variable regions as a result of short-term fluctuations in methylation levels; 
such fluctuations would also lead to the considerable fluctuations seen 
between the different pairs of cell culture experiments by Sequenom. If this 
possibility were correct, one would expect to see large fluctuations in 
methylation within a single cell-line culture over time. For three cell culture 
experiments, DNA was taken at various time points that would allow one to 
determine whether this is indeed the case; however, time and resources 
prevented all of these samples from being able to be analysed. This said, the 
Morison lab recently received a Laurenson grant that would allow this 
experiment to be carried out in the future. 
 
In addition, the regions chosen for analysis by Sequenom are not typical of 
the significant differences in general. They were chosen on the basis of a 
> 50% methylation difference between the dexamethasone treated and control 
libraries. However, they also have considerably higher within-read 
correlation (as estimated using the exchangeable correlation structure) 
compared with the average for all significant differences by GEE. The average 
mean correlation for the fragments that were validated was 0.78, compared 
with 0.29 for all significant differences (p = 0.01 by Wilcoxon rank sum test, 
the Wilcoxon test was used due to skewed distribution of correlation values). 
If this experiment were to be repeated, therefore, it might be preferable to 
include fragments with lower within-read correlation, to determine whether 
such fragments show more reproducible differences in methylation. 
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As a brief aside, all the fragments chosen for validation by Sequenom showed 
highly significant differences when using a Chi-squared or logistic regression 
analysis, so the use of the GEE analysis instead of these simpler statistical 
tests cannot explain the lack of validation. As previously discussed, GEE 
remains a superior analysis technique due to the empirically demonstrable 
presence of within-read correlation in the data.  
 
Another intriguing explanation (and I thank the marker of this thesis for 
suggesting this hypothesis) is that the methylation analyses with the RRBS 
and sequenom methods may have been carried out with cells in different 
phases of the cell cycle. As is shown by the sing CFSE peaks in the 
proliferation study of this thesis (Figure 3.2), the NALM-6 cells seem to divide 
in unison and, therefore, most of the cells will likely be in the same stage of 
the cell cycle. Furthermore, as dexamethasone slows NALM-6 transit through 
the cell cycle (shown by a slower decay of CFSE fluorescence, Figure 3.2), the 
dexamethasone and control cells are likely to be dominated by cells in 
different phases of the cell cycle. Given that a cell’s position in the cell cycle 
may be associated with methylation changes (Brown et al., 2007), some 
differences between the dexamethasone-treated and control cell cultures may 
represent differences in the cell cycle and these differences will not be 
replicated unless subsequent analyses are performed with the two cultures in 
the same respective positions in the cell cycle. If this hypothesis is correct, 
further work is needed to distinguish between cell-cycle changes and any 
possible specific effects of dexamethasone. 
 
Overall, while the variability in the Sequenom results or the fact that non-
representative fragments may explain the poor validation of the methylation 
differences detected by RRBS, there are no data to support these hypotheses 
in this report. As such, it must be concluded that, while many highly 
significant differences in methylation were found by RRBS, these significant 
differences have not been independently replicated. 
 
4.4 Overview of Conclusions and Future Directions 
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In summary, this project aimed to analyse dexamethasone treated NALM-6 
cells in culture and untreated cells and compare cell number, cell death, cell 
proliferation and DNA methylation. On the basis of the data in this report it 
can be concluded that dexamethasone treated cells had a lower cell number 
than untreated cells after 72 hours cell culture in otherwise identical 
conditions, cell death was higher for dexamethasone treated cells and cell 
proliferation was reduced in dexamethasone treated cells. These conclusions 
clearly match previous results in the literature (Bachmann et al., 2007; Juarez 
et al., 2003). 
 
The comparison of DNA methylation between dexamethasone treated and 
untreated NALM-6 cells was the more novel section of this project, and a 
genome wide comparison was carried out using RRBS. As presented, within-
read correlation lead to the conclusion that an alternative statistical analysis 
technique was required that did not assume statistical independence of 
observations (as many statistical tests used to analyse DNA methylation do). 
Therefore, we used GEEs, developed by Liang and Zeger (1986) and Zeger 
and Liang (1986) to overcome the issue of correlation and to ensure that the 
statistical test used was appropriate to the type of data being analysed. Using 
this technique, 281 MspI fragments were shown to display statistically 
significant differences in methylation, when using a Bonferroni correction to 
account for multiple testing. However, when the methylation of 6 fragments 
was compared between dexamethasone treated cells and untreated cells using 
Sequenom MassArray for validation, the RRBS results were not replicated. As 
such, it must be concluded that a large number of statistically significant 
differences in methylation, associated with dexamethasone exposure, were 
found using RRBS; however, the lack of validation means that it is not known 
how many, if any, of these findings represent real, reproducible changes in 
methylation caused by dexamethasone exposure. 
 
Therefore, a logical future direction for this project is the issue of validation of 
the RRBS results. As mentioned, DNA was taken from cell cultures with and 
without dexamethasone throughout the 72-hour cell cultures (at 24-hour 
intervals). Analysing the methylation of MspI fragments across time would 
determine whether the differences in methylation detected by RRBS are the 
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result of temporal variation of DNA methylation within the separate cell 
cultures (which would also explain the variation seen in the Sequenom 
results). Additionally, choosing many (or at least, many more than 6) of the 
significantly different fragments for Sequenom validation would give a more 
accurate indication of how many (if any) of the results found by RRBS are 
likely to be reproducible. This should include fragments with varying within-
read correlation and absolute differences in methylation, as the 6 chosen in 
this report had both unusually high within-read correlation and high absolute 
methylation differences in the RRBS data. 
 
Additionally, the identification of within-read correlation as a factor that 
influences the statistical interpretation of RRBS data is an area worthy of 
future research work. It has been shown in the literature that GEE is a flexible 
technique that is capable of easily handling even very complex correlation 
structures and that is suitable for use in genome-wide studies (Diggle et al., 
2002; Sitlani et al., 2014). However, simulation work should be carried out to 
formally establish the limits of the technique in the context of RRBS data, 
including whether the technique begins to fail to accurately estimate p values 
for methylation differences when they get beyond the p value range 
investigated by Sitlani et al. (2014). Additionally, work is being carried out 
currently to try to apply the GEE technique (or another technique that can 
candle correlation) to RRBS studies involving groups of libraries (rather than 
single libraries). In theory, GEEs should be able to handle correlation within 
read and within library; however, work is required to determine whether 
variable coverage between libraries affects the technique and whether these 
group-based studies fulfil the missing data requirements of the technique 
(these missing data requirements are outlined in Diggle et al. (2002)). The use 
of mixed effects models, an alternative technique developed for use in 
epidemiology and biostatistics, is also being investigated as these models may 
be more flexible for group based studies, though they have the disadvantages 
of being less simple to interpret than GEEs and requiring modelling of the 
true correlation structure; they are, however, an appropriate alternative to 
GEEs when there is correlation within a dataset (Diggle et al., 2002). 
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Looking further forward, if any of the methylation differences between the 
dexamethasone treated NALM-6 cells and untreated cells can be reliably 
reproduced, there are a range of experiments that can be carried out. Firstly, 
qPCR or Western blotting could be used to determine whether methylation 
differences lead to changes in gene expression. If so, this has the potential to 
identify new proteins involved in the response of ALL cells to glucocorticoids. 
As such, it would be theoretically possible to target these proteins to try to 
mimic the antileukaemic effects of glucocorticoids without incurring the 
glucocorticoid effects on other body systems (such as the gastrointestinal 
system), which are likely to be characterised by the activation and repression 
of different genes (Rhen and Cidlowski, 2005). Additionally, if it were 
possibble to reproduce methylation differences in NALM-6 cells in response 
to dexamethasone, one would wish to try to demonstrate that such 
differences occurred in other ALL cells and cell-lines and possibly also try to 
demonstrate such changes in other glucocorticoid-sensitive leukaemias. Such 
experiments would allow results to be generalised beyond NALM-6 cells. 
Indeed, generalisability is a current weakness of this project as all 
experiments were carried out with NALM-6 cells only. 
 
In a more general sense, there is some thought that ALL may represent an 
abnormality of development whereby a primitive lymphoblast with a fetal 
phenotype persists beyond fetal life and becomes the cell-of-origin for some 
cases of ALL (Morison, 2014). This would make (at least some cases of) ALL a 
disorder of development, similar to other childhood cancers such as Wilms 
tumour (Hastie, 1994). In this context, methylation changes in response to 
glucocorticoids may be of some interest, as it seems that DNA methylation is 
likely to play a significant role in ALL pathogenesis and development 
(Martin-Subero et al., 2009). Therefore, it may be possible that the response of 
fetal blasts to glucocorticoids may be of some importance, particularly as 
rising glucocorticoid levels rise throughout fetal life, with important effects on 
organ system development (including the glucocorticoid-sensitive immune 
system) (Braun et al., 2013). Differences between the responses of normal fetal 
lymphoblasts and ALL cells to glucocorticoids may indicate how cells 
destined to be ALL cells-of-origin behave differently to normal lymphoblasts 
under rising glucocorticoid levels in utero. 
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As such, a large body of future work should be possible to build on this 
project. As such, I look forward to seeing the results of work linked to this 
project; in particular, the results of more extensive validation experiments to 
determine whether any of the differences found between dexamethasone 
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